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PROPOSITIONS 
 
 
1. Harmonizing micronutrient recommendations requires harmonized definitions of requirements. 
(This thesis) 
 
2. Vitamin B12 requirements can yet not be based on optimal status for cognitive performance. 
(This thesis) 
 
3. Considering the “unquestionable positive effects of music on cognitive functioning”, it could be 
considered to establish recommendations on daily music intake. (Inspired by Honing and 
Swaab, Volkskrant 18-06-2011) 
 
4. Complying with micronutrient recommendations by a healthy varied diet is preferable over 
supplement use. 
 
5. Evidence-based decision making in policy development requires expert judgement. 
 
6. Going for a run during working hours is a distracting task that stimulates the unconscious 
mind to select the best ideas. 
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There is no such thing as exact science 
(after Heisenberg’s uncertainty principle, 1927) 
  
 
ABSTRACT 
Background: Most countries in Europe provide recommendations on the 
micronutrient composition of diets to fulfil requirements of nearly all 
individuals in the general apparently healthy population. However as each 
country uses its own methods for deriving such recommendations, there is 
large variation between countries in the recommended micronutrient 
intakes. The objectives of this thesis are to signal key issues for harmonizing 
approaches for establishing micronutrient recommendations for adults and 
elderly across Europe and to illustrate standardized and transparent review 
methods that can be used to summarize and evaluate the evidence-base for 
setting recommendations, using vitamin B12 as a case micronutrient. 
Methods: First the need for harmonization is substantiated by a descriptive 
study on the variation in published micronutrient recommendations across 
Europe. In addition methodological factors were identified that should be 
considered for alignment of recommended intakes across Europe. Secondly, 
the evidence-base for establishing recommended vitamin B12 intakes was 
summarized in two systematic reviews. One review focused on requirements 
for the compensation of daily obligatory losses (factorial approach) and the 
other review evaluated the relation of vitamin B12 intake and status with 
cognitive performance (dose-response approach). Whether interactions 
between folate and vitamin B12 on cognitive performance should be 
considered for establishing recommended vitamin B12 intakes was evaluated 
using data from 2203 Norwegian elderly from the Hordaland Homocysteine 
Study. 
Results: For harmonizing approaches for establishing micronutrient 
recommendations, standard methods are needed to a)-select health 
indicators and define adequate biomarker concentrations, b)-make 
assumptions about inter-individual variation in requirements, c)-derive 
bioavailability factors, and d)-select and interpret evidence on requirements. 
The first systematic review showed that daily vitamin B12 losses in 
apparently healthy adults and elderly probably range between 2.6-3.9 µg 
and bioavailability from the usual diet may range between 29 and 37% 
rather than the generally assumed 50%.  
Dose-response evidence from 2 randomized controlled trials and 19 
prospective cohort studies showed no or inconsistent associations between 
vitamin B12 intake or status and dementia, Alzheimer’s Disease, global 
cognitive function or domain-specific cognitive function in adults and elderly 
people. Cross-sectional analyses in the Norwegian cohort study showed that 
low plasma vitamin B12 in combination with high folate was associated with 
better cognitive performance. However, these associations were not 
observed for sensitive markers of vitamin B12 status.  
Conclusion: The main conclusion of this thesis is that evidence underlying 
current recommended vitamin B12 intakes is old and has large uncertainties, 
whereas the available evidence on the relation between vitamin B12 and 
cognitive performance is yet not convincing and thereby limits its use as an 
outcome for estimating vitamin B12 requirements. 
The relation between vitamin B12 intake and markers of vitamin B12 status 
seems the best alternative, but sound statistical methods to define 
recommendations based on these dose-response data should be further 
developed.  
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Micronutrients, such as vitamins and minerals, are essential for proper 
growth and metabolism in humans. Although only small quantities of 
micronutrients are needed, their lack may have serious consequences for 
health and development of populations across the world (1). Most countries 
in Europe provide recommendations on the micronutrient composition of 
diets to avoid deficiency in the general apparently healthy population. These 
recommendations serve as a basis for national or regional nutrition policies, 
nutritional education programs and food regulation. However as each 
country uses its own methods for deriving recommendations, there is large 
variation between countries in the recommended micronutrient intakes (2-
4). The EURRECA Network of Excellence was established in the beginning of 
2007 with the aim to harmonize the process of setting micronutrient 
recommendations across Europe with special focus on vulnerable population 
groups, including elderly people (5, 6). This thesis was written in the context 
of the EURRECA network and includes a critical review of the variation in 
recommendations for adults and elderly across Europe to signal key issues 
for harmonizing the process for setting micronutrient recommendations. 
Furthermore, this thesis illustrates standardized, transparent and objective 
review methods that can be used to summarize and evaluate the evidence-
base for setting recommendations, using vitamin B12 as a case 
micronutrient. 
 
RECOMMENDATIONS 
Although different terms are used by different national and international 
agencies to express micronutrient recommendations, e.g. Population 
Reference Intake, Recommended Intake, Recommended Daily Allowance, 
they all refer to the daily intake level that is sufficient to fulfil the 
requirements of nearly all healthy individuals in a defined population (7, 8). 
Requirements are here defined as the intake that is sufficient to fulfil 
micronutrient needs. These micronutrient needs are not fixed values, but 
depend on an a priori definition of adequate health using selected 
physiological, biochemical or clinical outcome measures and a cut-off level 
indicating the desired or acceptable level of the selected health outcome 
measures. 
For an individual, the requirement for any micronutrient depends on a 
variety of factors such as age, gender, genotype, physical activity, health 
status and the efficiency with which an individual absorbs and metabolizes 
micronutrients. The requirement for a specific micronutrient can thus vary 
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both within and between individuals. For setting recommendations on intake 
of a specific micronutrient, one needs to estimate the distribution of 
requirements within a defined population. From this distribution, the average 
nutrient requirement (ANR) can be estimated, indicating the intake level that 
would be sufficient to fulfil the requirements of 50% of individuals in the 
population. Subsequently the recommended intake can be estimated as the 
ANR+2SD, to account for variation in needs between individuals. An intake 
equal to the recommended intake would thus be sufficient to fulfil the 
requirements of circa 97.5 % of the individuals in a population.  
Often the distribution of requirements cannot be estimated and therefore no 
ANR can be derived. The recommended intake is then approximated based 
on observations of usual intakes in the specific population and estimated as 
the mean level of intake at which the prevalence of inadequacy is apparently 
low. A recommended intake derived in this way is referred to as the 
adequate intake (AI) (9). Thus, a recommended intake derived as ANR+2SD 
and the AI both target the intake that seems to cover requirements of nearly 
all individuals within a population, but methods used to derive them are 
different.  
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Figure 1 Overview of the different concepts related to micronutrient 
recommendations (10) 
 
The upper nutrient level (UNL), also referred to as upper level, is defined as 
the highest level of usual intake that is likely to pose no risk of adverse 
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health effects in almost all individuals in the general population. Establishing 
UNLs requires a toxicological risk assessment method that is outside the 
scope of this thesis. Figure 1 gives an overview of all the concepts 
introduced above.  
 
Application of recommendations 
Two main applications of micronutrient recommendations can be 
distinghuished, namely evaluation and planning of intakes of population 
groups. These two application form the basic activities for developing 
nutrition policies by both national and international authorities (e.g. 
WHO/FAO)(11). Although recommendations are intended to be used for 
groups of individuals, they are in practice also used for evaluating and 
planning intakes of individuals (12-14). However in this thesis the focus is on 
applications for population groups only. 
For evaluating intakes of population groups, the cut-point method can be 
used that, under some assumptions, estimates the proportion of individuals 
in the population that have an intake below their requirements by the 
proportion of the population with intakes below the ANR. In case the ANR 
cannot be estimated and therefore the recommended intake is derived as an 
AI instead of ANR+2SD, the prevalence of inadequate intakes in a 
population cannot be estimated quantitatively because the AI is higher than 
the requirements of most individuas within a population. It can be assumed 
that when the mean intake of a population approximates the AI, the 
prevalence of inadequacy is low. However when the mean intake of a 
population is below the AI, no such statements on the prevalence of 
inadequate intakes can be made (15).  
For planning micronutrient intakes for a group/population, two methods 
have been proposed. The aim of the first method is to minimize the 
prevalence of intakes below the ANR following the cut-point method as 
described before (11, 16). Whereas the aim of the second and most 
commonly used method is to compose a diet with a micronutrient content 
equal to the recommended intake or AI (13, 14). 
Current micronutrient recommendations vary largely between European 
countries which is likely due to differences in methods used by 
recommendation-setting bodies. Because variation in recommendations can 
be confusing for those involved in the evaluation and planning of 
micronutrient itnakes such as consumers, food producers and nutrition 
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policy makers, harmonization of the process for setting micronutrient 
recommendations is needed. 
 
Network of Excellence EURRECA 
The overall aim of the EURRECA network of excellence is to produce 
harmonized scientific guidelines for developing micronutrient 
recommendations to move towards a uniform, transparent and evidence-
based process for deriving recommended micronutrient intakes (6).  
A framework has been proposed that describes the process for deriving 
micronutrient recommendations in several steps. The first steps include the 
selection of micronutrients, population groups and health outcomes that 
require a revision of recommendations and the formation of an expert 
committee that has responsibility for deriving the specific micronutrient 
requirements and/or recommendations. Next, scientific data on 
requirements for the specific micronutrient and population group should be 
collated, summarized and integrated according to predefined best practice 
methods. Data on requirements may be obtained from studies focusing on 
dose-response relations between dietary micronutrient intake and health 
outcomes such as physical function or disease with measures of 
micronutrient status as an intermediate between intake and health (dose-
response approach). Requirements may also be derived from data on 
micronutrient losses and maintenance and data on absorption/bioavailability 
(factorial approach). The two approaches for estimating micronutrient 
requirements are schematically shown in Figure 2. 
Based on the available evidence, the expert committee has to decide 
whether it is possible to estimate the requirements distribution and derive a 
recommended intake either as an ANR+2SD or an AI. Subsequently, if 
appropriate, policy instruments can be selected to change the nutrition 
situation in order to maximize the likelihood of achieving a desired health 
outcome for the relevant population. 
With this approach, rather than merely focusing on the prevention of severe 
deficiencies and maintaining stores, chronic disease and long-term outcomes 
related to micronutrient intake may also be considered for establishing 
micronutrient recommendations. Although the selection of appropriate long 
term health outcomes can be challenging because there is generally a lack 
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Figure 2 Two approaches for estimating micronutrient requirements 
 
of established data on the precise association between dietary intake levels, 
nutrient status, and long term health outcomes. In addition, etiologies of 
such health outcomes are generally not nutrient-specific but multifactorial, 
reflecting a combination of genetics, environmental exposure, and lifestyle 
patterns. A systematic review approach for collating and summarizing data 
on micronutrient requirements can highlight these challenges by making 
transparent what evidence is available addressing populations and health 
outcomes of interest and what evidence is missing (17-19). 
In the context of the EURRECA network, several micronutrients were 
prioritized for which the available evidence on requirements was 
systematically reviewed. These micronutrients were prioritized according to 
a) the amount of new scientific evidence available on the micronutrient for 
different life-stage groups since 2003, particularly that from randomized 
controlled trials, b) the public health relevance of the micronutrients, and c) 
variations in current micronutrient recommendations (20). One of these 
priority micronutrients was vitamin B12. 
 
VITAMIN B12 
Vitamin B12 is a water soluble vitamin characterized by a large and complex 
chemical structure containing a cobalt ion. Compounds with vitamin B12 
activity are therefore also known as cobalamins. In humans, cobalamins 
function as a cofactor for two enzymes, methionine synthase and 
methylmalonyl coenzyme A (CoA) mutase (21, 22).  
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Methionine synthase catalyzes the remethylation proces of homocysteine to 
the amino acid methionine in which folate serves as donor of a methyl 
group. Methionine is required for the synthesis of S-adenosylmethionine, 
which functions as a methyl group donor in many biological methylation 
reactions, including the methylation of DNA and RNA (21). 
Methylmalonyl CoA mutase catalyzes the conversion of Methylmalonyl-CoA 
(MMA) into succinyl CoA which is an important step in the production of 
energy from proteins and fats. Succinyl CoA is required for the synthesis of 
hemoglobin (22).  
 
Intake  
Humans are unable to synthesize vitamin B12 and therefore fully depend on 
dietary intake (23). The vitamin must be supplied by animal-source products 
in the diet, including meat, fish, dairy, eggs, and liver. Mean vitamin B12 
intakes in Europe range from 3.8 to 9.3 µg per day in men and from 3.5 to 
8.8 µg per day in women based on nine surveys including 28015 adults and 
elderly people (24). A recent food consumption survey in the Netherlands 
showed median intakes of 4.8-5.2 µg per day among 1055 men and 3.6-4.2 
µg per day among 1051 women (25). 
 
Absorption 
Absorption of vitamin B12 is a complex process which is illustrated in Figure 
3. After ingestion of foods containing vitamin B12, first, vitamin B12 needs 
to be released from the proteins in the food by pepsin, which happens in the 
acidic environment in the stomach. The free form of the vitamin immediately 
binds to R-proteins (haptocorrins) secreted by the salivary glands and the 
gastric mucosa. In the duodenum, pancreatic proteases degrade the R-
proteins, releasing the vitamin which then binds to Intrinsic Factor (IF), a 
glycoprotein that the parietal cells in the stomach secrete after being 
stimulated by food. This vitamin B12-IF complex then proceeds to the 
terminal end of the ileum where it is absorbed by specific ileal receptors. 
The capacity of IF mediated absorption is limited, because ileal receptors 
become saturated at intakes of ca 1.5-3.0 µg from a single meal (26, 
27).Once absorbed, vitamin B12 binds to transcobalamin II, also referred to 
as holoTC II. Then it enters the portal circulation and is delivered to cells in 
the body. Only about 20% of the circulating vitamin B12 is bound to 
transcobalamin II and available for cellular uptake, the other 80% is bound 
to the R-proteins Transcobalamin I and III (28, 29). Active absorption of 
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Figure 3 Schematic presentation of the absorption process of vitamin B12  
 
vitamin B12 thus depends on the amount consumed and normal functioning 
of the gastrointestinal tract (30). Small amounts of vitamin B12 (1-3% of the 
ingested amount) can also take place by passive diffusion, which is 
independent of intrinsic factor secretion and normal functioning of the 
gastro-intestinal tract (31, 32). 
Malabsorption of vitamin B12 can occur due to a lack of IF or due to 
intestinal abnormalities, but it may also be the result of a reduced ability to 
release the vitamin B12 from food as in gastric atrophy, a clinical condition 
common among elderly people (28, 33).  
 
Status 
Concentrations of vitamin B12 in serum or plasma are most commonly used 
as a marker of vitamin B12 status. Although the major fraction of circulating 
vitamin B12 is bound to R-proteins that are not involved in delivery of 
vitamin B12 to body cells, it may reflect the general underlying state of 
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vitamin B12 stores (34). Serum/plasma vitamin B12 is therefore better for 
assessing long-term than short-term intake. Functional markers of vitamin 
B12 status including serum or plasma concentrations of holoTC II and MMA, 
have been suggested as more sensitive and specific marker of vitamin B12 
status. HoloTC II represents the fraction of vitamin B12 that is delivered to 
body cells and MMA is the substrate for the vitamin B12 dependent enzyme 
methylmalonyl CoA mutase, so in case of vitamin B12 deficiency MMA levels 
will increase. Each of these markers of vitamin B12 status have been 
reviewed for their effectiveness in responding to oral vitamin B12 
supplementation (32, 35). The available evidence from randomized 
controlled trials (RCT’s) suggested that plasma and serum concentrations of 
total vitamin B12 and MMA were effective biomarkers of a change in vitamin 
B12 intake; although data were limited (n=8 and n=3 respectively). The 
effectiveness of holoTC II as a biomarker of vitamin B12 status could not be 
evaluated as it was measured in only one study. Plasma homocysteine 
concentrations were also evaluated as a potential marker for vitamin B12 
status. Although concentrations of serum and plasma total homocysteine 
were significantly lowered by intervention with vitamin B12, this is not very 
specific for measuring vitamin B12 status because folate and vitamin B12 
both affect this measure (32). 
Based on observations from population-based studies, the prevalence of low 
vitamin B12 status among adults and elderly people is 5-60% depending on 
the cut-off levels used to indicate deficiency (36-38). About 2% of these 
cases result from inadequate intake due to a strict vegetarian or vegan diet 
or limited access to food of animal origin (39, 40), but most cases of low 
vitamin B12 status in adults and elderly are caused by malabsorption of 
protein-bound vitamin B12.  
 
Health outcomes 
Severe vitamin B12 deficiency is associated with megaloblastic anemia, 
gastrointestinal effects, bone metabolism and neurological manifestations 
such as peripheral neuropathy, myelopathy, and most severely, subacute 
combined systems disease characterized by demyelination of dorsal columns 
and corticospinal tract (28, 37, 39, 41, 42). Furthermore low vitamin B12 
status is associated with cognitive decline and it has been suggested that 
cognitive function is associated with vitamin B12 status across the normal 
range (43). Cognitive function includes processes of being aware, knowing, 
thinking, learning and judging (44-46). Several specific domains of cognitive 
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function can be distinguished including memory, executive function, 
processing speed and language (47). Global measures of cognitive function, 
such as the Mini-Mental State Examination, evaluate functioning in different 
domains at the same time (48). A serious loss of cognitive function is 
referred to as dementia and can be characterized by difficulties with many 
areas of cognitive function including memory, language, emotional behavior, 
perception, thinking and judgment (44, 45). Dementia is a very substantial 
cause of morbidity in any aging population, with profound social and 
economic effects. Alzheimer’s Disease (AD) is a common form of dementia, 
circa 60% of the cases, that gets worse over time (49, 50).  
There are many possible mechanisms through which low normal vitamin B12 
status could influence cognitive function. The commonest hypothesis is that 
low vitamin B12 status leads to a deficiency of S-adenosylmethionine and 
thereby to deficient methylation reactions in the central nervous system 
(43). As folate is also involved in the synthesis of S-adenosylmethionine, the 
association of low vitamin B12 status with cognitive impairment may depend 
on the folate status of the population. Whether an optimal vitamin B12 
status has a role in preventing cognitive impairment or dementia should be 
confirmed. If so, this relation could be considered when setting 
recommendations on vitamin B12 intake.  
 
OUTLINE OF THIS THESIS 
The general aim of this PhD-thesis is to contribute to standardization of the 
process for setting evidence-based, transparent and harmonized 
micronutrient recommendations across Europe by addressing two objectives: 
1-To identify the variation in European micronutrient recommendations and 
to explore factors that could explain the observed variation. 
2-To systematically review data on vitamin B12 requirements for adults and 
elderly people. 
 
The first objective is addressed by a descriptive study including comparisons 
of micronutrient recommendations across European countries and a critical 
review of the methods used for establishing these recommendations 
(chapter 2 and 3). 
The second objective is addressed by:  
a-a systematic review on vitamin B12 requirements based on daily losses of 
vitamin B12 and its bioavailability (factorial approach) (chapter 4).  
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b-a systematic review and meta-analysis to evaluate whether the 
associations between vitamin B12 and cognitive function should be 
considered for estimating vitamin B12 requirements (dose-response 
approach) (chapter 5) 
c-cross-sectional and prospective data analyses in cohort data from the 
Hordaland Homocysteine Study to evaluate whether there is an interaction 
between vitamin B12 and folate in relation to cognitive performance 
(chapter 6). 
As low vitamin B12 status in Europe mainly occurs in older adults, the focus 
in this thesis is on adults and elderly people. 
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ABSTRACT 
Background: This paper gives an overview of the available micronutrient 
recommendations in Europe, and provides information on their origin, 
concepts and definitions. Furthermore this paper illustrates the diversity in 
European recommendations on vitamin A and vitamin D, and explores 
differences and commonalities in approaches that could possibly explain 
variations observed. 
Methods: Questionnaires were sent to key informants in the field of 
micronutrient recommendations across Europe to collect information on the 
process of establishing micronutrient recommendations. Furthermore the 
latest reports on nutrient recommendations in Europe were collected. 
Recommendations for vitamin A and vitamin D were compared per sex at 
the ages 3m, 9m, 5y, 10y, 15y, 25y, 50y and 70y. 
Information extracted from the questionnaires and reports was compared 
focusing on: 1) concepts of recommendations, 2) publication years of the 
reports (proxy for available evidence), 3) population groups defined, 4) 
other methodological issues such as selected criteria of adequacy, the type 
of evidence used, and assumptions made.  
Results: In total 23 countries, WHO/FAO and the EC published their own 
reports on nutrient recommendations. France, the Netherlands, Latvia, the 
United Kingdom, WHO/FAO and the EC defined their own recommendations 
and the DACH-countries (Germany, Austria and Switzerland) as well as the 
Nordic countries (Norway, Sweden, Finland, Denmark and Iceland) 
cooperated in setting recommendations. Fifteen countries based their 
micronutrient recommendations on those from other countries or 
organizations.  
Rather than by concepts, definitions, and defined population groups, 
variability in recommendations on intake of vitamins A en D seemed to result 
from differences in criteria for adequacy, assumptions made and type of 
evidence used to establish micronutrient recommendations.  
Discussion: The large variation in current micronutrient recommendations 
for population groups as illustrated for vitamin A and vitamin D strengthens 
the need for guidance on setting evidence based, up-to-date European 
recommendations. Differences in endpoints, type of evidence used to set 
recommendations, experts’ opinions and assumptions are all likely to 
contribute to the identified variation.  
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INTRODUCTION 
Most likely, the first true dietary recommendations were proposed by Dr. 
Edward Smith in 1862 in response to a request from the British Privy Council. 
The council wanted to determine the least cost for which enough food could 
be purchased to prevent starvation and associated diseases among the 
population that was unemployed as the result of the economic depression of 
the time. Since then, many other nutrient recommendations have been 
proposed that were used for the planning of food supplies and ration scales 
during times of war and food shortages, focussing merely on the prevention 
of deficiencies (1). Due to the continuously increasing knowledge on the 
physiological role of nutrients, and the health consequences of micronutrient 
deficient diets, the concept of dietary and nutrient recommendations still 
receives much attention (2). Nowadays most countries in Europe have 
established their own nutrient recommendations to assess the adequacy of 
dietary intakes and to plan desirable dietary intakes both at the individual 
and population level (3-35). These recommendations serve as a basis for 
national or regional nutrition policies, nutritional education programs, food 
regulations and action programs. In 1993, population reference intakes 
(PRIs) were defined for the European Community (EC) to be used for food 
labelling in Europe (14).  
 
The approach to establish nutrient recommendations has changed over the 
course of time. The classical paradigm focused on an adequate intake of 
nutrients via food to prevent deficiencies based on clinical trials. In 1994, 
the Food and Nutrition Board of the Institute of Medicine (IOM) introduced 
dietary reference intakes (DRIs) for the United States of America and 
Canada including many aspects of the conceptual framework from the report 
published in the United Kingdom (35). These DRIs represented a paradigm 
shift in the way nutrient recommendations were established and used by 
practitioners, educators, and researchers. Besides the prevention of 
deficiencies, DRIs were intended to help individuals optimize their health, 
prevent disease, and avoid consuming too much of a nutrient. Furthermore 
the IOM paradigm placed greater emphasis on the distribution of nutrient 
requirements within a population, rather than on a single value and they 
quantified the relationship between a nutrient and the risk of disease based 
on scientific evidence (36). 
In Table 1 the classical paradigm and the new paradigm as presented by the 
IOM are shown.  The DRIs  included four  types of  nutrient-based  
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reference  values: the average nutrient requirement (ANR), the 
recommended intake, the adequate intake (AI) and the upper nutrient level. 
The ANR is defined as the average daily nutrient intake level that is 
estimated to meet the requirements of half of the healthy individuals in a 
particular life-stage and gender group. The recommended intake represents 
the average daily dietary nutrient intake level that is sufficient to meet the 
nutrient requirements of nearly all (97-98%) healthy individuals in a 
particular life-stage and gender group and is derived as ANR+2SD. When an 
ANR+2SD cannot be determined, an AI is estimated as the lowest level of 
intake estimated to be sufficient for nearly all healthy people within the 
population. The upper nutrient level is outside the scope of this paper (36).  
 
Pavlovic et al. (2), King et al. (38) and Prentice et al. (39) compared a 
selection of European nutrient recommendations to provide an overview of 
existing differences in terminologies and reference values. The 
countries/organizations included were: the Nordic countries (Norway, 
Sweden, Denmark, Finland and Iceland), the DACH-countries (Germany, 
Austria and Switzerland), the United Kingdom, the Netherlands, Italy, 
WHO/FAO, and EC. From these comparisons, it appeared that often nutrient 
recommendations have been established involving small and select 
committees of experts. As yet there is no standard approach for deriving 
nutrient recommendations they vary from country to country. This occurs 
even for well-defined population groups that are assumed to have the same 
physiological requirements. Given the lack of standardized methodologies, 
some nations/organizations provide, for example, one single 
recommendation for all adults grouped together, while others provide 
recommendations separately for men and women (38). 
Besides such differences in methodologies, national recommendations are 
reviewed at different times so they may not always be based on the same 
most up-to-date scientific information. Furthermore, cultural and regional 
factors may affect the weighing of evidence and the decision process. This 
results in different national recommendations causing confusion for policy-
makers, health professionals, industry, and consumers within Europe. 
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Harmonization will improve the objectivity and transparency of values that 
are derived by various national, regional and international groups. Where 
harmonization is not possible, transparency is needed on the approaches to 
establish recommendations. This will improve understanding and explanation 
of potential differences between recommendations and simplifies their 
application in policy making.  
 
EURRECA Network of Excellence (www.eurreca.org) 
EURRECA (EURopean micronutrient RECommendations Aligned) is a network 
of excellence funded by the EC and established to identify and address the 
problem of differences between countries in micronutrient recommendations. 
It is originally made up of 34 partners based in 17 countries, drawn not only 
from nutrition science but also from industry, consumer groups, national 
nutrition societies and health professions. Based on previous experiences of 
the University of the United Nations (UNU) (40) and the International Life 
Sciences Institute (ILSI) in the WHO South-East Asia Region (41), EURRECA 
works towards a general framework including harmonized approaches, 
methods and key terms to be used for the development of micronutrient 
recommendations. This general framework will supply a basis for the use of 
micronutrient recommendations across countries/regions for establishing 
public and clinical health objectives, food and nutrition policies, and for 
addressing trade and regulatory issues (38). Further details on the network 
can be found in the article by Ashwell et al. (42). 
 
Aims and objectives  
One of the research activities within EURRECA aims to collate, compare and 
critically evaluate existing micronutrient recommendations for all population 
groups set by European countries/organizations. The objective of this paper 
is to give an overview of the availability of micronutrient recommendations 
in Europe and to provide information on the origin, concepts and definitions 
used, and population groups defined. Furthermore this paper shows the 
diversity in European recommended intakes of vitamin A and vitamin D, and 
aims to explore differences and commonalities in approaches that could 
possibly explain variations observed. These two nutrients were selected 
because vitamin D already had some attention in earlier stages of the 
EURRECA network and vitamin A was selected because much work on this 
nutrient was already done by the authors. In the near future other nutrients 
will be studied and more in depth comparisons will be made. The results of 
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these explorations will be used to identify gaps and opportunities on which 
subsequent activities within EURRECA can build. 
 
METHODS 
Data collation 
To obtain a comprehensive overview of currently used concepts and 
methods in European countries, a questionnaire was developed by the 
Division of Human Nutrition of Wageningen University and Research Centre 
(WUR) in the Netherlands in cooperation with the Food, Consumer 
Behaviour and Health Research Centre of the University of Surrey in the 
United Kingdom. Questions addressed three stages of the process of 
micronutrient policy development. The first stage concerned the approach 
for setting micronutrient recommendations, while the other two investigated 
the process from micronutrient recommendations to nutrition policies and 
options and applications for public health policy. Only the first stage will be 
reported in this overview. 
The questionnaire included open-ended questions on the process of setting 
up recommendations and close-ended questions on the people involved in 
the process and the type of evidence used. Each of the 11 questions 
addressed the nutrients considered to be most relevant to public health: 
vitamins A, D, E, C, B1 (thiamin), B2 (riboflavin), B3 (niacin), B6 (pyridoxine), 
B11 (folate) and B12 (cobalamin), and the minerals sodium, potassium, 
calcium, magnesium, iron, zinc, copper, phosphorus, selenium, and iodine.  
Questionnaires were distributed among seven EURRECA partners, 
(University of Oslo (Norway), National Institute of Public Health (Czech 
Republic), Institute for Medical Research (Serbia), Warsaw Agricultural 
University (Poland), University College Cork (Ireland), WHO Regional Office 
for Europe, and WUR, in August 2007. Subsequently, these partners sent 
the questionnaires to key informants in the field of micronutrient 
recommendations to cover all European countries/regions. Key-informants 
were asked to fill out the questionnaire, if necessary with help of others, and 
return it in September 2007 also providing the latest report on nutrient 
recommendations. After the deadline had expired, the key-informants of the 
missing countries were followed up to increase response rate.  
 
Data extraction 
Both the completed questionnaires and the recommendation reports were 
used to extract micronutrient recommendations, information on their origin, 
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the approach used for deriving them, definitions and concepts, scientific 
evidence used, and population groups considered. Any unclear information 
given in the returned documents was re-checked with the key-informants to 
be sure that correct information was extracted.  
 
Comparison of recommended intakes of vitamin A and vitamin D 
As micronutrient recommendations usually consist of values, ranges, 
multiple values applying to one population group, (for example values for 
different activity levels), or additional amounts for sub groups (for example 
pregnant women), standardization procedures were defined to enable 
comparison of the recommendations. In case of multiple recommendations 
for one population group, the mean of all given values was used. In case of 
a range, the mid value was used. In cases where recommendations were 
not given in the most common unit, values were converted into that unit. 
Standardized recommended intakes of vitamin A and vitamin D were 
compared per sex at the ages 3m, 9m, 5y, 10y, 15y, 25y, 50y and 70y. 
These ages were selected because they indicate points of time in the 
different population groups as defined by countries. More population groups 
were defined for children and adolescents and therefore more ages between 
0 and 18 years were selected. Also comparisons of recommendations for 
pregnant and lactating women were made. To depict the diversity between 
recommended intakes of vitamin A and vitamin D, boxplots were constructed 
in SPSS version 12.0.  
In exploring commonalities and differences between micronutrient 
recommendations, background information extracted from the 
questionnaires and recommendation reports was compared focusing on the 
following items that could help to explain the commonalities and differences 
found: 
1)-The concept of recommendation (ANR+2SD or AI),  
2)-The year of publication of the recommendations (proxy for available 
evidence),  
3)-Population groups for which recommendations were defined,  
4)-Other methodological issues from the paradigm used to establish 
recommendations as selected criteria of adequacy or health endpoints  (e.g. 
preventing deficiencies, plasma concentration), the type of evidence used 
(e.g. review of randomized controlled trials (RCT), experts’ opinion), and 
assumptions made (e.g. physical activity, body weight, sunlight). 
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Information on the first three items was extracted from the recommendation 
reports and information on the last item came mainly from the 
questionnaires. 
 
RESULTS 
Data collation 
Of the total 35 questionnaires sent out, 32 have been completed. No 
reaction after follow up was received from Montenegro and the Russian 
Federation. No reaction from Iceland was received due to a delay in sending 
the questionnaire.  
From 31 European countries, WHO/FAO, and the EC the latest versions of 
reports on nutrient recommendations were collected, including varying 
amounts of background documentation. Reports from Republika Srpska 
(entity of Bosnia and Herzegovina) and Croatia could not be collected in time 
and reports from Federation of Bosnia and Herzegovina (entity of Bosnia and 
Herzegovina) and Montenegro were not received after follow up. No national 
report on nutrient recommendations has been published for the Czech 
Republic.  
 
Available nutrient recommendations in Europe 
Current publications on nutrient recommendations in Europe are listed in 
Table 2. Most of the reports were published since the year 2000. The oldest 
report dates from 1990 (Romania) and the most recent one is published in 
2007 (Spain). 
Table 2 also shows that 23 countries and WHO/FAO and the EC have their 
own reports on nutrient recommendations (own, own+adopted and 
own+shared). France, Latvia, the Netherlands, the United Kingdom, 
WHO/FAO and the EC defined their own recommendations (own) and 15 
countries based their recommendations on those from other countries or 
organizations (own+adopted). The DACH-countries as well as the Nordic 
countries cooperated in setting recommendations, indicated by ‘shared’ in 
Table 2. Greece, Portugal, Estonia and Slovenia adopted recommendations 
from the EC, WHO/FAO, the Nordic countries and the DACH-countries 
respectively. The publication from which Albania and Federation of Bosnia 
and Herzegovina adopted their recommendations was not clear. The origin 
of recommendations was unknown for 2 countries (Romania and the Russian 
Federation). 
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Table 2 List of European and key non-European countries with published 
micronutrient recommendations and their recommendation report’s origin  
Country/ 
Organisation 
Year 
published 
Origin Remark 
Own Shared Adopted 
Albania (3) 2005 x  x Adopted from literature, especially from 
the Linus Pauling institute 
Austria (4) 2000  x  Shared document with Germany and 
Switzerland (the DACH-countries) 
Belgium (5) 2006 x  x Based on WHO (2003) (44), EC (1990) [no 
ref], European countries that are 
geographically and culturally related to 
Belgium, e.g. The United Kingdom (1991) 
(35), the Netherlands (2001) (45) and 
France (2001) (13) 
Federation of 
Bosnia and 
Herzegovina-1 
(6) 
2004   x Adopted from Food and Nutrition Board 
(1989) [no ref] 
Republika of 
Srpska-1 (7) 
2005 x  x Based on WHO/FAO-reports (46-49), and 
IOM (2003) (50) 
Bulgaria (8) 2005 x  x Based on IOM-reports (50) and WHO 
(2003) (44) 
Croatia (9) 2004 x  x Aligned with EU legislation 
Czech Republic  Not 
published 
  x Adopted from Nutrition Society [no ref] 
and EC (1993) (14) 
Denmark (10) 2004  x  Shared document with Finland, Iceland, 
Norway, Sweden (Nordic countries) 
Estonia (11) 2006   x Adopted from the Nordic countries (2004) 
(10). Translated in local language 
Finland (10, 12) 2004  
2005 
x x  Shared document with Denmark, Iceland, 
Norway, Sweden (the Nordic countries) 
and translated into own country specific 
document 
France (13) 2001 x    
Germany (4) 2000  x  Shared document with Austria and 
Switzerland (the DACH-countries) 
Greece  1993   x Adopted from EC (1993) (14)  
Hungary (15) 2005 x  x Based on EC (1993) (21) and IOM-reports 
(50) 
Iceland (10,16) 2004  
2006 
x x  Shared document with Denmark, Finland, 
Norway, Sweden (the Nordic countries) 
and translated into own country specific 
document; Own recommendations for 
vitamin D and calcium 
Ireland (17)  1999 x  x Adopted from EC (1993) (14) and the 
United Kingdom (1991) (35); Own 
recommendations for folate, iron, calcium, 
vitamin C 
Italy (18) 1996 x  x Based on Food and Nutrition Board (1989) 
(51) and EC (1993) (14) 
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Table 2 (continued)  
Country/ 
Organisation 
Year 
published 
Origin Remark 
Own Shared Adopted 
Latvia (19) 2001 x    
Lithuania (20) 2000 x  x Adopted from the Nordic countries (1989) 
[no ref]; EC (1992) [no ref]; the United 
Kingdom (1991) (35), Food and Nutrition 
Board (1989) (51) 
Montenegro 2002   x Adopted from IOM (2001) (36) 
Netherlands 
(21-23) 
1992 
2000 
2003 
x    
Norway (10, 24) 2004  
2005 
x x  Shared document with Denmark, Finland, 
Sweden, Iceland) (the Nordic countries) 
and translated into own country specific 
document 
Poland (25) 1996 x  x Based on Food and Nutrition Board (1989) 
(51), the United Kingdom (1991) (35) and 
EC (1993) (14) 
Portugal  2004   x Adopted from WHO/FAO (2004) (26) 
Romania (27) 1990 x  x Partly based on WHO/FAO (2004) (26) 
Russian 
Federation (28) 
1992    No data on origin 
Serbia (29)  1994 x  x Adopted from unknown source(s) 
Slovakia (30) 1997 x  x Adopted from unknown source(s) 
Slovenia (31) 2000   x Adopted from the DACH-countries (4). 
Translated in local language  
Spain (32) 2007 x  x Adopted from unknown sources. Published 
as a book chapter 
Sweden (10, 
33) 
2004 2005 x x  Shared document with Denmark, Finland, 
Iceland, Norway (the Nordic countries) 
and translated into own country specific 
document 
Switzerland (4) 2000  x  Shared document with Austria and 
Germany (the DACH-countries); Own 
recommendations for Iodine 
FYR Macedonia 
(34)  
2001 x  x Based on recommendations of Former 
Republics of Yugoslavia (no ref) and the 
United Kingdom (35) 
United Kingdom 
(35) 
1991 x    
EC (14) 1993 x    
WHO/FAO (26) 2004 x    
 1 Entities of Bosnia and Herzegovina 
FYR Macedonia, Former Yugolslav Republic of Macedonia; EC, European Community; WHO/FAO, 
World Health Organization/Food and Agricultural Organization of the United Nations; No ref, No 
reference available 
own = country specific recommendations developed 
shared = recommendations set by one collaborative committee representing different countries 
adopted = recommendations adopted  from at least one other country/organization 
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Concepts and definitions to define micronutrient recommendations 
Different terms have been used for the total set of nutrient 
recommendations (DRIs, DRVs RDAs etc). Within these sets, various terms 
have been used to express the different types of reference values. Though 
terminology differed substantially between countries (e.g. recommended 
nutrient intake, recommended daily amount of absorption, population 
reference intake), all these concepts could be considered as equivalent to 
the three basic concepts: ANR+2SD, AI and an acceptable range which is 
defined as a range of intakes high enough to avoid deficiency and low 
enough to avoid undesirable toxic effects (14). Only the Hungarian and 
Polish publication included a deviating term, which was defined as the intake 
level that is sufficient for 100% of the healthy population (Table 3). For 
Albania, Latvia, Romania, Slovakia, Spain, and the former Yugoslav Republic 
of Macedonia, the concept of the recommendation (ANR+2SD or AI) was not 
clear from the reports and questionnaires. In general, reports provided an 
ANR+2SD for most nutrients, but for sodium, potassium, selenium, copper, 
vitamin D, vitamin E, and magnesium, an AI was often provided instead.  
 
Population groups 
Age span 
Table 4 lists the population groups encountered in the collated reports on 
nutrient recommendations. Deviations from generally defined population 
groups per country are given in foot notes. Table 4 shows that except for a 
few countries, most recommendations cover all ages. Exceptions include the 
Nordic countries, Italy, and the EC, which do not give recommendations for 
infants under 6 months, and Serbia provides values only for children ages 1 
to 14 years. Lithuania covers people up to the age of 65 years. 
 
Children and adolescents 
The first year of life is split up in two to four age categories. For the age 
span of 1 to 18 years, the grouping of ages differs substantially: the number 
of age categories varies between four and six and different age cut-off 
points are used. All publications, except for the Netherlands, start to 
separate recommendations for men and women between the age of 10 to 
15 years. The report from the Netherlands provides gender-specific separate 
recommendations from the age of 1 year, although actual recommendations 
for men and women do not differ for all age groups and nutrients.  
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Table 3 Description of currently available recommendations across Europe 
Country Type of recommendation used Micronutrients 
Albania (3) Insufficient information All 
Belgium (5)   ANR+2SD 
 AI/AR 
AI/AR for vitamin D, sodium, 
potassium, iodine, copper, other 
ANR+2SD 
Bulgaria (8)  ANR+2SD 
 AI 
AI for calcium, sodium, potassium, 
other ANR+2SD 
DACH-countries (4)  ANR+2SD 
 AI/AR 
AI/AR for vitamin E, sodium, 
potassium, copper, selenium, other 
ANR+2SD 
France (13)  ANR+2SD 
 AI 
AI for vitamin D, vitamin E, folate, 
riboflavin, thiamin, selenium, iodine, 
other ANR+2SD 
Hungary (15)  Safe intake: Intake level that fulfils the 
need of 100% of the population 
 Maximum intake :insufficient information 
Maximum intake for sodium , other 
safe intake  
Ireland (17)  ANR+2SD All 
Italy (18)   ANR+2SD 
 AR 
AR for vitamin E, sodium, 
magnesium, other ANR+2SD 
Latvia (19)   Insufficient info provided All 
Lithuania (20)  ANR+2SD All 
Netherlands (21-23)  ANR+2SD 
 AR 
 AI 
 
ANR+2SD for vitamin B6, vitamin 
B12, folate, thiamin, riboflavin, 
niacin; AR for magnesium, zinc, 
copper, phosphorus, selenium; other 
AI 
Nordic countries (10)  ANR+2SD All 
Poland (25)  ANR+2SD 
 Recommended intake: Intake level that 
fulfils the need of 100% of the 
population.  
 AI/AR 
AI/AR for copper, sodium, 
potassium, other ANR+2SD and 
recommended intake  
 
Romania (27)  Insufficient information All 
Russian Federation 
(28) 
 Insufficient information 
 AI 
AI for copper 
 
Serbia (29)  ANR+2SD All 
Slovakia (30)  Insufficient information All 
Spain (32)  Insufficient information Insufficient information provided 
FYR Macedonia (34)  ANR+2SD All (ranges for copper, selenium, 
sodium, potassium) 
United Kingdom (35)  ANR+2SD 
 AI/AR 
AI/AR for copper, iodine, potassium, 
selenium, sodium, , other ANR+2SD 
EC (14)  ANR+2SD 
 AR 
AI/AR for vitamin D, sodium, 
magnesium, other ANR+2SD 
WHO/FAO (26)  ANR+2SD 
 Safe intake: intake level that prevents 
clinical signs of deficiency and allows 
normal growth, but is does not protect 
vitamin A status during prolonged 
periods of infection or other deceases 
 AI 
Safe intake for vitamin A; AI for 
vitamin E, other ANR+2SD  
 
 
 
DACH-countries, Germany, Austria and Switzerland; Nordic countries, Norway, Sweden, Finland, Denmark 
and Iceland; FYR Macedonia, former Yugoslav republic of Macedonia; EC, European Community; WHO/FAO, 
World Health Organization/Food and Agricultural Organization; ANR+2 SD, Average Nutrient Requirement 
plus two standard deviations (=Recommended intake); AR, Acceptable Range; AI, Adequate Intake 
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Adults 
The number of age categories defined for adults varies from one to five but 
most reports include recommendations for four age categories. 
Discrepancies also emerge for the higher age levels. Most often the highest 
age group is ≥ 60, ≥ 65, or ≥ 75 years of age. The United Kingdom, 
however, have ≥ 51 years as an upper age group, Italy defined ≥ 51 years 
for women and ≥ 60 years for men, both Albania and Latvia defined the 
upper age group as ≥ 19 years and the EC as ≥ 18 years. All countries, 
except Latvia, give recommendations separately for men and women, 
although Latvia does separate recommendations on minerals for the two 
sexes. 
 
Other criteria considered in setting micronutrient recommendations 
All countries except Romania provide separate micronutrient 
recommendations for pregnant and lactating women. The Albanian and the 
Bulgarian recommendations for both pregnant and lactating women have 
been further split up in ≤ 18 years and ≥ 19 years. The United Kingdom and 
the Russian Federation split up the group of lactating women according to 
the period of lactation (≤ 4 months and > 4 months for the United Kingdom 
and < 7 months and ≥ 7 months for the Russian Federation). 
Some countries distinguish physical activity levels (PAL) per age group. 
Lithuania provides micronutrient recommendations for four physical activity 
levels and two different body weights per age category and sex. The Russian 
Federation splits up the recommendations for adults in five physical activity 
levels for men (1.4, 1.6, 1.9, 2.2, and 2.5), and four levels for women (1.4, 
1.6, 1.9, and 2.2). Poland, Romania and Slovakia distinguish three physical 
activity levels: low, moderate and high. In addition Slovakia also gives 
recommendations for students with and without physical workload. For 
specific nutrients other subgroups are sometimes distinguished, for example 
for vitamin C, Bulgaria and the DACH-countries provide a separate 
recommendation for smokers. Other characteristics influencing requirements 
that are mentioned in recommendations for specific nutrients are: sunlight 
exposure, skin colour, menstrual blood loss, energy intake (especially for 
thiamin, riboflavin, and niacin), protein intake (vitamin B6) or fat intake 
(vitamin E) and bioavailability for the nutrients iron and zinc. 
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Diversity in recommended intakes of vitamin A and vitamin D 
Vitamin A 
Figure 1 shows box plots that illustrate the variability in recommended 
vitamin A intakes in Europe separately for men and women. Supplemental 
Tables S1 and S2 present the current available standardized recommended 
vitamin A intakes (retinol equivalents, RE) by country and sex. 
The median recommendation on intake of vitamin A for men and women are 
the same up to the age of 10 years, 400 μg for ages 3 and 9 months, 450 
μg for age 5 and 650 μg for age 10. For the other ages the median 
recommendation for women is 800 μg (15 years) and 700 μg (>15 years), 
which is lower than for men (i.e. 900 μg for ages 15, 25 and 50 years and 
850 μg for age 70 years).  
Recommended vitamin A intakes from the EC, Ireland, Italy, and the United 
Kingdom are lower than the median for all ages for both men and women 
and recommendations from Belgium only for men. Recommendations higher 
than the median for all ages are found in reports of the DACH-countries, and 
Romania for both men and women.  
For men the largest absolute difference in recommended vitamin A intakes 
between countries amounts to 500 μg RE/day (range at 10 years: 500-1000 
μg; range at 15 years: 600-1100 μg). The smallest range is observed at age 
3 months, i.e. 150 μg (range: 350-500 μg). For women, the largest variation 
is found at the ages 25 and 50y, with a range of 500-1000ug RE/day. The 
smallest difference is similar to that found for men. For pregnant women the 
median for recommended vitamin A intakes is 800 μg and for lactating 
women 1125 μg. The individual European recommendations range from 700 
to 1100 μg and from 850 to 1500 μg for pregnant and lactating women 
respectively. 
 
When comparing methodological approaches for recommended vitamin A 
intakes in Europe, all reports provide an ANR+2SD, except the Netherlands, 
which provide an AI (Table 2). The defined population groups in the 
different recommendations vary largely (Table 4). However, in each report 
recommended vitamin A intakes are mostly the same from the age of 15 up 
to 70 years. Comparing publication dates, Spain and the DACH-countries 
that were published more recently provided high values, although the 
relatively high recommendations from the Netherlands were published in 
1992 and the low recommendations from WHO/FAO in 2004. 
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Figure 1 Diversity of recommended vitamin A intakes (μg retinol 
equivalents (RE)) for men (top) and women (bottom) in Europe for selected 
life stages (3m, 9m, 5y, 10y, 15y, 25y, 50y, 70y, (pregnancy, lactation)) 
The boxes indicate the interquartile range (IQR=x75-x25) in which the median (x50) of all 
recommended vitamin A intakes is indicated by a horizontal line. Vertical lines connected to the 
upper and lower side of the box indicate values less than 1.5*IQR below the first quartile or 
above the third quartile. Values not included in this range are considered as an outlier and are 
indicated by open dots (>1.5*IQR above x75 or below x25) and stars (>3*IQR above x75 or 
below x25). DACH: Austria, Germany and Switzerland. 
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The criteria for adequacy or the health endpoints used for defining 
recommended vitamin A intakes were not always reported in the 
questionnaire responses or background documents (data not shown). 
General health and preventing deficiencies were most frequently mentioned. 
In the Netherlands (high values) Belgium (values just below the median) 
and the DACH-countries (high values) an adequate reserve in the liver was 
the main functional criteria of nutritional adequacy. Most recommended 
vitamin A intakes are based on data from observational cohort studies, or 
expert committees. Information on the type of evidence on which 
recommendations were based was, however, not always clear from the 
questionnaire responses and the type of evidence was unknown for some 
countries (Lithuania, Serbia, The former Yugoslav Republic of Macedonia) 
(data not shown). If, and what, assumptions were made when defining 
recommended vitamin A intakes was not clear from the information provided 
in the questionnaires response or from the reports.  
 
Vitamin D 
Figure 2 and supplemental Tables S3 and S4 present an overview of the 
available standardized recommended vitamin D intakes. The median of 
recommended intakes for both men and women is 10 μg for ages 3 and 9 
months, 5 μg for ages 5, 10, 25 and 50 years, 6.9 μg for age 15 years and 
7.5 μg for age 70 years. No publication includes values that are below or 
higher than the median for all ages. The differences between countries are 
largest for infants in the age of 3 and 9 months, with values ranging from 5 
μg (Albania, Bulgaria, the Netherlands and WHO/FAO) to 22.5 μg (France) 
and smallest for the ages of 5, 10, 15, 25 and 50 years with values ranging 
from 2.5 μg (the Russian Federation, the Netherlands) to 10 μg a day. 
Similar recommended vitamin D intakes are given for pregnant and lactating 
women, varying from 5 to 11.3 μg, with a median of 10 μg. The former 
Yugoslav Republic of Macedonia gives the highest recommendation and 
Albania, Bulgaria, the DACH countries, Romania, and the WHO/FAO (5 μg) 
the lowest.  
 
Most countries provide an ANR+2SD for vitamin D, except for Belgium 
(acceptable range and AI), the EC (acceptable range), France (AI), and the 
Netherlands (AI). These AIs and acceptable ranges are not higher over all 
ages than the other recommendations. The lowest recommended vitamin D 
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intakes were published by the Russian Federation and the United Kingdom in 
1991 but also by the Netherlands in 2000. 
In general, criteria for adequacy on which recommendations are based are 
‘health’ and ‘prevention of deficiency as measured by the serum level of 25-
hydroxy vitamin D3’. ‘Appropriate bone formation’ is mentioned as a criterion 
for adequacy in the questionnaire from Belgium, Italy, and the Netherlands 
(data not shown). Recommended vitamin D intakes appear to be based 
most often on expert’s opinion or on values that are borrowed from another 
country. Several countries reported that some assumptions were made when 
setting up recommended vitamin D intakes: the Italian recommendations are 
based on the assumption that in the Italian environment sun exposure 
guarantees adequate physiological vitamin D production. They provide a 
range starting from 0 µg for people with an adequate sun exposure. The 
upper level of the range applies to people without sunlight exposure (10 or 
25 μg depending on the age). Also recommendations from the United 
Kingdom for adults are 0 μg a day, based on the assumption that sun 
exposure will provide the amount sufficient for an adequate vitamin D status 
during summer and allow for stores to be laid down to support vitamin D 
status in winter. The Netherlands define normal exposure to sunlight as daily 
15 minutes with at least hands and face uncovered, whereas the Nordic 
countries assume that exposure of the face, arms, hands, and legs to 
sunshine for 6-8 minutes, 2 to 3 times a week is more than adequate to 
satisfy the vitamin D requirements. However, they indicate that dietary 
vitamin D is essential to ensure satisfactory vitamin D at northern latitudes. 
In setting vitamin D recommendations for the Polish population sunlight 
exposure was considered to be too diverse between adults and therefore no 
recommended intake for adults was set (data not shown).  
 
DISCUSSION  
The results from this comparison of micronutrient recommendations show 
similarity in concepts and definitions used to establish recommendations on 
micronutrient intake in European countries, but also considerable diversity in 
defined population groups and levels of current recommendations was 
observed as illustrated by two vitamins. In exploring elements of the 
paradigm, differences between publications in criteria of adequacy, type of 
evidence used, and assumptions made, were recognized that could explain 
disparities in recommendations between countries 
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Figure 2 Diversity in recommended vitamin D intakes (μg) for men (top) 
and women (bottom) in Europe for selected life stages (3m, 9m, 5y, 10y, 
15y, 25y 50y 70y (pregnancy, lactation)) 
The boxes indicate the interquartile range (IQR=x75-x25) in which the median (x50) of all vitamin 
D recommendations is indicated by a horizontal line. Vertical lines connected to the upper and 
lower side of the box indicate values less than 1.5*IQR below the first quartile or above the 
third quartile. Values not included in this range are considered as an outlier and are indicated 
by open dots (>1.5*IQR above x75 or below x25) and stars (>3*IQR above x75 or below x25).  
Russian_fed: Russian Federation; Nordic: Norway, Sweden, Finland, Denmark and Iceland; EC: 
European Community; UK: United Kingdom. 
Chapter 2: European micronutrient recommendations 
46 
 
Availability of current micronutrient recommendations 
Many countries (22 out of 33) adopted recommendations from other 
publications, most frequently from the EC, WHO/FAO and IOM (45, 43, 53). 
The EC report (14) was meant to provide practical advice and 
recommendations for a number of purposes including nutrition labelling and 
Community programmes on research and nutrition. The Scientific Committee 
for Food of the EC tried to harmonize existing national reports and also to 
include the most recent data. The WHO/FAO and the IOM publications both 
contain dietary reference values based on extensive scientific evidence 
evaluated by a large number of experts from all over the world or the United 
States/Canada respectively. They constituted an important source of 
information for all who work in the areas of nutrition, agriculture, food 
production and distribution, and health promotion (26, 50).  
 
Due to the continuous changes in scientific knowledge, revisions of 
recommendations should be planned for every 5 to 10 years in order to keep 
them updated in the light of the most up-to-date scientific evidence (38, 52). 
In view of this, the present overview of recommendations is time bound, as 
some countries have already planned to revise their recommendations soon. 
Belgium, the Republika Srpska (entity in Bosnia and Herzegovina), the Czech 
Republic, Italy, Lithuania, Poland, Slovakia, the Netherlands and the United 
Kingdom will have some or all of their recommendations revised or set 
before 2010. The EC publication dates from 1993 and one of the tasks of the 
European Food Safety Authority (EFSA) is to update this advice from the 
Scientific Committee on Food on PRI’s. The EFSA Panel on Dietetic Products, 
Nutrition and Allergies (NDA) intends to start revising the micronutrients 
PRIs in 2008. EURRECA on the other hand works towards a general 
framework including harmonized approaches, methods and key terms to be 
used for the development of micronutrient recommendations. Therefore 
EURRECA will work in close collaboration with EFSA, to improve the process 
and scientific basis on which micronutrient recommendations for European 
populations can be developed.  
 
Concepts and definitions  
One of the factors that could explain differences between countries are the 
concepts and definitions that were used. However, all countries or regions 
included in this paper provided recommendations that were based on an 
ANR with the recommended intake usually defined as 2SD above the 
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average. In the comparison of recommended vitamin A intakes it appears 
that all publications provide an ANR+2SD, except for the Netherlands that 
provide an AI (Table 2). By definition an AI may be higher than the 
ANR+2SD and therefore could explain the relatively higher values from the 
Netherlands. Most countries provide an ANR+2SD for vitamin D, but the 
recommendations of countries that provide an AI or an acceptable range for 
vitamin D were not higher over all ages than the others.  
 
Population groups in current micronutrient recommendations 
To estimate the nutrient requirement of a specific population, first one 
needs data on requirements of a population with similar characteristics (38). 
The definitions of age groups, each considered as relatively homogenous 
with regard to nutrient requirement, differ between countries, especially 
during childhood, puberty and at older age. This may be due to differences 
in reasoning in defining population groups; however in most publications 
these arguments are not clearly described. An example of an argument is 
given in the EC report that provides only one age group for adults (≥ 18 
years) (14). The report states that although elderly are prone to suffer from 
deficiencies due to a reduced food intake, inability to care for themselves or 
illness causing malnutrition, there is no evidence that micronutrient 
requirements of the elderly differ from those of middle-aged adults. Except 
for vitamin D the EC provides no different values for elderly. On the contrary, 
the Netherlands (22, 23), defined four age groups in adulthood, 19-21, 22-
49, 50-64, and ≥ 65 years, using reference weights and heights from a 
representative sample of the population, and in doing so they follow the IOM 
(50). These examples illustrate the differences in underpinning the definition 
of population groups. 
 
In general, when data specific to physiological state are not available to 
estimate nutrient requirements, extrapolation from other growth states or a 
factorial approach, which estimates nutrient requirement based on the 
expected nutrient losses via e.g. urine, feces, and skin and accounting for 
differences in assumed bioavailability, are used instead (52, 53). For some 
population groups, especially infants, children, adolescents, elderly, post-
menopausal women, pregnant and lactating women, nutrient requirements 
are often extrapolated from the recommendation applying for adults. For the 
recommendations included in this overview it is not clear whether values are 
originally based on average requirements of the population group, or if they 
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are based on requirements estimated by the factorial approach or 
extrapolation. Only for infants (0 to 1 years) it is often indicated that 
nutrient values are extrapolated from the composition of breast milk. 
Prentice et al. (39) showed that the wide differences in perceived nutrient 
requirements between countries might be partly attributed to real 
physiological and environmental differences, but were mostly due to the 
differences in judgements about the best methodological approach to use 
and in the way theoretical approaches were applied. Unless sufficient data 
on nutrient requirements will be available for all life-stage groups some time, 
extrapolation from one group to another is necessary. The scientific basis for 
the method chosen should be completely transparent and thoroughly 
described for each nutrient and life stage group (53). Atkinson and Koletzko 
(53) recommend that for the harmonization of dietary reference values, 
standardization of age groups should be biologically based (growth and 
pubertal stages) with consideration of relevant developmental milestones 
throughout childhood. This requires agreement and transparency on which 
data to use concerning growth standards, body sizes and composition, fetal 
and maternal accretion in pregnancy and milk composition, and on inclusion 
of appropriate adjustments (metabolic efficiency, weight change or physical 
activity). 
 
In the comparison of recommended intakes of vitamin A and vitamin D in 
this paper, values were mostly the same for the age of 15 up to 70 years 
within publications. Therefore it seems unlikely that differences in population 
groups are a key issue for disparities between publications. The definition of 
population groups might be an issue for other nutrients, but this needs to be 
studied further.  
 
A few countries, Lithuania, Latvia, Poland, Romania and Slovakia, provide 
recommendations for different physical activity levels. An explanation could 
be that these countries are all from Eastern Europe where lifestyles might be 
less sedentary than in Western Europe (54). 
 
Criteria for adequacy, assumptions and type of evidence 
As they may explain differences between recommendations, questions on 
the criteria/endpoint(s) used to determine adequate intake per nutrient were 
included in the questionnaire. This information was, unfortunately, often not 
included in the received reports. However, the answers were often 
Chapter 2: European micronutrient recommendations 
49 
 
formulated in a very general manner, for example ‘health’ or ‘prevention of 
deficiencies’. This limited the comparison of criteria for adequacy. In all 
probability the question as included in the questionnaire was not clearly 
enough formulated, resulting in answers that were too less informative. 
  
It is obvious that estimated requirements may vary with the endpoint or 
criteria for adequacy chosen. Nutrients have multiple sites of action in 
human metabolism and therefore it is possible to demonstrate abnormal 
function in one parameter measured or observed as a result of inadequate 
intake of a nutrient, while other parameters requiring the same nutrient 
intake appear adequate. For example a nutrient requirement based on the 
amount that prevents the clinical symptoms of a nutrient deficiency will be 
lower than one based on the amount that sustains nutrient stores or 
reserves (38). Nutrient adequacy is a matter of definition, and may be a 
policy decision. Thus it is possible to have multiple requirements, each 
corresponding to a different indicator or criterion of adequacy. It is then up 
to nutrition and public health policy planners to determine which level of 
adequacy is desirable or possibly attainable in the population group of 
interest (52). 
 
Besides criteria for adequacy, the type of evidence used when establishing 
recommendations could explain differences between recommendations. In 
the questionnaire informants were asked to indicate the type of evidence 
that was used for each nutrient against a list with different possibilities 
(including RCT’s, observational studies, mechanistic studies, experts’ opinion, 
and borrowed from another country). Experts’ opinion was the most 
frequently given answer, which unfortunately does not reveal on which 
types of evidence the experts have based their opinion, and how. Although 
some reports list all the experts that were included in the working groups, 
for the countries without clear background reports, this information was 
often missing.  
 
The year of publication was used as a proxy for the age of the available 
scientific evidence. Even though publication years varied between 1990 and 
2006, we cannot conclude that the year of publication was related to the 
level of the recommendation: For both vitamin A and vitamin D high intakes 
were recommended in both relatively old and recent publications, and the 
same was true for low values.  
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Opportunities: What can EURRECA do with this information on the 
status quo? 
From the results of this comparison of micronutrient recommendations 
across Europe, it became clear that the concepts and definition used for 
setting them is quite similar throughout Europe. But even though many 
countries adopt and adapt recommendations from other publications, 
disparities remain. In our search for possible explanations for these 
disparities, we aimed at comparing different aspects of underlying 
approaches for setting up micronutrient values, but unfortunately there was 
a lack of transparency and completeness of the available information. An 
important opportunity for EURRECA is to develop tools to show how 
micronutrient recommendations can be devised for different population 
groups in a transparent manner. These tools should provide guidance on 
how to interpret data, how to take into account different criteria for 
adequacy and how to weigh different types of evidence in defining 
requirements. Expert committees throughout Europe can then use these 
tools to make decisions in a harmonized way and provide transparently 
based micronutrient recommendations. 
 
In the EC call which led to the commissioning of EURRECA, vulnerable 
groups were identified as population groups that are prone to extremes of 
intake and those identified were: infants, children, adolescents, adults, 
pregnant and lactating women, post-menopausal women, elderly, 
immigrants and low income groups. Our overview shows that immigrants, 
low-income, post-menopausal women were never a specified target groups 
in any recommendation report. The only exception is iron recommendations 
for post menopausal women. Within EURRECA variation in micronutrient 
needs based on micronutrient status, functional status and especially health 
and physiological status will be identified and parameters (biomarkers) for 
vulnerability will be explored. Based on this information population groups to 
be considered vulnerable will be identified. Guidance can then be given on 
whether and in what way micronutrient recommendations should be 
extended to these groups. 
 
CONCLUSIONS  
This paper provides an overview of the availability of micronutrient 
recommendations in Europe and provides information on the origin, 
concepts and definitions used, and population groups defined used for 
Chapter 2: European micronutrient recommendations 
51 
 
setting current micronutrient recommendations in Europe. A comparison of 
recommended intakes of vitamin A and vitamin D is included in order to 
explore possible explanations for disparities between publications. The large 
variation in current recommendations for population groups as illustrated for 
vitamin A and vitamin D strengthens the need for guidance on setting 
evidence based, up-to-date European recommendations. Differences in 
health endpoints, studies used to set recommendations, experts’ opinions 
and assumptions are all likely to contribute to the identified variation, but 
the background information we collated does not allow us to disentangle the 
relative contribution of these different aspects due to lack of transparency. 
EURRECA has an excellent opportunity to develop tools to improve 
transparency on the approaches used, including the selection of criteria for 
adequacy, weighing of evidence, and interpretation of data to support those 
who develop quality assured, evidence-based harmonized micronutrient 
recommendations across Europe and elsewhere. 
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ABSTRACT  
Objective: To signal key issues for harmonizing approaches for establishing 
micronutrient recommendations by explaining observed variation in 
recommended intakes of folate, vitamin B12, iron and zinc for adults and 
elderly people. 
Design: We explored differences in recommended intakes of folate, vitamin 
B12, iron and zinc for adults between nine reports on micronutrient 
recommendations. Approaches used for setting recommendations were 
compared as well as eminence-based decisions regarding the selection of 
health indicators indicating adequacy of intakes and the consulted evidence-
base. 
Results: In nearly all reports, recommendations were based on the average 
nutrient requirement. Variation in recommended folate intakes (200-400 
µg/d) was related to differences in the consulted evidence-base, whereas 
variation in vitamin B12 recommendations (1.4-3.0 µg/d) was due to the 
selection of different CVs (10-20%) and health indicators (maintenance of 
haematological status or basal losses). 
Variation in recommended iron intakes (men 8-10 mg/d, premenopausal 
women 14.8-19.6 mg/d, postmenopausal women 7.5-10 mg/d) was 
explained by different assumed reference weights and bioavailability factors 
(10-18%). Variation in zinc recommendations (men 7-14 mg/d, women 4.9-
9 mg/d) was also explained by different bioavailability factors (24-48%) as 
well as differences in the consulted evidence-base.  
Conclusions: For the harmonization of approaches for setting 
recommended intakes of folate, vitamin B12, iron and zinc across European 
countries, standardized methods are needed to a)-select health indicators 
and define adequate biomarker concentrations, b)-make assumptions about 
inter-individual variation in requirements, c)-derive bioavailability factors, 
and d)-collate, select, interpret and integrate evidence on requirements. 
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INTRODUCTION 
Adequate nutrient intakes are critical to health maintenance and contribute 
to the prevention of chronic diseases and functional decline (1-13). Many 
countries and organizations across Europe provide micronutrient 
recommendations that serve as a basis for good health(14). Although 
different terms are used to express such recommendations, e.g. Population 
Reference Intakes, Recommended Intake, Recommended Daily Allowance, 
they all refer to the daily intake level that is sufficient to fulfil the 
requirements of nearly all healthy individuals in a defined population (14, 
15).  
There are two main approaches for establishing micronutrient 
recommendations: the requirement-based approach, and the intake-based 
approach. The first approach evaluates evidence across intervention and 
observational studies on the relation between intake and selected health 
indicators. These health indicators indicate the adequacy of intake to fulfil 
physiological needs and may include physiological, biochemical and 
functional measures; equilibrium maintenance and disease incidence (16). 
Based on the distribution of nutrient requirements both the average nutrient 
requirement (ANR), also referred to as average requirement or estimated 
average requirement, and the recommended intake can be derived 
(ANR+2SD). 
The intake-based approach is used when evidence needed to estimate the 
distribution of nutrient requirements is lacking or incomplete. Consequently, 
recommendations are based on the lowest level of intake estimated to be 
sufficient for nearly all healthy people within the population, also referred to 
as Adequate Intake (AI).  
Micronutrient recommendations serve as an important basis for public health 
nutrition policy. If the distribution of requirements can be estimated, the 
ANR can be used to assess the prevalence of adequate intakes within a 
population. Furthermore, if the prevalence of adequate intakes is not 
satisfactory, recommended intakes can be used for planning interventions to 
improve the situation (17-19) 
Currently, there is considerable variation in micronutrient recommendations 
between countries and this can cause confusion among policy makers, 
consumers, food industry and health professionals (14, 20-22). This 
variation may be due to differences between populations, e.g. in 
bioavailability from national diets, but it may also be due to differences in 
approaches used for establishing recommendations (ANR+2SD vs. AI) (23), 
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and eminence-based decisions regarding the selection of relevant health 
indicators and data underlying recommendations (16, 19, 23, 24). 
Harmonization of the process for establishing micronutrient 
recommendations will increase transparency, objectivity and reliability of 
recommendations and contribute to aligned nutrition policy across 
Europe(19, 23)  
This paper aims to contribute to the understanding of the variation in 
recommendations and to signal key issues for harmonizing approaches for 
establishing recommended intakes for adults and elderly people of four 
micronutrients (folate, vitamin B12, iron and zinc) that were prioritized by 
the Network of Excellence EURRECA(25-27). First we explored differences in 
current recommendations between reports from key European and non-
European countries/organizations. Secondly, we examined whether the 
approaches used and the eminence-based decisions made for establishing 
recommendations contribute to the observed variation. 
 
METHODS  
Collection and comparison of recommended micronutrient intakes  
By the end of 2007, and early 2008, the latest reports on micronutrient 
recommendations were collected from 31 European countries and 
organizations in collaboration with local key-informants involved in setting 
these recommendations as described elsewhere (14).  
Eight European countries, clusters of countries or organizations provided 
reports on micronutrient recommendations based on a review of the 
available literature on nutrient requirements (14): United Kingdom (GB) (28), 
Netherlands (NL) (29, 30), France (FR) (31), Latvia (32), Germany-Austria-
Switzerland (DACH) (33), Norway-Sweden-Finland-Denmark-Iceland (NNR) 
(34), European Community (EC) (35) and WHO/FAO (36). The latter two 
defined recommendations to be used in an international perspective. Seven 
of these reports were included in this study: the Latvian report was excluded, 
because no information was available on the approaches and eminence-
based decisions underlying recommendations.  
In other European countries, micronutrient recommendations were adopted 
from at least one of the reports mentioned above or from guidance provided 
in USA/Canada (14, 37, 38). Therefore, we also included the report of 
USA/Canada (US/CA) in this study. In addition the report of Australia/New-
Zealand (AU/NZ) (39) was included, because it includes an extensive 
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evaluation of the recommendations previously published in USA/Canada and 
considers the literature up to 2003.  
From the nine reports, we extracted recommended intakes of folate, vitamin 
B12, iron and zinc for adults and elderly people (age ≥18 y). To quantify the 
extent of heterogeneity between reports the ratio of the highest to the 
lowest recommendation observed per gender was calculated. Within-report 
comparisons were used to identify differences between men and women and 
between younger and older adults.  
Collection and comparison of approaches  
From each report we retrieved information on the approach used for 
establishing the recommendations of interest (ANR+2SD , or AI). If an 
ANR+2SD was reported, we obtained the ANR and inter-individual variation 
coefficient (CV=SD/ANR). In case the ANR or CV was not explicitly reported, 
the missing value was calculated based on the following equation: 
ANR+2SD=ANR*(1+2*CV/100). We evaluated whether variation in 
ANR+2SD was more strongly related to between-report differences in ANRs 
or CVs. For each combination of two reports with a different ANR+2SD, we 
checked in what way applying the same CV would change the difference 
between the recommendations. 
 
Collection and comparison of eminence-based decisions  
In general there are two ways to establish an ANR: 1)-based on intake-
health associations or 2)-based on physiological needs estimated by basal 
losses (i.e. factorial approach). If intake-health associations are used, the 
ANR is estimated by the mean intake needed to reach a specified cut-off 
level of the selected health indicator. The factorial approach includes the 
summation of basal losses via skin, faeces, urine and additional needs for 
accretion. By correcting total needs for bioavailability from the usual diet, 
the ANR is estimated (ANR=mean physiological needs*100/bioavailability 
factor). To explain potential variation in ANRs between reports we collected 
and compared health indicators and cut-off levels or basal losses and 
bioavailability factors depending on the method used to establish the ANR. 
Finally, to assess the data underlying recommendations the references that 
were given greatest weight by the authors of the reports were compared 
between reports that used similar methods for deriving an ANR or AI. 
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RESULTS  
Recommended intakes of folate, vitamin B12, iron and zinc for adults (>18 y) 
from European countries, US/CA and AU/NZ are presented in Tables 1 and 2. 
Since recommendations were similar across adult ages, for each report we 
only present one recommendation per gender. Due to the diminished iron 
needs after onset of menopause, all reports provided recommended iron 
intakes for pre- and postmenopausal women separately. 
WHO/FAO and FR provided recommended intakes of iron and zinc for 
different bioavailability factors. In our comparison, we included the 
recommendations estimated with the bioavailability factor most frequently 
used in the other reports (iron 15%, zinc 30%).   
 
Variation in recommendations 
Between-report ratios of highest to lowest recommendations were about 2.0 
for folate (200-400 µg), vitamin B12 (1.3-3 µg) and zinc (men 7-14 mg, 
women 4.9-9 mg), whereas for iron the variation was less with a ratio 
around 1.3 (men 8-10 mg, premenopausal women 14.8-19.6 mg, 
postmenopausal women 7.5-9 mg).  
Within reports, we observed no gender differences for folate and vitamin 
B12; only FR recommended a higher folate intake for men (+30 µg). For 
iron, higher recommendations were established for premenopausal as 
compared to postmenopausal women (+3 mg to +12 mg), whereas 
recommendations for men and postmenopausal women were similar or 
slightly different (EC, NL, WHO/FAO; maximum difference 1.6 mg). For zinc 
all reports provided higher recommendations for men than for women (+1 
to +6 mg). 
In general few differences existed between recommendations for younger 
and older adults, due to limited knowledge of the effects of the aging 
process on utilization and absorption of folate, vitamin B12, iron and zinc. 
However, all reports, except the one from GB, indicated that consumption of 
vitamin B12 via fortified foods or supplements is recommended for elderly 
people suffering from food-bound malabsorption. Due to the high prevalence 
of atrophic gastritis among elderly people (10-30%), US/CA applied this 
recommendation for all those aged 51y and older. 
Both for folate and vitamin B12 we observed a clear difference in 
recommended intakes  between reports of GB and EC published until 1993 
(folate 200 µg, vitamin B12 1.4-1.5 µg) and the other reports published 
since 1998 (folate 300-400 µg, vitamin B12 2.0-3.0 µg). 
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Variation in approaches  
In general, reports suggested that recommendations were established using 
the requirements-based approach (ANR+2SD); only FR indicated providing 
an AI for folate, iron and zinc (Tables 1 and 2).  
To derive recommended iron intakes for premenopausal women, five reports 
(EC, NNR, WHO/FAO, US/CA, GB) used an alternative approach since the 
distribution of menstrual iron losses was found to be skewed. EC, NNR, 
WHO/FAO and US/CA estimated the distribution of iron requirements for this 
population group as the convolution of the distributions of menstrual and 
basal iron losses and subsequently derived recommended iron intakes as the 
90th (EC, NNR), 95th (EC, WHO/FAO) or 97.5th (US/CA) percentile of iron 
requirements. EC and NNR argued that considering a usual diet, an iron 
intake fulfilling requirements of 95% would be unrealistically high for the 
majority of premenopausal women. GB derived an ANR for iron as the sum 
of mean basal losses and the 75th percentile of menstrual iron losses 
corrected for the bioavailability factor. The ANR+2SD was estimated by 
applying a CV of 15%.  
 
Between reports CVs varied from 10-20% (vitamin B12 and iron) or 10-25% 
(folate and zinc). Part of the observed between-report differences in 
ANR+2SD can be explained by variation in CVs. In general for folate, zinc 
and iron, between-report differences in ANRs contributed more to the 
variation in recommendations than differences in CVs, as between-report 
differences in ANR+2SD stayed similar, only slightly decreased or even 
increased after applying the same CV (data not shown). The variation in CVs 
only fully explained the differences in ANR+2SD for vitamin B12 established 
by France, NL and US/CA, and differences in ANR+2SD for zinc established 
by NL and US/CA. In these cases, ANRs were the same in all specified 
reports and only CVs varied. For zinc, some variation in ANR+2SD was more 
strongly related to between-report differences in CVs than in ANRs both for 
men (GB-NL, EC-NL) and women (NL-AU/NZ). 
 
Variation in eminence-based decisions 
For folate and vitamin B12, the maintenance of blood or tissue levels at a 
concentration not accompanied by deficiency symptoms was generally 
considered as health indicator for establishing an ANR (Table 1). For folate 
all countries/organizations used at least one biomarker of folate status as 
primary  health  indicator  for  establishing  an ANR.  Cut-off levels indicating 
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adequate concentrations of biomarkers showed some variation between 
reports: erythrocyte folate >300-340 nmol/l, serum folate >6.8-10 nmol/l, 
serum homocysteine <10-16 µmol/l. EC, NL, NNR and US/CA all used 
adequate serum and erythrocyte folate as health indicators, but ANRs varied 
from 140 to 320 µg. All four reports referred to the same depletion-repletion 
study by Sauberlich et al. (40). In addition, EC based their ANR on two older 
depletion-repletion studies (41, 42), and NL, NNR and US/CA on a more 
recent depletion-repletion study (43) and a balance study (44). NL and 
US/CA also considered the RCT by O’Keefe et al.(45). However, NL did not 
use this study for estimating the ANR because requirements based on the 
results of this study were much higher than those in other studies. In 
contrast, in the report of US/CA this study was given greatest weight, as 
subjects in the other depletion-repletion studies would have received more 
folate than reported due to underestimation of the folate content in food.  
 
GB based recommended folate intakes on observational data on the relation 
between long-term folate intake and adequate concentrations of folate in 
liver and erythrocytes (43). An optimal concentration of homocysteine was 
selected as health indicator for folate in reports of FR (46) and DACH (47, 
48), which was explained as the level at which the risk for cardiovascular 
diseases is minimized. 
 
On the contrary, NL, NNR and US/CA reported that available evidence on 
minimizing cardiovascular disease risk by lowering homocysteine 
concentrations is not strong enough to take this biomarker into account for 
estimating folate requirements. 
 
For vitamin B12, GB, EC, NNR and US/CA selected the maintenance of 
adequate haematological status as primary health indicator for estimating 
the ANR (1.0-2.0 µg). EC, NNR and US/CA mainly based the ANR of vitamin 
B12 on Darby et al. (49), studying the effects of various intramuscular doses 
of vitamin B12 on subjects with pernicious anemia. NNR and US/CA 
corrected these levels for reabsorption of biliary vitamin B12 as occurs in 
healthy people (50-52). EC did not perform these corrections, but assumed 
that adjustments for reabsorption will cancel out adjustments needed for 
incomplete absorption from the diet. Studies in vegetarians were used as 
supportive data (53). In GB (ANR: 1.25 μg) studies given largest weight 
were different (53-57).  
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FR and NL estimated the ANR for vitamin B12 following the factorial 
approach using estimates of basal losses (0.8-1.0 µg) and a bioavailability of 
60 and 50% respectively. Estimations of basal losses were based on 
different studies (FR (51, 58), NL (50, 52), but ANRs were similar (2.0 μg).  
The DACH report mentioned several health indicators, but from the 
information provided we could not deduct which indicator and data were 
used to estimate an ANR. 
 
For iron and zinc all reports used the factorial approach to estimate the ANR 
(Table 2). For iron, the maximum difference between reports in basal losses 
was 0.3 mg (premenopausal women DACH vs. NL). All reports, except GB 
and NL, stated that basal iron losses were based on physiological needs per 
kg body weight, namely 14 μg/kg per day. Reference body weights selected 
for estimating an ANR varied between reports (men 74-77.4 kg, women 59-
64 kg). Using the highest or lowest observed reference weight would result 
in a difference in ANR of ≤1.2 mg. 
In most countries/organizations, basal iron losses were based on a single 
experimental study by Green et al. (59) using radio-labelled iron to measure 
losses from different body compartments. US/CA reported that this was the 
only study with reliable quantitative data for basal iron losses in humans. A 
previous report on recommendations published by FAO (60) was also 
indicated three times as an important reference.  
In contrast, FR, DACH and NL did not refer to the experimental study by 
Green et al. (59): FR referred to the FAO report (60), NL used data from 
other balance, turnover and depletion-repletion studies (61-63) and DACH 
did not provide information on their evidence-base. 
For estimates of menstrual iron losses, all reports, except FR and NL, 
referred to the same study from year 1966 (64). Although the evidence-base 
used in FR and NL was different, their estimated basal losses were similar to 
estimates provided in the other reports.  
Bioavailability factors for iron varied between reports from 5-18%. They 
were mainly based on studies investigating bioavailability from diets with 
heme:non-heme ratios representative of national (NL, FR, NNR, US/CA) or 
Western/mixed diets (GB, DACH, WHO/FAO, EC) in iron replete subjects 
with minimal or normal iron stores. FR applied a bioavailability factor of 10%, 
but indicated that in subjects without iron stores bioavailability could reach 
15-20%, whereas US/CA estimated an ANR for those with normal iron status 
but minimal stores and applied a factor of 18%.  
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For zinc, total losses varied substantially (men:1.3-3.8 mg; women:1.0-3.3 
mg); on intestinal losses in particular there was no agreement (men:0.3-
2.57 mg; women:0.3-2.3 mg). All countries/organizations used different 
combinations of studies to estimate the ANR, but all, except FR and NNR 
refer to the balance study by Milne et al (65). Other important sources of 
evidence reported in at least three reports were a depletion-repletion study 
(66) (NL, NNR, WHO/FAO), the study by Hess et al. (67) measuring zinc 
excretion in young women on low zinc intakes (NNR, WHO/FAO, US/CA, 
AU/NZ), a book chapter (68) (GB, EC, DACH) and a cohort study (69) 
(WHO/FAO, US/CA, AU/NZ).  
 
Bioavailability factors for zinc varied between reports from 15-50%. US/CA 
and AU/NZ applied higher bioavailability factors for women than for men, 
which contributed to observed gender differences in ANR (respectively 2.6 
mg and 5.5 mg). More recent reports (NNR, US/CA, AU/NZ) based 
bioavailability factors on the relationship between the amount of zinc 
absorbed and that excreted via the intestine based on mixed diets. AU/NZ 
estimated their factor with results from IZiNCG (70), which was lower than 
factors provided by NNR and US/CA (40-48%). The other reports based 
bioavailability factors on studies investigating absorption efficiency from 
different types of diets. Although the evidence base varied between reports 
bioavailability factors in these reports were similar (25-30%). 
 
DISCUSSION  
Based on our comparisons of approaches and eminence-based decisions 
underlying the establishment of recommended intakes of folate, vitamin B12, 
iron and zinc, we identified explanations for the variation in current 
recommendations. For folate selected health indicators were similar between 
reports and the variation was mainly related to differences in the underlying 
data. In contrast, for vitamin B12 variation in CVs and selected health 
indicators (maintenance of haematological status or basal losses) seemed to 
contribute most to the observed variation. For iron, differences in reference 
weights and bioavailability factors were the main explanatory factors for the 
variation in recommendations as the underlying data and consequently the 
estimates of basal losses were similar in most reports. For zinc the variation 
in recommended intakes was related to differences in CVs, bioavailability 
factors and the large variation in the evidence-base.  
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Although the reports that we considered were published over 13-14 years, 
access to new data and changes in concepts of nutrition did not seem to 
have altered the estimates made by the newer panels, except for folate. 
Recommended folate intakes published until year 1993 (GB and EC) were 
based on older studies as compared to the other reports published since 
1998. 
This paper describes the situation at the beginning of 2008. Since then 
several countries have published updates for one or more micronutrients. 
However, for the countries/organizations, micronutrients and age groups 
included in this comparison, no updates were identified. All most recent 
recommendations and ANRs provided by European countries and 
organizations are collated in EURRECA’s web-based tool Nutri-RecQuest (71). 
 
In general, the requirements-based approach was used to establish 
recommendations. Only FR indicated providing an AI for folate, iron and zinc, 
although the type of health indicators and data selected as the basis for 
recommendations were similar to other reports providing an ANR+2SD. 
Apparently there is no consensus on the use of this term.  
In 2007, a working group of international experts reviewed the 
harmonization of approaches for developing recommendations on nutrient 
intakes. They proposed new terminology and developed a new statistical 
approach for establishing recommendations. With this new approach, 
recommendations do not necessarily reflect ANR+2SD covering the needs of 
97.5 % of the population, but lower levels in the distribution of requirements 
may also be chosen when this is more likely to be achieved with current 
nutrition policies (23). Clearly, estimates of inter-individual variation depend 
on the health indicator selected to be most reflective of meeting nutritional 
needs. However, for folate, vitamin B12 and zinc, CVs varied largely 
between reports using the same health indicators, as data on inter-individual 
variation in requirements is unavailable, inadequate or inconsistent and 
therefore assumptions are made based on variation in metabolic rates, 
variation in bioavailability and/or the level of uncertainty in the ANR estimate. 
More research is needed to define CVs, but as long as appropriate data are 
lacking, international consensus on how to make assumptions regarding 
inter-individual variation in requirements of folate, vitamin B12 and zinc will 
help to harmonize approaches for setting recommendations. 
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Health indicators selected for estimating requirements for folate, vitamin B12, 
iron and zinc varied between reports and included biomarker concentrations 
rather than associations between intake and health outcomes such as organ 
function or chronic disease risk. Cut-off levels indicating adequate 
concentrations of biomarkers were based on the prevention of deficiency 
symptoms, whereas their predictive value for health outcomes was not often 
considered. Moreover, along with the observation that similarities in the 
consulted evidence-base often lead to different ANRs of folate and vitamin 
B12, the example on optimal concentrations of homocysteine for the 
prevention of CVD illustrates that methods used for the selection, evaluation 
and integration of data were not consistent between reports. The Institute 
of Medicine (IOM) developed an analytical framework for setting nutrient 
reference values for optimal health based on associations between dietary 
exposure (intake) and clinical health outcomes (chronic diseases) (72). The 
use of standard systematic review methodology including meta-analyses for 
evaluating data on these associations will contribute to increased 
transparency of the decision-making process and could therefore be an 
important step in harmonizing approaches for setting micronutrient 
recommendations (72, 73). However, the use of chronic disease outcomes 
for setting recommended micronutrient intakes may be challenging due to 
the lack of data on associations between intake and such clinical outcomes 
and due to the multi-factorial nature of chronic diseases including factors 
such as genetics, age, diet, environment and lifestyle (73). In addition, it 
could be questioned whether establishing an ANR based on associations 
between intake and chronic disease risk would be possible as it seems very 
challenging to estimate the intake at which 50% of the population is at risk 
and 50% is not. Setting an AI seems more feasible as it represents the 
intake level that resulted in the greatest reduction of risk of disease (72, 74). 
As data on direct associations between intake and clinical outcomes are 
often lacking, biomarkers that correlate both with intake and with a disease 
or physiological state may be used as an intermediary between intake and 
health (72, 73). Recently, within the scope of the EURRECA Network of 
Excellence, best practice methods for assessing intake (75, 76) and best 
practice biomarkers have been evaluated for all nutrients of interest (11, 77-
79) by means of standardized systematic review methodology (80). Up to 
now, these best practice biomarkers have not yet been used for estimating 
requirements, except for folate (erythrocyte folate and serum/plasma folate). 
Currently within EURRECA, systematic reviews including meta-analyses are 
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carried out to evaluate the strength and quality of dose-response relations 
between intake and status of the priority micronutrients and between 
micronutrient intake or status and various health outcomes. Following 
standardized protocols, these reviews will make transparent what evidence 
is available addressing populations and outcomes of interest and they may 
enhance the selection of health indicators (73). 
 
Dose-response relations for iron and zinc might be especially difficult to 
estimate due to a lack of sensitive and specific biomarkers reflecting status 
and due to the strong homeostatic regulation of body iron and zinc (81). 
The factorial approach may therefore be the most appropriate way of 
estimating ANRs on both minerals assuming a certain level of bioavailability. 
Bioavailability of iron and zinc is influenced by the composition of the diet as 
well as individual characteristics including micronutrient status, age, 
genotype and clinical conditions influencing absorption and utilization (81-
83). Absorption of iron depends on the form of iron (heme or non-heme), 
and the presence of factors enhancing or inhibiting absorption like vitamin C 
and phytate (81, 84). In addition, homeostatic adaptations occur, increasing 
or decreasing fractional absorption when intake or status is low or high (81). 
For zinc, bioavailability is also influenced by factors enhancing or inhibiting 
absorption, by individual zinc intake and status, and it may also be 
influenced by ageing (85). Variation in bioavailability factors between reports 
was related both to differences in diet composition between countries, and 
differences in methodologies for deriving bioavailability factors. To align 
methods of deriving bioavailability factors for iron and zinc, agreement is 
needed on how to estimate the effects of meal composition and individual 
characteristics such as micronutrient status, genetic variation (single 
nucleotide polymorphisms) and age on bioavailability (83, 86, 87). 
 
In conclusion, for the harmonization of approaches for setting recommended 
intakes of folate, vitamin B12, iron and zinc across European countries, 
standardized methods are needed to a)-select health indicators and define 
adequate biomarker concentrations, b)-make assumptions about inter-
individual variation in requirements, c)-derive bioavailability factors, and d)- 
select and interpret evidence on requirements.  
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ABSTRACT 
Aims: To systematically review literature on daily losses and bioavailability 
of vitamin B12. These estimates could be used for deriving 
recommendations on vitamin B12 intake for adults and elderly. 
Methods: We identified publications on daily vitamin B12 losses (July 2011) 
and publications on bioavailability of vitamin B12 from foods or diets (June 
2010) in MEDLINE, EMBASE and Cochrane Library. 
Results: A pooled analysis of five studies (52 subjects) showed that 
0.13±0.03% of total body stores is lost per day. Absorption of vitamin B12 
ranged from 4.5% (dose of 38 µg from consumption of liver) to 83% (dose 
of 3.0 µg from consumption of mutton meat). Data from eight studies 
including 83 subjects suggested that the amount of vitamin B12 absorbed 
from food (Ai) increased with increasing doses of vitamin B12 (Di) as 
described by the equation: ln(Ai)=0.7694*ln(Di)-0.9614.  
Conclusion: Daily vitamin B12 losses in apparently healthy adults and 
elderly probably range between 2.6-3.9 µg. Based on usual intake data, 
bioavailability from the diet may range between 29-37% rather than the 
generally assumed 50%. These results suggest that a vitamin B12 intake of 
7.0-13.4 µg is needed to compensate daily vitamin B12 losses in apparently 
healthy adults and elderly people.  
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INTRODUCTION 
Current recommendations on vitamin B12 intake for adults and elderly vary 
between European countries from 1.4 to 3 µg per day. The variation in these 
recommendations results from different approaches used for estimating 
vitamin B12 requirements and from different assumptions regarding the 
inter-individual variation in requirements (1). 
One of the approaches used for estimating vitamin B12 requirements for 
adults and elderly in Europe (The Netherlands and France) is the factorial 
approach, which includes a summation of daily vitamin B12 losses that need 
to be compensated for by dietary intake of vitamin B12. Daily vitamin B12 
losses can be measured with the whole body counting method (WBC). 
Subjects are given labelled vitamin B12 and the rate of loss of vitamin B12 
(µg per day) is calculated based on the decrease in radio-activity during 
follow-up.  
As an approximation to this approach, daily vitamin B12 losses can be 
estimated by determining vitamin B12 excretion in bile and accounting for 
the partial reabsorption of this excreted vitamin B12 in the small intestine. 
This approximation assumes that excretion of vitamin B12 via other routes, 
e.g. skin and urine can be neglected (2). 
To estimate vitamin B12 requirements, estimates of daily vitamin B12 losses 
need to be corrected for bioavailability of the vitamin from the usual diet. 
Bioavailability is defined as ‘the efficiency with which a dietary component is 
used systematically through normal body functions’ and expressed as a 
percentage of intake (3). Currently, bioavailability of vitamin B12 is generally 
assumed to be 40 or 50% for healthy adults with normal gastrointestinal 
functioning (2, 4-7). This assumption is based on the absorption of labelled 
vitamin B12 from a few food products including mutton meat, chicken meat, 
rainbow trout, eggs or fortified foods (8-12).  
Recommended vitamin B12 intakes indicate the daily intake that is sufficient 
to fulfil requirements of nearly all individuals within a defined population. 
When the distribution of vitamin B12 requirements is known, the 
recommended vitamin B12 intake is derived as the average nutrient 
requirement (ANR) plus twice the SD of the ANR, with the ANR defined as 
the intake level that is sufficient to fulfil requirements in 50% of individuals 
in a defined population. As there is very limited evidence on the shape of 
this distribution, usually a standard assumption of a CV of 10 to 20% is 
made. 
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Box 1 Calculations used for establishing vitamin B12 recommendations with 
the factorial approach 
 
General formula: 
ANR= 
sum of losses (faeces, urine, skins, menstrual losses) + needs for growth 
bioavailability factor 
 
The Netherlands (6): 
Assumption 1: Daily vitamin B12 losses are maximally 0.2% of vitamin B12 stores 
(11, 13, 14)  
Assumption 2: Minimal body stores are 500 µg (14) 
Assumption 3: Bioavailability is 50% (8-10, 12) 
Assumption 4: CV=20% 
Daily losses=0.2%*500 µg=1.0 µg 
ANR=1.0/0.5=2.0 µg.  
Recommended intakea=2.0*1.4=2.8 µg. 
 
France (2) 
Assumption 1: Daily vitamin B12 excretion in bile is 1.4 µg (15) 
Assumption 2: 40% of vitamin B12 excreted in bile is reabsorbed in the small 
intestine (16, 17) 
Assumption 3: Bioavailability is 40% (17) 
Assumption 4: CV=10% 
Daily losses= 1.3*60%=0.8 µg 
ANR=0.8/0.4=2.0 µg 
Recommended intakea=2.0*1.2=2.4 µg. 
ANR, Average nutrient requirement; CV, coefficient of variation 
a-) the recommended intake is derived as (1+2*CV/100)*ANR 
 
As shown previously, European recommendations on vitamin B12 intake for 
adults and elderly established using the factorial approach (The Netherlands 
and France) are based on a limited number of studies that were published 
between 1963 and 2001 (Box 1) (1). The aim of this article was to 
systematically review the available literature on daily vitamin B12 losses and 
bioavailability of vitamin B12 from different food sources including estimates 
of inter-individual variation. The results of this review could serve as input 
for establishing vitamin B12 recommendations using the factorial approach.
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METHODS 
This systematic review was conducted according to standardized 
methodology as developed within the scope of the EURRECA (EURopean 
micronutrient RECommendations Aligned) Network of Excellence (18) , 
which is shortly described below. 
 
Search 
We conducted two systematic literature searches to identify publications on 
1) basal vitamin B12 losses (MEDLINE, 12 July 2010) and 2) bioavailability of 
vitamin B12 from diets (MEDLINE, EMBASE and Cochrane Library, 15 June 
2010). The first search included terms on vitamin B12 or labelled vitamin 
B12 in combination with terms on excretion routes, kinetics or maintenance 
and the second search included terms on vitamin B12 in combination with 
terms on absorption. Both searches were restricted to studies in humans. To 
be able to use the same search to identify publications for younger 
population groups, no terms regarding the age of the study population were 
added. The second search also included terms regarding folate to identify 
papers on folate bioavailability as will be described elsewhere. The search 
strategies are included in Supplemental file 1. Additional studies were 
identified by hand searching, i.e. screening of reference lists from all 
selected articles, review articles and reports including recommendations on 
micronutrient intakes.   
 
Study selection and data extraction 
In general, studies were eligible for inclusion when they had an 
experimental design and the study population included apparently healthy 
adults (age 18 years and older) or adult patients with diseases not 
associated with disturbance of vitamin B12 metabolism or absorption. 
Studies on losses were included when 1) the exposure was oral or 
parenteral administration of vitamin B12 and 2) the outcome was an 
estimate of daily vitamin B12 losses measured with WBC or estimated based 
on vitamin B12 excretion in bile. Studies on bioavailability were included 
when 1) the exposure concerned diets, meals or individual foods in- or 
extrinsically labelled with vitamin B12 and 2) the outcome was a measure of 
fractional vitamin B12 absorption. Four reviewers screened all titles and 
abstracts of papers identified through the literature searches according to 
the inclusion criteria and full-text of potentially relevant papers were 
evaluated against the same criteria (PitV, AS, MD, ED). For the purpose of 
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alignment and quality control, each reviewer screened and evaluated 10% of 
the total number of references in duplicate with another reviewer. Each 
included study was extracted by a single reviewer (PitV or AS) and a second 
reviewer independently verified the extracted data (ED). Any disagreements 
during the selection and extraction process were resolved by discussion.  
From all studies we extracted general characteristics of the study design 
(duration, dose), and study population (number of participants, age, gender, 
ethnicity). In addition, from each study reporting on total vitamin B12 losses 
measured with WBC, we extracted the rate of loss indicating the mean 
decay in radioactivity per day as a percentage of the radioactivity measured 
after redistribution of the labelled vitamin B12 through different body 
compartments (i.e. at the time that a constant excretion rate was 
established). The underlying assumption is that labelled vitamin B12 is 
distributed throughout the body in a manner similar to non-labelled vitamin 
B12. We did not merely extract estimates based on measurements in 
healthy subjects (11, 13, 19-21), but also on subjects with low serum 
concentrations of vitamin B12 (20) and patients with pernicious anemia (PA) 
(11, 13), because it appeared that the rate of loss does not significantly 
differ between these subpopulations (11, 13, 20). One study reported the 
absolute mean loss of vitamin B12 per day and the total body content of 
vitamin B12 (21). To allow comparison with the other studies, the rate of 
loss was calculated as (mean loss per day/ total body content) * 100%.  
From each study reporting on vitamin B12 excretion in bile, we extracted the 
rate of excretion, the vitamin B12 concentration of bile, or the absolute 
vitamin B12 excreted in bile per day. The rate of excretion reflected the 
radioactivity measured in excreted bile as a percentage of the ingested dose 
minus total losses during the first four days (i.e. period of redistribution of 
vitamin B12 throughout the body) after administration of labelled vitamin 
B12 (22, 23). 
From studies on bioavailability of vitamin B12 we extracted the percentage 
of the ingested dose that was absorbed. Furthermore we extracted the 
absolute amount of vitamin B12 that was absorbed. In case this latter 
estimate was not reported, it was calculated as % absorbed*ingested dose 
(9, 24-26). 
To describe the relation between the amount absorbed (Ai) and the dose 
administered (Di) via the foods provided in the intervention studies we 
performed linear regression with both variables transformed to their natural 
logarithm in order to achieve linearity of the regression.  
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As an upper limit of inter-individual variation we calculated the coefficient of 
variation (CV) for each outcome measure reported per study (standard 
deviation (SD)/mean)*100%., ignoring the measurement errors and within-
subject variation. When no SD was provided we estimated it based on 
individual subject data (SD=√[∑(xi-xmean)
2)/(N-1)]) (8, 10, 11, 13, 19, 20, 
27), on the standard error (SE) (SD=SE*√n) (22, 23, 28), or we 
approximated it by the total range (SD≈0.25*total range) (11, 22). 
Where applicable, amounts of vitamin B12 were converted from nmol to µg 
using the molar weight of vitamin B12 (1355.38 g/mol) (15, 26). 
 
If three or more studies were comparable with regard to exposure and 
outcome measures, we calculated summary estimates using random effects 
meta-analysis. Applying the methods of DerSimonian and Laird, the 
between-study variance is estimated which is then used to modify the 
weights for calculating the summary estimate (29). SE’s were calculated as 
SD/√n. If no SD was reported and no individual data were available, we 
imputed an SE based on the pooled SD from the other studies included in 
the pooled analysis: SDpooled=√[∑((ni-1)*SDi
2)/∑(ni-1)] (21). Heterogeneity 
between studies was evaluated using the I2 statistic, which expresses the 
percentage of variation attributable to between-study heterogeneity rather 
than chance (30). Meta-analyses were performed using STATA version 11.0 
(College Station, TX), with statistical significance defined as a p-value <0.05. 
 
RESULTS 
Study characteristics 
In total, we identified 523 potentially relevant papers on daily vitamin B12 
losses and 5556 on bioavailability of vitamin B12 and folate (combined 
search). After evaluation of titles, abstracts and full texts, ten papers were 
included for vitamin B12 losses (five papers for daily vitamin B12 losses 
measured with WBC, and five papers for daily vitamin B12 excretion in bile) 
and eight papers were included for bioavailability of vitamin B12 (Figure 1). 
All studies were performed in Western countries (USA, United Kingdom, 
Sweden, Norway or Finland). Unfortunately, information on age, sex and 
ethnicity of the study populations was not provided for most of the studies. 
Serum vitamin B12 concentrations were reported to be normal in all but one 
study including subjects with low serum concentrations (20), but only five 
studies (8-10, 24, 25, 31) actually reported concentrations (137-546 pmol/l). 
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Vitamin B12 losses measured with WBC 
Table 1 presents estimates of daily vitamin B12 losses measured with WBC 
expressed as the percentage of total body stores lost per day. Estimates 
were based on measurements in healthy subjects (11, 13, 19-21), subjects 
with low serum concentrations of vitamin B12 (20) and PA patients (11, 13). 
Absolute amounts of vitamin B12 lost per day varied in these 
subpopulations, as the absolute amount depends on the size of total body 
stores: the larger the body stores, the larger the losses (13, 21). Across 
studies, the rate of loss varied from 0.04% (SD not available) to 0.17% per 
day (SD=0.017). Reizenstein et al. (1966) (21) observed the lowest rate 
(0.04%), which was based on observations in only two individuals. This 
result deviated from the other four studies that reported a rate of loss in the 
range 0.13-0.17% per day (SDpooled=0.03%). A meta-analysis of all five 
studies showed a summary estimate for the rate of loss of 0.13% per day 
with high heterogeneity between studies (I2=91.5%, p<0.0001) (Figure 2). 
When the estimate of the rate of loss from the study by Reizenstein et al. 
(1966) (21) was omitted from the meta-analysis, the summary estimate only 
slightly changed to 0.14 % per day (95% confidence interval: 0.12, 0.16), 
and the observed heterogeneity between studies remained large (I2=87.6%, 
p<0.0001).  
 
Vitamin B12 excretion in bile 
Studies reporting on vitamin B12 excretion in bile included healthy subjects 
or patients with normal vitamin B12 metabolism subjected to duodenal 
lavage (22, 23), patients with post-operative drain in common bile duct (22, 
23, 27, 32), patients undergoing surgery for lithiasis of the bile duct (15), 
patients undergoing cholesystectomy (27) or autopsy (27). Results of the 
included studies are shown in Table 2. Two studies (22, 23) reported on the 
rate of excretion, indicating similar amounts of vitamin B12 excreted in bile 
per day as a percentage of total body stores (rate of loss 1.1% and 1.5%, 
respectively). One study measured absolute vitamin B12 excretion in bile 
and concentrations of the vitamin in bile (15), and two studies only 
measured concentrations of vitamin B12 in bile. Halsted et al. (32) observed 
no excretion of vitamin B12 in bile in one subject, whereas the two other 
studies showed mean vitamin B12 concentrations in bile of 3248 pg/ml (27) 
and 2955 pg/ml (15). 
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NOTE: Weights are from random effects analysis
Overall  (I-squared = 91.5%, p = 0.000)
Heyssel et al. 1966
Boddy & Adams 1968
Reizenstein et al. 1966
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Bozian et al. 1963
Adams and Boddy 1968
14
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2
n
16
6
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0.13 (0.12, 0.14)
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0.04 (-0.00, 0.08)
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0.17 (0.16, 0.18)
100.00
22.27
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%
14.27
Weight
20.35
21.68
   
Figure 2 Pooled analysis of the daily rate of loss of vitamin B12 as a 
percentage of total body stores - CI, Confidence interval 
 
Bioavailability of vitamin B12 
We did not identify any study that assessed bioavailability of vitamin B12 from 
specific diets. All studies rather addressed absorption of vitamin B12 from a 
specific food product alone or in combination with a meal free of vitamin B12. 
Study populations included healthy subjects and subjects with a disease not 
affecting vitamin B12 absorption. Table 3 shows quantitative estimates of 
absorption obtained by the faecal excretion method (33), or WBC based on 
observations in 2-13 subjects per study (11). Overall, absorption ranged from 
4.5% (dose of 38 µg from consumption of liver) to 83% (dose of 3.03 µg 
from consumption of mutton meat) (11). CV’s for absorption estimates within 
studies ranged from 11% to 84%, whereas SD’s were more similar ranging 
from 1.7% (11) to 22% (26), with most estimates in the range 5.2-14%. Per 
specific food groups and doses absorption ranged from 24% to 36% for egg 
products (dose 0.3-0.94 µg), from 52% to 83% for lean meat (dose 0.54-5.11 
µg), from 30% to 42% for fish (dose 2.1-13.1 µg) and from 4.5% to 49% for 
liver products (dose 0.5-38 µg). 
Four studies measured absorption from a food product with varying vitamin 
B12 contents. In two out of four studies, the percentage absorption decreased 
with increasing vitamin B12 content (10, 26), whereas the other two did not 
show such clear trend (8, 11 ). Overall, the amount of vitamin B12 absorbed 
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 (Ai) increased with increasing doses of vitamin B12 (Di) and the relation was 
estimated as ln(Ai) = 0.7694*ln(Di)-0.9614 as illustrated in Figure 3. Since 
we applied a natural logarithmic transformation on both the vitamin B12 
dose and the amount of vitamin B12 absorbed, the regression coefficient of 
0.7694 means that for every doubling in vitamin B12 dose, the difference in 
absorbed amount is 20.7694 (=1.70), which is 70%. 
 
DISCUSSION 
Main findings 
Currently in Europe, ANRs for vitamin B12 established with the factorial 
approach are based on a selection of the studies as summarized in this 
review. This systematic review indicated that the total amount of vitamin 
B12 lost per day is 0.13% (CV=23%) of total body stores. Observations of 
the rate of vitamin B12 excretion in bile were similar (1-1.5% of total body 
stores per day, CV=72-77%), whereas the absolute amount of vitamin B12 
excreted in bile per day and vitamin B12 concentrations in bile varied largely 
between and within studies (CV within studies= 34-133%). Estimates of 
vitamin B12 absorption varied between 4.5% and 83% (CV 11-84%) based 
on studies with varying vitamin B12 contents and different types of food 
products. The relation between absorbed amount (Ai) and ingested dose of 
vitamin B12 (Di) was estimated as ln(Ai)= 0.7694*ln(Di)-0.9614. 
 
Implications of our findings for estimates of vitamin B12 
requirements  
Inter-individual variation in requirements 
Most studies reporting on daily vitamin B12 losses or absorption are old, 
include a small number of subjects and details on the study subjects are 
very limited. Moreover, we observed a large variation between and within 
studies, especially among studies reporting on vitamin B12 excretion in bile. 
Estimating vitamin B12 requirements with the factorial approach, as in the 
Netherlands, requires assumptions regarding the rate of loss, total body 
stores and bioavailability (Box 1). Each assumption is a component of 
uncertainty and following the simple error-propagation formula for 
independent measurements, for any given value of body stores the CV of 
the ANR for vitamin B12 can be estimated as: √(CV2rate of loss+CV
2
bioavailability). 
Based on the observations of within–study variation for the rate of loss 
(CV=23%, based on the pooled SD) and bioavailability (CV=8-81%), this 
would imply a CV for the ANR of at least 24%. These calculations suggest 
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that the CV is larger than the 20% which is currently assumed for estimating 
recommended intakes of vitamin B12 in the Netherlands. However it must 
be noted that the CVs used in these calculations are based on studies with 
few subjects, which may result in an overestimation of the inter-individual 
variation. Moreover, there is some evidence that lower body stores of 
vitamin B12 go together with higher absorption (23), as for many other 
nutrients. If bioavailability of vitamin B12 depends on total body stores, the 
CV of vitamin B12 requirements may be less than predicted with the error-
propagation formula. 
The French recommended intake of vitamin B12 is derived as the ANR 
multiplied by 1.2 (2 times a CV of 10%). However, this review showed that 
measures of vitamin B12 excretion bile vary largely between and within 
studies (CV: 34-133%). So, considering the additional assumptions required 
for estimating vitamin B12 requirements based on daily losses in bile (% 
reabsorption from the intestine, % bioavailability) it seems likely that a CV of 
10% underestimates the inter-individual variation and uncertainty in 
requirements.  
 
Total vitamin B12 losses measured with WBC 
Current recommendations based on the factorial approach include the 
assumption that compensation of daily losses will be sufficient to maintain 
vitamin B12 body stores, and thereby prevent deficiency disorders. 
Estimates of body stores (500 µg) were based on observations in patients 
suffering from malabsorption that remained both hematologically normal (no 
megaloblastic changes of the bone marrow, no anemia, no macrocytosis) 
and serum vitamin B12 concentrations at 96-148 pmol/l. As 
recommendations on micronutrient intake are designed for apparently 
healthy populations, it may be more appropriate to use estimates of body 
stores based on apparently healthy subjects for estimating daily losses. The 
Food and Nutrition Board/Institute of Medicine summarized mean total body 
stores in adults with most estimates between 2 and 3 mg (5). Based on 
these stores and a rate of loss of 0.13% of stores per day, total losses would 
range between 2.6 and 3.9 µg per day under the assumption that size of the 
total body stores of vitamin B12 is the major determinant of the amount of 
vitamin B12 lost per day (Table 4). 
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Vitamin B12 excretion in bile 
The absolute amount excreted in bile per day was 1.4 µg as reported in one 
study. Based on the reported mean rate of loss of 1.1 or 1.5% of total body 
stores and assuming body stores to range between 2 and 3 mg as also 
referred to above (5), daily vitamin B12 excretion in bile may range between 
22 and 45 µg. Daily biliary excretion of vitamin B12 derived from the 
reported concentration of the vitamin in bile was 1.6 µg per day, assuming a 
daily output of bile of 493 ml (15). So, using the French assumption that 
40% of vitamin B12 excreted in bile is reabsorbed in the small intestine (Box 
1), total losses of vitamin B12 range between 0.8 µg and 27 µg per day as 
shown in Table 4. It must be noted however, that in two studies included in 
this review, excretion of vitamin B12 was measured both in bile and in 
faeces and results showed that losses in faeces were about one third (28-
33%) of the amount of vitamin B12 excreted in bile (22, 23). This would 
imply that more than two thirds of the vitamin B12 excreted in bile is 
reabsorbed in the small intestine and that daily losses range between 0.5 µg 
and 14.9 µg per day (Table 4). 
 
Bioavailability of vitamin B12 
Absorption of vitamin B12 from food is influenced by the type of food source 
and its vitamin B12 content as shown in this review and in other publications 
(4, 7). Studies included in our review measured absorbed amounts up to 6 
µg from a single meal. This is not consistent with previous data showing that 
the average maximum amount of vitamin B12 that can be absorbed from 
amounts usually consumed with a meal is about 1.5 µg due to saturation of 
the vitamin B12-Intrinsic factor receptors, which are key-factors in the 
absorption of vitamin B12 from the ileum (34). Although, passive diffusion of 
1% of the ingested dose also takes place, this only becomes relevant when 
high doses are ingested, e.g. via supplements.  
In general, absorption of 50% from the diet was assumed for estimating 
vitamin B12 requirements. Although two studies observed vitamin B12 
absorption of more than 50% (chicken or mutton mean), absorption from 
other food products was lower than 50%. So, it seems that the generally 
assumed 50% overestimates real absorption, leading to an underestimation 
of the requirements. Moreover, as it is suggested that there is a maximum 
amount of vitamin B12 that can be absorbed per meal, it does not seem 
right to report on the percentage absorption of a specific food without 
referring to the actual dose ingested (4). Usual vitamin B12 intakes among 
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adults and elderly people across Europe range from 3.5 µg to 9.3 µg per day 
(35). Assuming that each day three meals contribute to vitamin B12 intake, 
and that these three meals contain equal amounts of vitamin B12 (1.2 µg to 
3.1 µg per meal), the regression equation derived in this review (ln(Ai)= 
0.7694*ln(Di)-0.9614), could be used to predict the bioavailability as follows:  
ln(Bioavailability) = ln(A/D) = ln(A) – ln(D)= (0.7694 –1) * ln(D)-0.9614  
and bioavailability is = (1.2 to 3.1 µg)(0.7694-1) * (e-0.9614) which is 29-37%.  
 
Vitamin B12 requirements 
Combing the estimates of daily vitamin B12 losses based on WBC 
measurements or excretion in bile and a bioavailability from diet of 29-37%, 
the dietary vitamin B12 intake needed to compensate daily losses would 
range from 7.0 to13.4 µg per day or from 1.2 to 51 µg per day, respectively 
as shown in Table 4. These intake ranges indicate the daily intake necessary 
to maintain body stores in apparently healthy adults and elderly people 
rather than the intake level at which requirements of 50% of individuals in a 
population are fulfilled. Therefore the intake ranges reflect the 
recommended vitamin B12 intake rather than the ANR.  
As vitamin B12 requirements based on excretion in bile vary with a factor 
30, these estimates seem less adequate for deriving recommended vitamin 
B12 intakes. Although vitamin B12 requirements based on total losses 
measured with WBC vary with a factor two, these estimates are in line with 
findings from five studies that showed that plasma concentrations of 
markers for vitamin B12 status (total vitamin B12, methylmalonic acid and 
holotranscobalamin II) leveled off at daily intakes between 4 and 10 µg per 
day (36-40). Daily intakes between 4 and 10 µg per day will therefore likely 
be adequate for the prevention of subclinical deficiencies of vitamin B12 that 
may be associated with potential health risks including neurologic and 
cognitive risks (41). However, more evidence is needed on the relation 
between plasma concentrations of markers for vitamin B12 status, vitamin 
B12 body stores and long-term health outcomes to define whether it is 
beneficial to maintain maximal vitamin B12 status and stores of 2-3 mg. 
 
It must be noted that all studies included in our review were based on 
subjects with normal absorption. From the age of 60y on, the prevalence of 
food-bound malabsorption increases, which is a primary cause for vitamin 
B12 deficiency affecting about 20% of elderly populations in industrialized 
countries (42). Food-bound malabsorption is characterized by the inability to 
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release vitamin B12 from food or from intestinal transport proteins. 
Therefore this vitamin B12 cannot or only partly bind to intrinsic factor and 
so absorption of vitamin B12 does not take place or only to a lesser extent. 
Absorption of crystalline vitamin B12 is usually not affected in subjects with 
food-bound malabsorption and therefore most European countries 
recommend elderly people to consume a high proportion of their vitamin 
B12 intake as fortified foods and supplements (1). In two studies 
investigating absorption from bread, squash or milk fortified with 0.25-0.5 
µg vitamin B12, an absorption between 55 and 74% was observed (12, 31). 
 
CONCLUSIONS 
This review showed that daily vitamin B12 losses in apparently healthy 
adults and elderly probably range between 2.6-3.9 µg. Based on usual 
intake data and the relation between vitamin B12 intake and the amount 
absorbed, bioavailability from the diet seems to range between 29 and 37% 
rather than the generally assumed 50%. These results suggest that a 
vitamin B12 intake between 7.0 and 13.4 µg is needed to compensate daily 
vitamin B12 losses in apparently healthy adults and elderly people, which is 
2.5 to 5 times higher than the amount needed to prevent deficiency. Current 
recommendations on vitamin B12 intake of 1.4-3.0 µg may be inadequate to 
maintain body stores of 2-3 mg and optimal plasma concentrations of 
markers of vitamin B12 status. However, more evidence is needed on the 
relation between plasma concentrations of markers for vitamin B12 status, 
vitamin B12 body stores and long-term health outcomes to evaluate whether 
current recommended vitamin B12 intake need to be changed. 
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Supplemental file 1:  
Search strategy to identify papers on vitamin B12 losses in MEDLINE (12-07-
2010) 
 Searches 
1 ("vitamin b12" or vitamin-b12 or "vitamin b 12" or "vitamin-b 12" or cobalamin* or cyanocobalamin* 
or hydroxocobalamin* or methylcobalamin* or adenosylcobalamin*).mp. [mp=title, original title, 
abstract, name of substance word, subject heading word, unique identifier] 
2 exp Transcobalamins/ 
3 exp Vitamin B 12/ 
4 1 or 2 or 3 
5 (radio-isotop* or radioisotop* or radio-label* or radiolabel* or radio-active or radioactive or 
"isotopically labelled").mp. [mp=title, original title, abstract, name of substance word, subject heading 
word, unique identifier] 
6 radioisotopes/ or exp radioactive tracers/ 
7 5 or 6 
8 4 and 7 
9 ("Cobalt-57" or "Co-57" or "57Co" or "(57)Co").mp. [mp=title, original title, abstract, name of 
substance word, subject heading word, unique identifier] 
10 4 or 8 or 9 
11 exp urine/ 
12 exp sweat/ 
13 exp feces/ 
14 exp bile/ 
15 exp skin/ 
16 exp menstruation/ 
17 exp integumentary system/ 
18 11 or 12 or 13 or 14 or 15 or 16 or 17 
19 10 and 18 
20 exp kinetics/ 
21 exp tissue distribution/ 
22 exp enterohepatic circulation/ 
23 20 or 21 or 22 
24 10 and 23    
25 exp maintenance/ 
26 10 and 25 
27 19 or 24 
28 limit 27 to (english language and humans) 
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Search strategy to identify papers on vitamin B12 bioavailability in MEDLINE 
(15-06-2010)* 
 
Searches 
1 ("vitamin b12" or vitamin-b12 or "vitamin b 12" or "vitamin-b 12" or cobalamin* or cyanocobalamin* 
or hydroxocobalamin* or methylcobalamin* or adenosylcobalamin*).mp. [mp=title, original title, 
abstract, name of substance word, subject heading word, unique identifier] 
2 exp Vitamin B 12/ 
3 exp Transcobalamins/ 
4 (radio-isotop* or radioisotop* or radio-label* or radiolabel*).mp. [mp=title, original title, abstract, 
name of substance word, subject heading word, unique identifier] 
5 radioisotopes/ or exp radioactive tracers/ 
6 1 or 2 or 3 or 4 or 5 
7 (bioavailab* or bio-availab* or bioaccess* or bio-access* or absorption).mp. [mp=title, original title, 
abstract, name of substance word, subject heading word, unique identifier] 
8 exp Intestinal absorption/ or exp Absorption/ or exp biological availability/ 
9 (("vitamin b12" or "vitamin-b12" or "vitamin b 12" or "vitamin-b 12" or $cobalamin*) adj5 (status or 
metabol* or retention* or concentrat* or homocysteine* or hcy or tHcy or holo-tc or 
Holotranscobalamin* or holo-transcobalamin* or holoTC or plasma or serum)).mp. [mp=title, original 
title, abstract, name of substance word, subject heading word, unique identifier] 
10 (diet* or meal* or food* or lactat*).mp. [mp=title, original title, abstract, name of substance word, 
subject heading word, unique identifier] 
11 bottle feeding/ or breast feeding/ or weaning/ or infant food/ or infant formula/ or milk, human/ 
12 10 or 11 
13 7 or 8 or 9 
14 6 and 12 and 13 
15 limit 14 to humans 
*The search terms presented here were part of a larger search that also contained terms to identify papers 
on folate bioavailability. Here we only present the terms included for vitamin B12 
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ABSTRACT 
The objective of this systematic review was to evaluate whether the relation 
between vitamin B12 intake and cognitive function should be considered for 
underpinning vitamin B12 recommendations in the future. The authors 
summarized dose-response evidence from randomized controlled trials 
(RCTs) and prospective cohort studies on the relation of vitamin B12 intake 
and status with cognitive function in adults and elderly people. Random-
effect meta-analyses were used to pool the relative risk (RR) (binary 
outcomes) or regression coefficients (β) (continuous outcomes) from 
multiple adjusted models. Two RCTs and 4 cohort studies showed no or 
inconsistent associations between vitamin B12 intake and cognitive function. 
Serum/plasma vitamin B12 (50 pmol/l) was not associated with dementia (4 
cohort studies, RR=1.01, 95% confidence interval (CI)=0.99, 1.03) and 5 
cohort studies reported no association between vitamin B12 status (serum 
vitamin B12 n=3, holotranscobalamin II n=2) and Alzheimer’s disease. 
Baseline serum/plasma vitamin B12 (50 pmol/l) was not associated with the 
additional rate of change in global cognition z-scores (4 cohort studies, 
β=0.00, 95% CI= -0.00, 0.01) or memory z-scores at follow-up (4 cohort 
studies, β=0.01; 95% CI= -0.01, 0.03). Five cohort studies reported no 
associations between serum/plasma vitamin B12 and executive function, 
language or speed. Current evidence on the relation between vitamin B12 
intake or status and cognitive function does not suffice for being considered 
in deriving vitamin B12 recommendations.  
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INTRODUCTION 
Dietary recommendations provide guidance on nutrient intakes that should 
be sufficient to fulfil requirements of nearly all apparently healthy people in 
a specified population. Traditionally, these recommendations were intended 
to prevent deficiency disorders, but today the focus is slowly changing 
towards optimal health also including relations between diet and prevention 
of chronic diseases (1, 2). Current recommendations on vitamin B12 intake 
are similar for adults and elderly people and vary from 1.4-3.0 μg per day in 
Europe. They are based on the amount needed for the maintenance of 
hematological status and on the amount needed to compensate obligatory 
losses (3-5). Relations between vitamin B12 intake and health related 
outcomes, e.g. cardiovascular diseases, cognitive function, and osteoporosis, 
are not yet taken into account when deriving vitamin B12 recommendations. 
To support transparent decision-making on whether these relations should 
be considered for setting vitamin B12 recommendations in the future, 
systematic reviews and meta-analyses are needed to objectively evaluate 
and integrate the available evidence (6). Previously, 5 systematic reviews 
addressed the relation between vitamin B12 intake or status and cognitive 
function in a qualitative manner (7-11). The aim of this review was to 
summarize dose-response evidence from randomized controlled trials (RCTs) 
and prospective cohort studies on the relation of vitamin B12 intake and 
status with cognitive function in adults and elderly people and to identify 
research gaps relevant for deriving vitamin B12 recommendations. 
 
METHODS 
This systematic review with dose-response meta-analyses was conducted 
according to standardized methodology as developed within the scope of the 
EURRECA (EURopean micronutrient RECommendations Aligned) Network of 
Excellence, which is shortly described below. 
 
Search 
We conducted a systematic literature search in the databases MEDLINE, 
EMBASE and Cochrane library Central through February 17, 2009, using 
search terms on study designs in humans AND vitamin B12 AND (intake OR 
status). The search terms both included MeSH terms and words to be found 
in title or abstract. The strategy was adapted for each database to fit 
database specific features. To be able to use the same search to identify 
publications on other health related outcomes both in adults and elderly and 
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in younger population groups, no terms were added to limit the search to 
health outcome or study population. Moreover, by using a broad search we 
expected a more complete retrieval of relevant publications. The search was 
not limited by language. Supplemental file 1 shows the full MEDLINE search 
strategy. The initial search yielded 5,219 references after exclusion of 
duplicates using Endnote XII. In addition, we reviewed reference lists of 10 
review articles reporting on the relation between vitamin B12 intake or 
status and cognitive function to identify potentially relevant references that 
were not yet collected on basis of the database search (n=134). We 
updated the searches on February 11, 2010 (n=560) and from February 
2010 to July 2011 we checked database alerts.  
 
Selection of studies 
For the selection of relevant papers for our systematic review, we used 
predefined in- and exclusion criteria. In general, studies were eligible for 
inclusion if they were conducted in apparently healthy human subjects aged 
≥18 y, addressed cognitive function as a health outcome and reported 
baseline data of the outcome measure. We defined 4 categories of cognitive 
function: incident dementia, incident Alzheimer’s disease (AD), global 
cognition, and domain-specific cognition. The specific domains of cognitive 
function used in this review were based on the classification of cognitive 
tests proposed by Wald et al. 2010 (12): memory, speed, language and 
executive function. Global cognition comprised assessment methods 
addressing different domains of cognition e.g. a compound z-score 
combining z-scores of different cognitive performance tests or the mini-
mental state examination (MMSE) combining aspects of orientation, memory 
and attention into one questionnaire (13). Domain-specific cognition includes 
cognitive performance tests assessing a single domain of cognitive function. 
Observational studies were included if they 1) had a prospective cohort or 
nested case-control design, and 2) addressed exposure by either validated 
dietary assessment methods or by serum/plasma concentration of markers 
indicating vitamin B12 status (total vitamin B12, methylmalonic acid (MMA) 
or holotranscobalamin II (holoTC II)). Intervention studies were included if 
they 1) had a randomized controlled trial design, 2) studied the effects of 
supplements, fortified foods or micronutrient intake from natural food 
sources and included a placebo or untreated comparison group, and 3) had 
minimum intervention duration of 2 weeks. Studies were excluded if they 
only included patients with pre-existing disease because relations of vitamin 
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B12 intake or status with cognitive function in such study populations may 
not be representative for the general apparently healthy population.  
First, 2 reviewers (ED, SB) screened titles and abstracts of all references 
identified with the searches according to the in- and exclusion criteria. 
Secondly, 4 reviewers (ED, JvW, AS, MP) evaluated full texts of the 
remaining references against the same criteria. For the purpose of alignment 
and quality control, each reviewer screened and evaluated 10 percent of the 
total number of references in duplicate with another reviewer. The rare 
discrepancies were resolved by group consultation among all reviewers until 
consensus was reached. During the selection process all reasons for 
exclusion were registered and details are shown in Figure 1. 
 
Data extraction 
Data extraction was performed by a single reviewer (ED, JvW, or AS) using 
standardized data extraction forms in an Access database. A second 
reviewer verified the data. Disagreements were discussed and settled, if 
needed in consultation with a third reviewer. Data extracted included 
general characteristics of the study design and study population; details on 
measures of intake, status and cognitive function; details on data analysis 
and results. In addition, we extracted information concerning the validity of 
studies including sequence allocation (RCT), blinding (RCT), compliance 
(RCT), reproducibility and between-population comparability of intake, 
status and cognitive measures, control for confounders (at least age, sex, 
education, vascular disease, ApoE-ɛ4) and other forms of bias. We assessed 
the overall risk of bias of each individual study using standardized 
procedures largely based on guidance from the Cochrane Collaboration (14), 
resulting in one of the following judgments: low, moderate or high risk of 
bias. 
 
Data-synthesis 
Opportunities for meta-analysis were evaluated for comparability with regard 
to cognitive outcome, intake or status marker and the study population. If 
less than 3 comparable studies were available, results were qualitatively 
described. If 3 or more comparable studies were available, we carried out a 
dose-response meta-analysis that pools the relative risk (RR) per change in 
unit of exposure (binary outcomes) or the regression coefficient (β) 
(continuous outcomes) from multiple adjusted models. For serum/plasma 
vitamin B12 we chose to express association measures per 50 pmol/l. 
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Hazard ratios (HR) and odds ratios (OR) were considered as relative risk 
because the outcome was relatively rare. 
 
If articles reported insufficient data (missing data, inconsistencies or any 
other uncertainties), we requested corresponding authors for additional 
information.  
None of the studies on incidence of dementia or AD provided data in the 
desired format, but rather presented the risk of dementia or AD comparing 
subjects with low versus normal vitamin B12 status (15-18) or the number 
of cases and controls among subjects with and without vitamin B12 
deficiency (19). One author provided us with the log (RR) and its standard 
error (SE) upon request (15, 16) and for 3 other studies we were able to 
derive the log (RR) (SE) based on reported data (16, 19) and data provided 
by the authors (18) as described in detail in Supplemental file 2. One author 
did not respond to our requests, and data were insufficient to derive the log 
(RR) (SE) (17). 
 
All studies on global cognition included repeated measures of global 
cognition scores. Associations with vitamin B12 status were most frequently 
assessed by the use of linear mixed models including serum/plasma 
concentrations of a vitamin B12 status marker, a time variable and the 
interaction term of vitamin B12 status and time (20-22). In such models, the 
regression coefficient for the interaction term represents the rate of change 
in global cognition attributable to an increase in vitamin B12 status 
additional to the deterioration in global cognition as a result of aging. Other 
studies presented associations between baseline serum vitamin B12 
concentrations and serial (23) or follow-up (24) global cognition scores, 
associations between baseline serum vitamin B12 and changes in cognitive 
decline during follow-up (25, 26), or Spearman rank correlations between 
changes in serum vitamin B12 and MMSE-scores (27). In 4 studies 
concentrations of vitamin B12 status markers were log-transformed (20, 23-
25) and 1 study presented associations per SD increase in serum vitamin 
B12 (21). We requested corresponding authors to provide us with the 
regression coefficient (SE) for the interaction term including untransformed 
continuous serum vitamin B12 concentrations. One study already reported 
data in the desired format (22) and 3 authors (21, 24, 26) provided the data 
upon request. 
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We requested authors of studies only providing data on MMSE-scores (20, 
23-25, 27) to repeat the analyses with MMSE expressed as a z-score, one 
author provided us with the requested data (24).  
 
Studies identified for domain-specific cognition addressed several cognitive 
domains, however, only for the domains executive function (21, 24, 28) and 
memory (21, 24, 26, 28) 3 or more comparable studies were available. 
Although studies were comparable, there was still variation with regard to 
the cognitive performance tests used, the frequency of cognitive 
performance testing, and statistical methods used to assess the association 
between executive function or memory and vitamin B12 status. Therefore 
we requested corresponding authors to provide us with the regression 
coefficient (SE) for the association between untransformed vitamin B12 
status measured at baseline and cognitive performance test scores at follow-
up expressed as z-scores. Four authors provided these data upon request 
(21, 24, 26, 29), enabling us to perform a meta-analysis for the domain 
memory.  
 
Statistical analyses 
We calculated summary estimates of comparable studies using random 
effects meta-analysis. Applying the methods of DerSimonian and Laird, the 
between-study variance is estimated which is then used to modify the 
weights for calculating the summary estimate (30). Heterogeneity between 
studies was evaluated using the I2 statistic, which expresses the percentage 
of variation attributable to between-study heterogeneity rather than chance 
(31). All statistical analyses were performed using STATA version 11.0 
(College Station, TX), with statistical significance defined as a P-value <0.05. 
 
RESULTS 
In total, we identified 5,913 potentially relevant papers, of which 5,005 
papers were excluded based on title and abstract. Of the remaining 908 
papers, 889 were excluded based on full texts, leaving 19 papers addressing 
the relation between vitamin B12 intake or status and cognitive function. 
Two additional papers were identified from the database alerts (Figure 1). 
From the 21 included studies, 2 RCTs and 4 prospective cohort studies 
addressed the relation between vitamin B12 intake and cognitive function. 
Chapter 5: Vitamin B12 and cognitive function 
117 
 
 T
a
b
le
 1
 I
n
ta
ke
 o
f 
V
it
a
m
in
 B
1
2
 i
n
 R
e
la
ti
o
n
 t
o
 I
n
ci
d
e
n
ce
 o
f 
D
e
m
e
n
ti
a
, 
In
ci
d
e
n
ce
 o
f 
A
lz
h
e
im
e
r’
s 
D
is
e
a
se
 (
A
D
),
 G
lo
b
a
l 
a
n
d
 D
o
m
a
in
-S
p
e
ci
fi
c 
In
d
ic
a
to
rs
 o
f 
C
o
g
n
it
io
n
: 
 
R
C
T
s 
a
n
d
 P
ro
sp
e
ct
iv
e
 C
o
h
o
rt
 S
tu
d
ie
s 
 
R
C
T
, 
ra
n
d
o
m
iz
e
d
 c
o
n
tr
o
lle
d
 t
ri
a
l;
 M
M
S
E
: 
m
in
i-
m
e
n
ta
l 
st
a
te
 e
x
a
m
in
a
ti
o
n
; 
H
R
, 
h
a
za
rd
 r
a
ti
o
; 
O
R
, 
o
d
d
s 
ra
ti
o
; 
n
.s
. 
n
o
t 
si
g
n
if
ic
a
n
t,
 b
u
t 
n
o
 p
-v
a
lu
e
 p
ro
v
id
e
d
 
V
a
lu
e
s 
in
 i
ta
lic
s 
a
re
 c
a
lc
u
la
te
d
 b
a
se
d
 o
n
 p
ro
v
id
e
d
 v
a
lu
e
s.
 *
V
a
lu
e
s 
B
a
se
d
 o
n
 t
o
ta
l 
p
o
p
u
la
ti
o
n
 
(a
) 
m
e
a
n
 (
S
D
) 
a
ll 
su
ch
 v
a
lu
e
s,
 u
n
le
ss
 s
ta
te
d
 o
th
e
rw
is
e
; 
(b
) 
m
e
a
n
, 
u
n
le
ss
 s
ta
te
d
 o
th
e
rw
is
e
; 
(c
) 
M
e
a
n
 (
ra
n
g
e
);
 (
d
) 
M
e
d
ia
n
 (
IQ
R
);
 (
e
) 
N
e
ls
o
n
 e
t 
a
l.
 a
d
ju
st
e
d
 f
o
r 
g
e
n
d
e
r,
 e
d
u
ca
ti
o
n
, 
B
o
d
y
 M
a
ss
 I
n
d
e
x
, 
to
ta
l 
e
n
e
rg
y
, 
p
h
y
si
ca
l 
a
ct
iv
it
y
, 
A
p
o
E
4
 s
ta
tu
s,
 a
lc
o
h
o
l,
 s
m
o
k
in
g
, 
M
y
o
ca
rd
ia
l 
In
fa
rc
ti
o
n
, 
st
ro
k
e
, 
D
ia
b
e
te
s 
a
n
d
 t
h
e
 o
th
e
r 
B
-v
it
a
m
in
s;
 (
f)
 M
o
rr
is
 e
t 
a
l.
 a
d
ju
st
e
d
 f
o
r 
a
g
e
, 
g
e
n
d
e
r,
 e
th
n
ic
it
y
, 
e
d
u
ca
ti
o
n
, 
v
it
a
m
in
 E
 i
n
ta
k
e
, 
n
ia
ci
n
 i
n
ta
k
e
, 
A
p
o
E
4
 s
ta
tu
s,
 
p
a
rt
ic
ip
a
ti
o
n
 i
n
 c
o
g
n
it
iv
e
 a
ct
iv
it
ie
s;
 (
g
) 
T
u
ck
e
r 
e
t 
a
l.
 a
d
ju
st
e
d
 f
o
r 
a
g
e
, 
e
d
u
ca
ti
o
n
, 
B
o
d
y
 M
a
ss
 I
n
d
e
x
, 
a
lc
o
h
o
l,
 s
m
o
k
in
g
, 
d
ia
b
e
te
s,
 s
y
st
o
lic
 b
lo
o
d
 p
re
ss
u
re
, 
b
a
se
lin
e
 c
o
g
n
it
iv
e
 m
e
a
su
re
s,
 t
im
e
 o
f 
se
co
n
d
 m
e
a
su
re
 r
e
la
ti
v
e
 t
o
 
fo
lic
 a
ci
d
 f
o
rt
if
ic
a
ti
o
n
, 
ti
m
e
 i
n
te
rv
a
l 
b
e
tw
e
e
n
 t
h
e
 2
 c
o
g
n
it
iv
e
 m
e
a
su
re
s,
 t
o
ta
l 
e
n
e
rg
y
 i
n
ta
k
e
; 
(h
) 
M
e
m
o
ry
 f
u
n
ct
io
n
 i
m
p
ro
v
e
d
 i
n
 a
ll 
tr
e
a
tm
e
n
t 
g
ro
u
p
s,
 b
u
t 
th
e
 i
m
p
ro
v
e
m
e
n
t 
in
 t
h
e
 p
la
ce
b
o
 g
ro
u
p
 w
a
s 
si
g
n
if
ic
a
n
tl
y
 b
e
tt
e
r 
th
a
n
 
th
e
 i
m
p
ro
v
e
m
e
n
t 
in
 t
h
e
 v
it
a
m
in
 B
1
2
 g
ro
u
p
; 
(i
) 
L
a
 R
u
e
 e
t 
a
l.
 a
d
ju
st
e
d
 f
o
r 
a
g
e
 
A
u
th
o
r 
Y
e
a
r 
 
P
o
p
u
la
ti
o
n
 c
h
a
ra
ct
e
ri
st
ic
s:
 
N
 (
%
 m
e
n
) 
A
g
e
 (
y
e
a
r)
 
 
S
tu
d
y
 c
h
a
ra
ct
e
ri
st
ic
s:
 
S
tu
d
y
 d
e
si
g
n
 
D
u
ra
ti
o
n
/F
o
llo
w
-u
p
 
R
is
k
 o
f 
b
ia
s 
E
x
p
o
su
re
: 
V
it
a
m
in
 B
1
2
 i
n
ta
k
e
 
(µ
g
/d
) 
 
C
o
g
n
it
iv
e
 o
u
tc
o
m
e
  
(n
u
m
b
e
r 
o
f 
ca
se
s 
o
r 
sp
e
ci
fi
c 
te
st
):
 
A
ss
o
ci
a
ti
o
n
/e
ff
e
ct
 m
e
a
su
re
: 
R
e
su
lt
s:
 
 
N
e
ls
o
n
 
2
0
0
9
 
[3
2
] 
3
6
3
4
 (
4
3
) 
7
4
.7
 (
6
.7
) 
(a
) 
 
C
o
h
o
rt
 
9
 y
e
a
rs
 
L
o
w
 r
is
k
 
9
.6
  
(1
0
.2
) 
 
In
ci
d
e
n
ce
 o
f 
d
e
m
e
n
ti
a
 (
3
5
2
 c
a
se
s)
 
In
ci
d
e
n
ce
 o
f 
A
D
 (
2
1
2
 c
a
se
s)
 
H
R
 (
9
5
%
 C
I)
 b
y
 q
u
in
ti
le
 o
f 
in
ta
k
e
 (
Q
5
/Q
1
) 
(e
) 
 
0
.8
7
 (
0
.5
2
-1
.4
6
) 
0
.9
1
 (
0
.5
2
-1
.6
0
) 
M
o
rr
is
  
2
0
0
6
 
[3
3
] 
1
0
4
1
 (
3
8
) 
7
2
.7
 (
b
) 
 
C
o
h
o
rt
 
3
.9
  
y
e
a
rs
 
M
o
d
e
ra
te
 r
is
k
 
1
1
.1
 (
0
.5
-1
2
7
.2
) 
(c
) 
 
In
ci
d
e
n
ce
 o
f 
A
D
 (
1
6
2
 c
a
se
s)
 
O
R
 (
9
5
%
 C
I)
 b
y
 q
u
in
ti
le
 o
f 
in
ta
k
e
 (
Q
5
/Q
1
) 
(f
) 
 
0
.6
 (
0
.2
-1
.6
) 
S
e
a
l 
 
2
0
0
2
 
[3
4
] 
1
0
 μ
g
:1
0
 (
4
0
),
 5
0
 μ
g
:1
0
 (
5
0
),
 
C
o
n
tr
o
l:
1
1
 (
4
5
) 
1
0
 μ
g
:8
2
, 
5
0
 μ
g
:8
4
.9
, 
C
o
n
tr
o
l:
7
7
.6
 
L
o
w
 v
it
a
m
in
 B
1
2
 s
ta
tu
s 
 a
t 
b
a
se
lin
e
 
R
C
T
 
4
 w
e
e
k
s 
M
o
d
e
ra
te
 r
is
k
 
1
0
 o
r 
5
0
 v
s 
p
la
ce
b
o
 
G
lo
b
a
l 
co
g
n
it
io
n
 (
M
M
S
E
) 
D
if
fe
re
n
ce
 b
e
tw
e
e
n
 t
re
a
tm
e
n
t 
g
ro
u
p
s 
 
 
P
=
0
.4
9
4
 
T
u
ck
e
r 
 
2
0
0
5
 
[2
4
] 
 
3
2
1
 (
1
0
0
) 
6
7
 (
7
) 
 
C
o
h
o
rt
 
3
 y
e
a
rs
 
M
o
d
e
ra
te
 r
is
k
 
9
.5
7
 (
5
.7
3
) 
 
G
lo
b
a
l 
co
g
n
it
io
n
 (
M
M
S
E
) 
E
x
e
cu
ti
v
e
 f
u
n
ct
io
n
 (
sp
a
ti
a
l 
co
p
y
in
g
) 
M
e
m
o
ry
 (
w
o
rk
in
g
 m
e
m
o
ry
) 
M
e
m
o
ry
 (
re
ca
ll 
m
e
m
o
ry
) 
L
a
n
g
u
a
g
e
 (
v
e
rb
a
l 
fl
u
e
n
cy
) 
β
 f
o
r 
a
ss
o
ci
a
ti
o
n
 b
e
tw
e
e
n
 
co
g
n
it
io
n
 a
t 
3
 y
 a
n
d
 b
a
se
lin
e
 
in
ta
k
e
 (
g
) 
 
0
.1
4
, 
n
.s
. 
0
.3
7
 (
p
<
0
.0
5
) 
0
.1
2
, 
n
.s
. 
-0
.0
1
, 
n
.s
. 
0
.3
8
, 
n
.s
. 
E
u
ss
e
n
  
2
0
0
6
 
[3
5
] 
In
te
rv
e
n
ti
o
n
: 
5
4
 (
2
3
),
  
C
o
n
tr
o
l:
 5
7
(2
2
) 
In
te
rv
e
n
ti
o
n
 :
8
2
 (
5
),
 C
o
n
tr
o
l:
 8
2
 
(5
) 
L
o
w
 v
it
a
m
in
 B
1
2
 s
ta
tu
s 
a
t 
b
a
se
lin
e
 
R
C
T
 
2
4
 w
e
e
k
s 
M
o
d
e
ra
te
 r
is
k
 
1
0
0
0
 v
s 
p
la
ce
b
o
 
E
x
e
cu
ti
v
e
 f
u
n
ct
io
n
 (
co
m
p
o
u
n
d
 z
-s
co
re
, 
n
=
7
) 
M
e
m
o
ry
 (
co
m
p
o
u
n
d
 z
-s
co
re
, 
n
=
6
) 
S
p
e
e
d
 (
co
m
p
o
u
n
d
 z
-s
co
re
, 
n
=
3
) 
D
if
fe
re
n
ce
 b
e
tw
e
e
n
 t
re
a
tm
e
n
t 
g
ro
u
p
s 
 
 
n
.s
. 
 p
<
0
.0
5
 (
h
) 
n
.s
. 
L
a
 R
u
e
  
1
9
9
7
 
[2
8
] 
 
1
2
2
 (
4
9
*
) 
7
1
.7
  
 
C
o
h
o
rt
 
6
 y
e
a
rs
 
H
ig
h
 r
is
k
 
 
5
.4
 (
2
.9
-1
1
.7
) 
(d
) 
 
E
x
e
cu
ti
v
e
 f
u
n
ct
io
n
 (
R
e
y
 O
st
e
rr
ie
th
 c
o
p
y
) 
 
E
x
e
cu
ti
v
e
 f
u
n
ct
io
n
 (
S
h
ip
le
y
-H
a
rt
fo
rd
 a
b
st
ra
ct
io
n
) 
M
e
m
o
ry
 (
R
e
y
-O
st
e
rr
ie
th
 r
e
ca
ll)
 
M
e
m
o
ry
 (
W
M
S
 l
o
g
ic
a
l 
m
e
m
o
ry
) 
M
e
m
o
ry
 (
W
M
S
 v
is
u
a
l 
re
p
ro
d
u
ct
io
n
) 
S
p
e
a
rm
a
n
 c
o
rr
e
la
ti
o
n
s 
b
e
tw
e
e
n
  
co
g
n
it
io
n
 a
t 
6
 y
 a
n
d
 
b
a
se
lin
e
 i
n
ta
k
e
 (
i)
 
 
n
.s
. 
0
.2
0
 (
p
<
0
.0
5
) 
 0
.1
9
 (
p
<
0
.0
5
) 
n
.s
. 
n
.s
. 
Chapter 5: Vitamin B12 and cognitive function 
118 
 
 T
a
b
le
 2
 V
it
a
m
in
 B
1
2
 S
ta
tu
s 
in
 R
e
la
ti
o
n
 t
o
 I
n
ci
d
e
n
ce
 o
f 
D
e
m
e
n
ti
a
 a
n
d
 I
n
ci
d
e
n
ce
 o
f 
A
lz
h
e
im
e
r’
s 
D
is
e
a
se
 (
A
D
):
 P
ro
sp
e
ct
iv
e
 C
o
h
o
rt
 S
tu
d
ie
s
 
A
u
th
o
r 
Y
e
a
r 
 
P
o
p
u
la
ti
o
n
 c
h
a
ra
ct
e
ri
st
ic
s:
 
N
 (
%
 m
e
n
) 
A
g
e
 (
y
e
a
rs
) 
S
tu
d
y
 c
h
a
ra
ct
e
ri
st
ic
s:
 
S
tu
d
y
 d
e
si
g
n
 
F
o
llo
w
-u
p
 (
y
e
a
rs
) 
R
is
k
 o
f 
b
ia
s 
E
x
p
o
su
re
: 
 
M
a
rk
e
r 
o
f 
v
it
a
m
in
 B
1
2
 s
ta
tu
s 
 
C
o
n
ce
n
tr
a
ti
o
n
  
O
u
tc
o
m
e
: 
In
ci
d
e
n
ce
 o
f 
d
e
m
e
n
ti
a
/A
D
 (
ca
se
s)
 
A
ss
o
ci
a
ti
o
n
 m
e
a
su
re
: 
R
e
su
lt
: 
C
ry
st
a
l 
1
9
9
4
  
[1
9
] 
4
1
0
 (
?)
 
7
5
-8
5
 (
a
) 
C
o
h
o
rt
 
5
 
H
ig
h
 r
is
k
 
S
e
ru
m
 v
it
a
m
in
 B
1
2
 (
p
m
o
l/
l)
 
4
1
2
 (
7
4
-3
6
6
0
)(
c)
 
D
e
m
e
n
ti
a
 (
6
0
) 
 A
D
 (
3
0
) 
R
R
 (
9
5
%
C
I)
 p
e
r 
5
0
 u
n
it
s 
in
cr
e
a
se
 
in
 b
a
se
lin
e
 s
ta
tu
s 
(e
) 
R
R
 (
9
5
%
C
I)
 p
e
r 
5
0
 u
n
it
s 
in
cr
e
a
se
 
in
 b
a
se
lin
e
 s
ta
tu
s 
(e
) 
1
.0
0
 (
0
.9
6
-1
.0
3
) 
 0
.9
8
 (
0
.9
2
-1
.0
5
) 
 
H
a
a
n
 
2
0
0
7
  
[1
5
] 
1
3
3
2
 (
4
2
*
) 
6
0
-1
0
1
  
C
o
h
o
rt
 
4
.5
 
M
o
d
e
ra
te
 r
is
k
 
P
la
sm
a
 v
it
a
m
in
 B
1
2
 (
p
m
o
l/
l)
 
3
3
4
 (
1
5
0
) 
D
e
m
e
n
ti
a
 o
r 
co
g
n
it
iv
e
 
im
p
a
ir
m
e
n
t 
n
o
 
d
e
m
e
n
ti
a
 (
C
IN
D
) 
(8
0
) 
H
R
 (
9
5
%
 C
I)
 p
e
r 
u
n
it
 i
n
cr
e
a
se
 i
n
 
sq
rt
 b
a
se
lin
e
 s
ta
tu
s 
 (
f)
 
H
R
 (
9
5
%
C
I)
 p
e
r 
5
0
 u
n
it
s 
in
cr
e
a
se
 
in
 b
a
se
lin
e
 s
ta
tu
s 
(f
) 
1
.0
5
 (
1
.0
1
-1
.0
9
) 
 1
.0
3
 (
0
.9
8
-1
.0
7
) 
K
im
 
2
0
0
8
  
[1
6
] 
5
1
8
 (
4
3
) 
7
1
.8
 (
5
.0
) 
(b
) 
C
o
h
o
rt
 
2
.4
 
M
o
d
e
ra
te
 r
is
k
 
S
e
ru
m
 v
it
a
m
in
 B
1
2
 (
p
m
o
l/
l)
 
3
8
0
.7
 (
1
4
9
.3
) 
D
e
m
e
n
ti
a
 (
4
5
) 
O
R
 (
9
5
%
 C
I)
 f
o
r 
lo
w
 (
<
2
5
8
 
p
m
o
l/
l)
 v
e
rs
u
s 
n
o
rm
a
l 
b
a
se
lin
e
 
st
a
tu
s 
(g
) 
O
R
 (
9
5
%
C
I)
 p
e
r 
5
0
 u
n
it
s 
in
cr
e
a
se
 
in
 b
a
se
lin
e
 s
ta
tu
s 
(g
) 
1
.5
3
 (
0
.6
9
-3
.3
8
) 
  1
.0
8
 (
0
.9
3
-1
.2
6
) 
W
a
n
g
 
2
0
0
1
  
[1
8
] 
3
7
0
 (
2
0
) 
7
5
-1
0
1
 
C
o
h
o
rt
 
3
 
M
o
d
e
ra
te
  
ri
sk
 
S
e
ru
m
 v
it
a
m
in
 B
1
2
 (
p
m
o
l/
l)
 
3
2
4
 (
5
1
0
) 
D
e
m
e
n
ti
a
 (
7
8
) 
    A
D
 (
6
0
) 
R
R
 (
9
5
%
 C
I)
 f
o
r 
lo
w
 (
≤
2
5
0
 
p
m
o
l/
l)
 v
e
rs
u
s 
n
o
rm
a
l 
b
a
se
lin
e
 
st
a
tu
s 
(h
) 
R
R
 (
9
5
%
C
I)
 p
e
r 
5
0
 u
n
it
s 
in
cr
e
a
se
 
in
 b
a
se
lin
e
 s
ta
tu
s 
(h
) 
 
R
R
 (
9
5
%
 C
I)
 f
o
r 
lo
w
 (
≤
2
5
0
 
p
m
o
l/
l)
 v
e
rs
u
s 
n
o
rm
a
l 
b
a
se
lin
e
 
st
a
tu
s 
(h
) 
R
R
4
 (
9
5
%
C
I)
 p
e
r 
5
0
 u
n
it
s 
in
cr
e
a
se
 
in
 b
a
se
lin
e
 s
ta
tu
s 
(h
) 
 
1
.3
 (
0
.8
-2
.1
) 
  1
.0
 (
1
.0
-1
.1
) 
 1
.8
 (
1
.0
-3
.0
) 
  1
.0
 (
1
.0
-1
.1
) 
R
a
v
a
g
lia
 
2
0
0
5
  
[1
7
] 
8
1
6
 (
4
7
) 
7
3
.6
 (
6
.3
) 
C
o
h
o
rt
 
4
 
M
o
d
e
ra
te
 r
is
k
 
S
e
ru
m
 v
it
a
m
in
 B
1
2
 (
p
m
o
l/
l)
 
tH
cy
≤
1
5
 µ
m
o
l/
l:
 2
5
9
 (
9
4
-7
0
8
) 
(d
) 
tH
cy
>
1
5
 µ
m
o
l/
l:
 2
1
2
 (
7
3
-6
1
2
) 
(d
) 
D
e
m
e
n
ti
a
 (
1
1
2
) 
A
D
 (
7
0
) 
H
R
 (
9
5
%
 C
I)
 f
o
r 
lo
w
 (
≤
2
5
1
 
p
m
o
l/
l)
 v
e
rs
u
s 
n
o
rm
a
l 
b
a
se
lin
e
 
st
a
tu
s 
(i
) 
0
.8
3
 (
0
.5
6
-1
.2
4
) 
0
.6
6
 (
0
.4
0
-1
.0
9
) 
K
iv
ip
e
lt
o
 
2
0
0
9
 
[4
2
] 
2
1
3
 (
2
5
) 
8
1
.0
 (
4
.6
) 
C
o
h
o
rt
 
6
.7
 
M
o
d
e
ra
te
 r
is
k
 
H
o
lo
-T
C
  
(p
m
o
l/
l)
 
1
0
5
 (
8
8
) 
 
D
e
m
e
n
ti
a
 (
8
3
) 
A
D
 (
6
1
) 
R
R
 (
9
5
%
C
I)
 p
e
r 
u
n
it
 i
n
cr
e
a
se
 i
n
 
b
a
se
lin
e
 s
ta
tu
s 
(j
) 
 
1
.0
0
 (
0
.9
9
–
1
.0
0
) 
1
.0
0
 (
0
.9
9
-1
.0
0
) 
 
Chapter 5: Vitamin B12 and cognitive function 
119 
 
 
T
a
b
le
 2
 (
co
n
ti
n
u
e
d
) 
A
u
th
o
r 
Y
e
a
r 
 
P
o
p
u
la
ti
o
n
 c
h
a
ra
ct
e
ri
st
ic
s:
 
N
 (
%
 m
e
n
) 
A
g
e
 (
y
e
a
rs
) 
S
tu
d
y
 c
h
a
ra
ct
e
ri
st
ic
s:
 
S
tu
d
y
 d
e
si
g
n
 
F
o
llo
w
-u
p
 (
y
e
a
rs
) 
R
is
k
 o
f 
b
ia
s 
E
x
p
o
su
re
: 
 
M
a
rk
e
r 
o
f 
v
it
a
m
in
 B
1
2
 s
ta
tu
s 
 
C
o
n
ce
n
tr
a
ti
o
n
  
O
u
tc
o
m
e
: 
In
ci
d
e
n
ce
 o
f 
d
e
m
e
n
ti
a
/A
D
 (
ca
se
s)
 
A
ss
o
ci
a
ti
o
n
 m
e
a
su
re
: 
R
e
su
lt
: 
H
o
o
sh
m
a
n
d
  
2
0
1
0
 
[4
3
] 
2
7
1
 (
3
8
) 
7
0
.7
 (
3
.6
) 
C
o
h
o
rt
 
7
.4
 
L
o
w
 r
is
k
 
H
o
lo
T
C
 I
I 
(p
m
o
l/
l)
 
9
1
.3
 (
 5
1
.0
) 
A
D
 (
1
7
) 
O
R
 (
9
5
%
C
I)
 p
e
r 
u
n
it
 i
n
cr
e
a
se
 i
n
 
b
a
se
lin
e
 s
ta
tu
s 
(k
) 
 
0
.9
7
7
 (
0
.9
5
8
-
0
.9
9
7
) 
A
D
, 
A
lz
h
e
im
e
r’
s 
d
is
e
a
se
; 
H
o
lo
T
C
 I
I,
 h
o
lo
tr
a
n
sc
o
b
a
la
m
in
 I
I;
 R
R
, 
re
la
ti
v
e
 r
is
k
; 
H
R
, 
h
a
za
rd
 r
a
ti
o
; 
O
R
, 
o
d
d
s 
ra
ti
o
; 
C
I,
 c
o
n
fi
d
e
n
ce
 i
n
te
rv
a
l 
V
a
lu
e
s 
in
 i
ta
lic
s 
a
re
 c
a
lc
u
la
te
d
 b
a
se
d
 o
n
 p
ro
v
id
e
d
 v
a
lu
e
s.
 U
n
d
e
rl
in
e
d
 v
a
lu
e
s 
a
re
 a
d
d
it
io
n
a
ly
 p
ro
v
id
e
d
 b
y
 t
h
e
 a
u
th
o
r 
*
V
a
lu
e
s 
b
a
se
d
 o
n
 t
o
ta
l 
p
o
p
u
la
ti
o
n
 
(a
) 
ra
n
g
e
 a
ll 
su
ch
 v
a
lu
e
s 
 
(b
) 
m
e
a
n
 (
S
D
) 
a
ll 
su
ch
 v
a
lu
e
s,
 u
n
le
ss
 s
ta
te
d
 o
th
e
rw
is
e
  
(c
) 
m
e
a
n
 (
ra
n
g
e
) 
 
(d
) 
g
e
o
m
e
tr
ic
 m
e
a
n
s 
(9
5
%
 c
o
n
fi
d
e
n
ce
 I
n
te
rv
a
l)
 
(e
) 
C
ry
st
a
l 
e
t 
a
l.
 u
n
a
d
ju
st
e
d
 
(f
) 
H
a
a
n
 e
t 
a
l.
 a
d
ju
st
e
d
 f
o
r 
a
g
e
, 
se
x
, 
e
d
u
ca
ti
o
n
, 
b
a
se
lin
e
 s
tr
o
k
e
, 
p
la
sm
a
 h
o
m
o
cy
st
e
in
e
, 
re
d
 b
lo
o
d
 c
e
ll 
fo
la
te
, 
(g
) 
K
im
 e
t 
a
l.
 a
d
ju
st
e
d
 f
o
r 
a
g
e
, 
se
x
, 
e
d
u
ca
ti
o
n
, 
sm
o
k
in
g
, 
a
lc
o
h
o
l,
 p
h
y
si
ca
l 
a
ct
iv
it
y
, 
b
o
d
y
 w
e
ig
h
t,
 d
is
a
b
ili
ty
, 
d
e
p
re
ss
io
n
, 
v
a
sc
u
la
r 
ri
sk
 s
co
re
, 
v
it
a
m
in
 i
n
ta
k
e
, 
se
ru
m
 c
re
a
ti
n
in
e
 
(h
)W
a
n
g
 e
t 
a
l.
 a
d
ju
st
e
d
 f
o
r 
a
g
e
, 
se
x
, 
e
d
u
ca
ti
o
n
 
(i
) 
R
a
v
a
g
lia
 e
t 
a
l.
 a
d
ju
st
e
d
 f
o
r 
a
g
e
, 
se
x
, 
e
d
u
ca
ti
o
n
, 
A
p
o
E
4
 s
ta
tu
s,
 h
is
to
ry
 o
f 
st
ro
k
e
, 
se
ru
m
 c
re
a
ti
n
in
e
, 
p
la
sm
a
 h
o
m
o
cy
st
e
in
e
, 
se
ru
m
 f
o
la
te
, 
 
(j
) 
K
iv
ip
e
lt
o
 e
t 
a
l.
 a
d
ju
st
e
d
 f
o
r 
a
g
e
, 
se
x
, 
e
d
u
ca
ti
o
n
 
(k
) 
H
o
o
sh
m
a
n
d
 e
t 
a
l.
 a
d
ju
st
e
d
 f
o
r 
a
g
e
, 
se
x
, 
e
d
u
ca
ti
o
n
, 
d
u
ra
ti
o
n
 o
f 
fo
llo
w
-u
p
, 
A
p
o
E
4
 s
ta
tu
s,
 B
o
d
y
 M
a
ss
 I
n
d
e
x
, 
M
in
i 
M
e
n
ta
l 
S
ta
te
 E
x
a
m
in
a
ti
o
n
-s
co
re
, 
sy
st
o
lic
 b
lo
o
d
 p
re
ss
u
re
, 
d
ia
st
o
lic
 b
lo
o
d
 p
re
ss
u
re
, 
sm
o
k
in
g
, 
h
is
to
ry
 o
f 
st
ro
k
e
 
Chapter 5: Vitamin B12 and cognitive function 
120 
 
Seventeen prospective cohort studies addressed the relation between 
vitamin B12 status, measured by serum/plasma vitamin B12 (n=15), MMA 
(n=2) or holoTC II (n=2) and cognitive function.  
 
Vitamin B12 intake and cognitive function 
Details on the studies addressing the relation between vitamin B12 intake 
and cognitive function are presented in Table 1. Due to the large variation in 
cognitive outcomes, no meta-analyses could be performed on this relation. 
Studies on incident dementia (32), incident AD (32, 33) or global cognition 
assessed by MMSE (24, 34) did not show significant associations with 
vitamin B12 intake. One RCT (35) and 2 prospective cohort studies (24, 28) 
addressed the association between vitamin B12 intake and domain-specific 
cognition. For the domain executive function the 2 prospective cohort 
studies found that higher vitamin B12 intakes at baseline were associated 
with a better cognitive performance after 3 or 6 years of follow-up (β=0.37, 
p<0.05 (24), Spearman correlation=0.20, p<0.05 (28)) whereas the RCT did 
not show beneficial effects of daily vitamin B12 supplementation (35). For 
the domain memory results were largely inconsistent showing a positive (28), 
negative (35) or no (24, 28) association. The cognitive domains speed and 
language were only addressed in single studies and no associations with 
vitamin B12 intake were observed (24, 35). 
 
Vitamin B12 status and incident dementia or AD 
Table 2 presents details of the prospective cohort studies investigating the 
association between vitamin B12 status and incidence of dementia or AD. 
Dementia and AD were diagnosed based on similar criteria (dementia: (36-
39); AD: (39-41)). Four studies involving 2,630 elderly people (age range: 
60-101 year) were included in a meta-analysis pooling relative risks for 
incidence of dementia (263 cases) during 2.4 to 4.5y follow-up per 50 pmol/l 
increase in serum/plasma vitamin B12 concentrations at baseline (15, 16, 18, 
19). The summary estimate showed no association between serum/plasma 
vitamin B12 and incidence of dementia (RR=1.01, 95% CI: 0.99, 1.03) with 
no heterogeneity between studies (I2=0%, p=0.61) (Figure 2). Similar to 
this finding, Ravaglia et al. (2005) (17) reported that low serum vitamin B12 
concentrations (≤250 pmol/l) did not significantly increase the risk of 
dementia (HR=0.83, 95% CI: 0.56, 1.24) and Kivipelto et al. (2009) (42) 
reported a relative risk of 1.00 for the risk of dementia per pmol/l increase in 
holoTC II concentrations (95% CI: 0.99, 1.00).  
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Five studies reported on the association between vitamin B12 status (serum 
vitamin B12 n=3, holoTC II n=2) and incidence of AD. Hooshmand et al. 
(2010) (43) reported a borderline significant odds ratio per pmol/l increase 
in holoTC II concentrations at baseline, but all other studies did not show 
significant associations (17-19, 42). 
 
NOTE: Weights are from random effects analysis
Overall  (I-squared = 0.0%, p = 0.611)
Haan, 2007 [15]
Wang, 2001 [18]
Kim, 2008 [16]
Crystal 1994 [19]
Study
1.01 (0.99, 1.03)
1.03 (0.98, 1.07)
1.02 (0.99, 1.05)
1.08 (0.93, 1.26)
1.00 (0.96, 1.03)
RR (95% CI)
100.00
%
20.82
48.04
1.73
29.41
Weight
  
1.792 1.26
 
Figure 2. Forest plot of association between serum vitamin B12 (50 pmol/l) and risk of dementia: 
Meta-Analysis of 4 prospective cohort studies (n=2630, 363 cases). RR, relative risk; CI, confidence 
interval 
 
i ure 2 Fores plot of association between serum/ lasm  vitamin B12 (50 
pmol/l) and risk of dementia: M ta-Analysis of 4 prosp c i e cohort studies 
(n=2630, 363 cases)  
RR, relative risk; CI, confidence interval 
 
Vitamin B12 status and global cognition 
For global cognition, we identified 3 prospective cohort studies on 
serum/plasma vitamin B12 and compound z-scores (21, 22, 26), and 5 
prospective cohort studies on serum/plasma vitamin B12 and MMSE-scores 
(20, 21, 23, 24, 35) (Table 3).  
From 4 cohort studies including 1,579 elderly people, we obtained the 
regression coefficient for associations between additional annual change in 
compound z-score (21, 22, 26) or MMSE z-score (24) and serum/plasma 
vitamin B12 concentrations (50 pmol/l). A pooled analysis of the results 
showed no overall association (β=0.00, 95% CI: -0.00, 0.01), with moderate 
heterogeneity between studies (I2=42.6%, p=0.16) (Figure 3).  
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For MMSE-scores we did not have sufficient data available in the desired 
format to perform a meta-analysis and therefore results are qualitatively 
described. In line with the finding from the pooled analysis, 3 studies 
showed that the additional rate of change in MMSE-score was not 
significantly associated with serum vitamin B12 concentrations (20, 21, 24).  
Eussen et al. (2002) (27) and Kado et al. (2005) (25) reported no significant 
associations  between  serum/plasma  vitamin B12  concentrations  and  
global cognition (Spearman correlation between changes in MMSE and 
changes in plasma vitamin B12, r=-0.069; risk of being in the worst quartile 
of cognitive decline comparing those in the lowest quartile of baseline status 
versus the rest, RR=1.42, 95% CI: 0.91, 2.06) (Table 3). In contrast, Feng 
et al. (2009) (23) showed that higher serum vitamin B12 concentrations at 
baseline (natural log transformed, pmol/l) were significantly associated with 
better repeated MMSE-scores during follow-up (β=1.07, SE=0.35, p=0.003). 
NOTE: Weights are from random effects analysis
Overall  (I-squared = 42.6%, p = 0.156)
Study
Tangney, 2009 [22]
Tucker, 2005 [24]
Kang, 2006 [26]
Mooijaart, 2005 [21]
0.00 (-0.00, 0.01)
B (95% CI)
0.01 (-0.00, 0.02)
0.02 (-0.01, 0.06)
0.00 (-0.01, 0.01)
-0.00 (-0.01, 0.00)
100.00
Weight
25.96
2.80
%
28.46
42.78
  
0-.0626 .0626
 
Figure 3 Forest plot of association between serum vitamin B12 (50 pmol/l) 
and additional rate of change in global cognition z-scores: Meta-Analysis of 4 
Prospective Cohort Studies (n=1579)  
B, regression coefficient; CI, confidence interval 
 
Longitudinal data on MMA and holoTC II in relation to global cognition 
scores were scarce. Clarke et al. (2007) (20) reported the additional change 
in MMSE-score during 10 y related to a doubling in MMA (μmol/l) (β=-0.65, 
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95% CI=-0.98; -0.32) and holoTC II concentrations (pmol/l) at baseline 
(β=0.59, 95% CI: 0.30,0.88); and showed that a doubling of MMA 
concentrations was associated with about 60 percent faster rate of cognitive 
decline and a doubling of holoTC II concentrations was associated with a 40 
percent slower rate of cognitive decline. In addition, Tangney et al. (2009) 
(22) reported that higher MMA concentrations (μmol/l) were associated with 
a more rapid deterioration of global cognition assessed with a compound z-
score of 4 tests (β=-0.00016, SE=0.0001). 
 
Vitamin B12 status and domain specific cognition 
Five prospective cohort studies investigated associations between 
serum/plasma vitamin B12 and memory (n=5), executive function (n=3), 
speed (n=1) and language (n=1) (Table 4).  
For the domain memory we pooled associations between memory z-scores 
at 3, 4, or 6 years follow-up and serum/plasma vitamin B12 concentrations 
at baseline (50 pmol/l) from 4 studies (21, 24, 26, 29) including 3,460 
elderly people. The studies of Mooijaart et al. (2005) (21) and Tucker et al. 
(2005) (24) both included 2 memory scores (word list and word list recall at 
30 min (21) or word list and backward-digit span (24)). Therefore we 
performed 2 meta-analyses, one with the word list scores and one with the 
other 2 memory scores, but for both analyses the overall associations were 
similar (β=0.01, 95% CI:-0.01, 0.03), with no evidence for heterogeneity 
between studies (I2=0.0%, p=0.99).  
In line with these results, La Rue et al. (1995) (28) reported that Spearman 
correlations between plasma vitamin B12 at baseline and 3 different memory 
scores at 6 years follow-up were not significant (no data available). 
Associations between serum vitamin B12 concentrations at baseline and 
executive function at follow-up were assessed in 3 cohort studies (21, 24, 
28). La Rue et al.(28) and Mooijaart et al. (21) showed no significant 
associations, whereas Tucker et al. (24) observed that higher serum vitamin 
B12 concentrations (50 pmol/l) were associated with a better executive 
function score at 3 years follow-up (β =0.026, SE=0.016 , p<0.05).  
The cognitive domains language (24) and speed (21) were both assessed in 
single studies, but no associations with serum vitamin B12 were found. 
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DISCUSSION 
Main findings 
The available evidence from a limited number of RCTs and prospective 
cohort studies in elderly people does not support the hypothesis that vitamin 
B12 intake or status is related with dementia, AD or global cognition. For 
domain-specific cognition, some prospective cohort studies observed 
associations between vitamin B12 intake or serum vitamin B12 and 
executive function or memory, however, results were inconsistent. 
Significant associations were shown between MMA or holoTC II and global 
cognition scores indicating better performance with better vitamin B12 
status, but these findings originate from only 2 prospective cohort studies. 
Overall, these results suggest that current evidence on the relation of 
vitamin B12 intake or status with cognitive function does not suffice for 
being involved in deriving recommendations on vitamin B12 intake as the 
evidence-base for the presence of an association is limited and not 
supportive.  
 
Methodological considerations of this meta-analysis 
Previous systematic reviews on the relation of vitamin B12 intake or status 
with cognitive function reported a large heterogeneity between studies, 
mainly with regard to cognitive outcomes, cut-off levels indicating low 
vitamin B12 status and data analyses (7-11). This heterogeneity limited 
previous meta-analyses. A strength of our review is that we dealt with these 
sources of heterogeneity by defining 4 clusters of cognitive outcomes that 
were separately reviewed: dementia, AD, global cognition and domain-
specific cognition. The domain-specific outcomes were further categorized as 
measuring memory, executive function, speed or language to cover the 
large variation in cognitive performance tests used between studies.  
To overcome the variation in cut-off levels for low vitamin B12 status and to 
allow comparison and subsequent combination of individual studies, we 
expressed results of individual studies in a standardized format: Relative risk 
(binary outcomes) or regression coefficient (continuous outcomes) per 
change in untransformed unit of exposure. Most of the included studies 
reported results based on untransformed vitamin B12 concentrations 
whereas few studies reported results based on log-transformed (23, 24) or 
square root transformed (15) units of exposure because the distribution of  
serum vitamin B12 concentration within the study population was skewed. 
We chose to use untransformed data as there is no evidence to assume 
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thatthe association between vitamin B12 and cognitive function is not 
continuous across the common range of exposure (44). Meta-analyses of 
associations based on log-transformed data would probably not alter our 
conclusions as both results from studies using log-transformed data and 
those using untransformed data were similar. 
 
A common concern in meta-analyses is statistical heterogeneity between 
studies. Among the meta-analyses reported here, we only observed 
moderate statistical heterogeneity for the association between serum 
vitamin B12 and global cognition. We were not able to explain this 
heterogeneity with meta-regression due to the limited number of studies 
included, however potential sources of heterogeneity are: age of the study 
populations (mean age 63-85 years), tests used to measure global cognition 
(MMSE, or compound z-score of 4-6 tests), duration of follow-up (3-10 years) 
and level of adjustment for confounders. Although most included studies 
adjusted for a wide range of confounders for cognitive function, residual 
confounding by other unmeasured or inadequately measured factors cannot 
be ruled out.  
 
As the quality of included studies determines the quality of the meta-analysis, 
we assessed the risk of bias for each study identified in our review. Five 
prospective cohort studies were evaluated as having a low risk of bias, as 
confounders were appropriately dealt with, measures of vitamin B12 intake 
or status were adequate and no other serious risks of bias were identified 
(20, 23, 29, 32, 43). The other 16 studies (2 RCTs and 14 prospective 
cohort studies) were evaluated as having moderate or high risk of bias as 
methods used for sequence generation or allocation concealment were 
unclear (34, 35), important risk factors were not evaluated for their 
confounding potential (ApoE-ɛ4 (15, 16, 18, 21, 22, 24-26), vascular disease 
(33, 42)), or data were not reported in sufficient detail to be used in meta-
analysis (17, 19, 27, 28). Due to the limited number of studies included in 
the different meta-analyses, we were not able to study the effect of study 
quality on the pooled effect measures. 
 
Reflection on our results and considerations for future research 
Observational studies 
Prospective cohorts studying associations between vitamin B12 intake and 
cognitive function were limited. This is likely to be related to difficulties in 
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interpreting values on vitamin B12 intake in elderly people. Although intakes 
of vitamin B12 generally exceed the current recommended amounts, the 
prevalence of vitamin B12 deficiency among elderly people in Western 
countries is estimated to be 20 percent (45). The main cause for vitamin 
B12 deficiency in elderly people is food-bound malabsorption due to atrophic 
gastritis, a clinical condition accompanied by limited or absent secretion of 
gastric acid (46). A study including elderly with this condition showed that 
plasma vitamin B12 levels were significantly correlated with vitamin B12 
intake from supplements and fortified foods, but not with vitamin B12 intake 
from unfortified foods (47). In addition intestinal absorption of vitamin B12 
may be compromised by the use of acid lowering agents including proton-
pump inhibitors and H2-blockers. These medicines are commonly used by 
elderly people, however available data on the association between vitamin 
B12 status and the use of these acid lowering agents is inconsistent (48, 49). 
To deal with the potential issue of malabsorption the use of markers for 
vitamin B12 status is preferred over measures of vitamin B12 intake when 
studying associations with cognitive function in elderly people. 
Prospective cohort studies on associations between vitamin B12 status and 
cognitive function mainly addressed serum vitamin B12 concentrations which 
is considered to be a less sensitive and specific marker of vitamin B12 status 
than MMA or holoTC II (50). MMA is a metabolic marker of vitamin B12 
status and holoTC II represents the fraction of vitamin B12 that is available 
for metabolic activity (50-53). Supported by findings from studies with a 
case-control or cross-sectional design MMA and holoTC II seem to be more 
sensitive to global cognition and domain-specific cognitive performance than 
serum vitamin B12 (20, 22, 54, 55) whereas results on incidence of AD were 
inconsistent (56). However, more prospective cohort studies are needed to 
confirm these observations.  
 
RCTs 
As shown in this review, the limited evidence from RCTs showed no effects 
of oral vitamin B12 supplementation on cognitive performance. RCTs on the 
effects of intramuscular injections with vitamin B12 were excluded from this 
review as they do not reflect dietary intake of vitamin B12, however these 
trials did not provide evidence for a beneficial effect of supplementation on 
cognitive performance either (57-59). Data from short-duration (<4 months) 
trials on the effect of vitamin B12 in combination with other B-vitamins (folic 
acid, vitamin B6) on cognitive performance tests did not show any effects 
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(35, 60-63). In contrast, 2 trials with a duration of 2 years did show a 
beneficial effect of B-vitamin supplementation on executive function/speed 
(trail making test-part B) (64, 65), although the latter study only observed a 
significant benefit in MCI patients with high homocysteine levels at baseline 
(≥11.3 µmol/l). When baseline homocysteine levels were not considered, no 
beneficial effect was observed. More RCTs on the effect of vitamin B12 on 
cognitive function are needed that are designed according to the 
recommendations from previous consensus meetings regarding sample sizes, 
selection of study populations, study duration and doses (44, 66-70). 
 
Measures of cognitive function 
Many different mechanisms have been suggested for the potential relation 
between vitamin B12 and cognitive performance as summarized by Smith 
and Refsum (2009)(44). A commonly suggested mechanism is that a low 
vitamin B12 status compromises methylation reactions in the central nervous 
system. Besides, low-normal vitamin B12 status may affect the brain via 
elevated levels of homocysteine, raised concentrations of MMA or changes in 
cytokine concentrations. Neuro-imaging studies have shown that changes in 
brain structures and brain volume are associated with cognitive decline (71). 
In addition, low-normal vitamin B12 status has been associated with loss of 
brain tissue (atrophy) (72-74)} and damage to the white matter (72, 75) in 
healthy elderly people. A recent trial including patients with mild cognitive 
impairment showed a 30 percent lower rate of brain atrophy in participants 
after 2 year supplementation with high doses of vitamin B6, folic acid and 
vitamin B12 as compared to placebo. In participants with elevated 
homocysteine levels, the rate of atrophy was even 53 percent lower after 
supplementation. The rate of atrophy was significantly inversely associated 
with change in vitamin B12 status as measured by serum vitamin B12 or 
holoTC II (76). These data indicate that measures of brain atrophy alone or 
in combination with domain-specific tests may be more sensitive for 
examining associations between vitamin B12 intake or status and cognitive 
performance. 
 
CONCLUSIONS 
Current evidence on the relation between vitamin B12 intake or status and 
cognitive function does not suffice for being involved in deriving 
recommendations on vitamin B12 intake as the evidence-base for the 
presence of an association is too narrow. Further studies should consider the 
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selection of sensitive markers of vitamin B12 status (MMA and holoTC II) as 
a proxy for vitamin B12 intake, and measures of brain atrophy alone or in 
combination with domain-specific tests as cognitive outcomes.  
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Supplemental file 1 Search Strategy in Medline 
 Search term 
1 Randomized controlled trial.pt. 
2 Controlled clinical trial.pt. 
3 Randomized.ab. 
4 Placebo.ab. 
5 Randomly.ab. 
6 Clinical trials as topic.sh. 
7 Trial.ab. 
8 Randomised.ab. 
9 6 or 3 or 7 or 8 or 2 or 1 or 4 or 5  
10 (animals not (human and animals)).sh. 
11 9 not 10 
12 (cohort* or “case control$” or cross-sectional$ or “cross sectional” or case-control$ or 
prospective or “systematic$ review$”).mp. [mp=title, original title, abstract, name of 
substance word, subject heading word] 
13  Exp meta-analysis/ or exp multicenter study/ or follow-up studies/ or prospective studies/ 
or intervention studies/ or epidemiologic studies/ or case-control studies/ or exp cohort 
studies/ or longitudinal studies/ or cross-sectional studies/  
14 12 or 13 
15 14 not 10 
16 15 or 11 
17 ((“vitamin b12” or vitamin-b12 or “vitamin b 12” or “vitamin-b 12” or cobalamin$ or 
cyanocobalamin$ or hydroxocobalamin$ or methylcobalamin* or adenosylcobalamin*) 
adj5 (intake* or diet* or supplement$ or deplet$ or status or serum or plasma or 
“methylmalonic acid” or MMA or methylmalonate or “propanedioic acid” or 
“methylpropanedioic acid” or “malonic acid” or Holotranscobalamin$ or holo-
transcobalamin$ or holoTC or holo-tc or concentration$ or expos$ or fortif$)).ti,ab. 
18 Nutritional support/ or Dietary supplements/ or nutritional requirements/ 
19 Exp Nutritional Status/ or exp Deficiency Diseases/ or supplementation/ or diet 
supplementation/ or dietary intake/ or exp diet therapy/ or Diet/ or Food, Fortified/ or 
nutrition assessment/ or Nutritive Value/ 
20 (intake$ or diet$ or supplement$ or deplet$ or status or serum or plasma or 
“methylmalonic acid” or MMA or methylmalonate or “propanedioic acid” or 
“methylpropanedioic acid” or “malonic acid” or Holotranscobalamin$ or holo-
transcobalamin$ or holoTC or holo-TC or concentration$ or expos$ or fortif$).ti,ab. 
21 Methylmalonic acid/ 
22 18 or 19 or 20 or 21 
23 Hydroxocobalamin/ 
24 Vitamin b 12/  
25  23 or 24 
26 25 and 22 
27 Vitamin b 12 deficiency/ 
28 17 or 26 or 27 
29 28 and 16 
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Supplemental file 2 Details on Transformations  
Transformation to convert units of exposure 
Serum/plasma vitamin B12 concentrations were expressed in pmol/l, if 
necessary using the following conversion factor: 1 pg/ml= 1 ng/l= 0.738 
pmol/l.  
β per pmol/l= β per pg/ml/0.738  
Standard error (se) per pmol/l= se per pg/ml/0.738 
 
Transformation to derive β(SE) for incidence dementia or 
Alzheimer’s Disease with continuous vitamin B12 levels 
Applied to studies of Crystal 1994 (19) (step 1-5) and Wang 2001 (18) (step 
3-5), Kim 2008 (16) (step 3-5): 
Step 1: Derive the relative risk (RR) (95% confidence interval (CI)) 
comparing subjects below and above the specified cut-off (111 pmol/l): 
N1 = N exposed 
N0= N unexposed 
p1= exposed cases/N1 
p0= unexposed cases/N0 
RR= (p1)/(p0)  
β= ln(RR)  
00
0
11
1 11
pN
p
pN
p
se



  
Upper limit 95% CI= e(β+1.96*se) 
Lower limit 95% CI= e(β-1.96*se) 
 
Step 2: Approximate the standard deviation (SD) of serum/plasma vitamin 
B12 concentrations in the population by assuming it to be equal to one 
quarter of the range of data values 
 
Step 3: Calculation of the standard normal deviate, zcut-off: 
zcut-off= (cut-off–meanvit B12 level) / SDvit B12 level 
 
Step 4: Calculate the log(RR or OR) per SD increase in serum/plasma 
vitamin B12, log(RRvit B12 level)sd (=standardized regression coefficient):  
log(RRvit B12 level)sd = log(RRcut-off) /dk, with dk representing the difference in 
the mean values of a standard normal distribution above and below zcut-off: 
)}z({)z(
)z(
d
offcutoffcut
offcut
k

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where  and  are the standard normal density and distribution functions 
respectively. 
 
Step 5: Calculate the β: 
β= log(RRvit B12 level)sd / SDvit B12 level 
 
Transformation to calculate mean exposure or mean age of the 
total population when only exposure or age per subpopulation 
groups are available  
Applied to studies of Eussen (2002) (27), Hooshmand (2010) (43), Kim 
(2008) (16), La Rue (1995) (28), Mooijaart (2005) (21), Morris (2006) (33), 
Nelson (2009) (32), Nurk (2005) (29): 
Step 1: Calculate the combined mean: 

 

xi
i xixi
x
N
N
 
where Nxi is the number of subjects in group i and µxi is the mean of group i. 
 
Step 2: Calculate the combined standard deviation: 
2
22
x
i xi
i xixixi
x
N
)(N





 
where Nxi is the number of subjects in group i, σxi is the standard deviation 
in group i, µxi is the mean of group I and µx is the combined mean. 
 
Transformation to calculate mean exposure (mx) and the standard 
deviation (sx) of the population when only the median (medx) and 
the interquartile range (IQR) are reported  
Applied to study of Mooijaart 2005 (21): 
Step 1: mx= ln(medx) 
 
Step 2: To obtain an estimate of sx from these quantities a search algorithm 
is employed to find the value of sx for which the following equation holds 
)ee*med(IQR xx zszsxx

  
where z= 0.6745 
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ABSTRACT  
Background: A combination of high folate with low vitamin B12 status has 
been associated with cognitive impairment in a population exposed to 
mandatory folic acid fortification of flour, but other studies yielded mixed 
results.  
Objective: To examine the interaction of folate and vitamin B12 markers in 
relation to cognitive performance in Norwegian elderly (n=2203, aged 72-74 
y) who were not exposed to mandatory food fortification with folic acid.  
Design: Plasma concentrations of folate and vitamin B12 markers (total 
vitamin B12, holotranscobalamin II (holoTC II) and methylmalonic acid 
(MMA)) were measured in 1992-1993 and 1997-1999. Cognitive 
performance was assessed in 1997-1999 by 6 cognitive tests from which a 
combined score was calculated with principal component analysis. 
Associations of folate, vitamin B12 markers and interactions between them 
in relation to cognitive performance were evaluated by quantile regression 
and ordinary least squares regression adjusted for gender, education, 
Apolipoprotein-E genotype, history of cardiovascular diseases or 
hypertension and creatinine.  
Results: Cross-sectional analyses revealed a significant interaction between 
folate and plasma vitamin B12 in relation to cognitive performance (β (se), 
p-value) -0.058 (0.022), 0.009). When including holoTC II or MMA instead of 
plasma vitamin B12 in the model, interaction between folate and the vitamin 
B12 markers was not significant. In addition, we observed no significant 
interaction between folate and plasma vitamin B12 concentrations measured 
in 1992-1993 in relation to cognitive performance. 
Conclusions: This large population based study in a population unexposed 
to mandatory folic acid fortification showed that low plasma vitamin B12 in 
combination with high folate was associated with better cognitive 
performance. However, these associations were not observed for sensitive 
markers of vitamin B12 status. 
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INTRODUCTION 
Folate and vitamin B12 status have been positively associated with cognitive 
performance in cross-sectional (1-8) and prospective studies (9-18). Some 
early case reports observed accelerated neurologic deterioration in patients 
with pernicious anemia and severe vitamin B12 deficiency after treatment 
with folic acid (19, 20). These observations in combination with the known 
metabolic interrelation of folate and vitamin B12 suggest that the effects of 
one of these B-vitamins on cognitive performance might be modified by 
blood concentrations of the other B-vitamin. In line with this, cross-sectional 
analyses within the NHANES study, performed after the introduction of folic 
acid fortification of flour in the United States, revealed that high folate 
concentrations were associated with an increased risk of cognitive 
impairment in individuals with vitamin B12 deficiency (21, 22). It has been 
hypothesized that unmetabolized folic acid, which is likely to be present in 
individuals living in areas with folic acid fortification of food items (23), may 
mask or exacerbate metabolic and clinical consequences of vitamin B12 
deficiency (21, 22, 24-29). Hematologic and neuropsychiatric disorders in 
vitamin B12 deficiency have been attributed to reduced function of the 
enzyme methionine synthase requiring vitamin B12 as cofactor and 5-
methyltetrahydrofolate as substrate. This enzyme catalyzes the 
remethylation of homocysteine to methionine, which is the precursor of the 
universal methyldonor, S-adenosylmethionine (SAM). Lack of SAM and 
trapping folate as 5-methyltetrahydrofolate may compromise methylation 
reactions involving proteins, phospholipids, and neurotransmitters and cause 
insufficient folate needed for DNA synthesis and red blood cell maturation 
(30, 31). 
The finding from NHANES that high folate concentrations were associated 
with an increased risk of cognitive impairment in individuals with vitamin 
B12 deficiency was not confirmed in other larger study populations not 
exposed (9) or exposed to folic acid fortification (32, 33). However, these 
previous studies used only one or two cognitive performance tests and 
measured either plasma vitamin B12 or holotranscobalamin II (holoTC II). It 
is therefore unclear whether the combination of high folate and low vitamin 
B12 status worsens certain aspects of cognitive performance. We 
investigated a combination of sensitive markers of folate and vitamin B12 
status in relation to cognitive performance based on six cognitive tests in a 
large population-based study not exposed to mandatory food fortification 
with folic acid.  
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SUBJECTS AND METHODS 
Study population 
The study population consisted of residents of Bergen (Norway) born 
between 1925 and 1927, who participated both in the Hordaland 
Homocysteine Study in 1992-1993 and in the Hordaland Health Study 
(HUSK) in 1997-1999. A total of 2,841 elderly individuals were invited to 
participate in a sub study on cognitive tests in 1997-1999; 2,203 (77.5%) 
agreed. Details of this study are described elsewhere (34, 35). The Regional 
Committee for Medical Research Ethics of Western Norway approved the 
study and all participants provided written informed consent.  
 
Assessment of cognitive performance  
Cognitive performance was assessed at the study location by trained nurses 
and included six tests (36): a modified version of the Mini-Mental State 
Examination (m-MMSE; global cognition, maximum score=12) (37, 38), a 
modified version of the Digit Symbol test (m-DST; perceptual speed) (39), a 
short form of the Block Design (m-BD; visuospatial skills, maximum 
score=16) (39), the Kendrick Object Learning test (KOLT; episodic memory, 
maximum score=70) (40), an abridged version of the Controlled Oral Word 
Association test (COWAT; access to semantic memory) (41),and the Trail 
Making Test-part A (TMT-A; executive function) (42). For all tests, a higher 
score indicates a better performance, except the TMT-A where the test score 
is the time needed to complete the test and thus a shorter time used 
indicated a better performance.  
 
Other covariates 
Both in 1992-1993 and 1997-1999, participants underwent a brief health 
examination including measurements of height and weight. In addition, 
information on cardiovascular risk factors and lifestyle factors including 
smoking status (current smokers, ex-smokers or never smokers), 
consumption of coffee (0-1, 1-4 or more than 5 cups a day), and alcohol use 
(number of glasses per week), was collected via self-administered 
questionnaires as previously described (43). History of cardiovascular 
diseases (CVD) was based on self-reported information on history of 
myocardial infarction, angina pectoris and stroke as recorded both in 1992-
1993 and 1997–1999, and on history of thrombosis and phlebitis as 
recorded in 1992-1993. Seventy-nine % of self-reported CVD cases were 
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validated with hospitalization records used in an earlier study (44), whereas 
the remaining 21% of CVD cases were presumably less severe and did not 
require hospitalization or occurred before 1992. A history of hypertension 
was defined as current or previous use of antihypertensive drugs and was 
based on self-reported data collected in 1997-1999.  
Diabetes was based on self-reported information collected in 1997-1999. 
Depression score was assessed in 1997-1999 by a 7-item subscale for 
depression from the Hospital Anxiety and Depression Scale (HADS-D) (45). 
Educational level was classified as no primary school, primary school (≤9 y), 
vocational secondary school (10-12 y), theoretical secondary school (10-12 
y), college or university <4 y, and college or university ≥4 y. 
 
Plasma measurements 
Non-fasting EDTA blood samples were collected for analyses of plasma 
markers for folate and vitamin B12 status. The EDTA samples were kept at 
4oC until centrifugation. Samples collected in 1992-1993 were stored at -
20°C for up to 10 years, whereas samples collected in 1997-1999 were 
stored at -80°C for up to 12 months before analyses. Plasma concentrations 
of folate and vitamin B12 were determined by microbiological assays (46, 
47). A recent study showed folate degradation during storage (48). We 
therefore measured folate as pABG equivalents in 200 randomly selected 
samples collected in 1992-1993 and 1997-1999 by a method designed to 
recover degraded folate (48). Based on the results of these additional 
analyses we corrected for folate degradation during storage by using 
separate correction factors for the samples collected at baseline (corrected 
folate concentration ’92-‘93=5.3373+1.4045*folate concentration measured 
in ’92-’93) and those collected at follow-up (corrected folate concentration 
’97-‘99= 8.0512+1.1012*folate concentration measured in ’97-’99). 
Plasma concentrations of methylmalonic acid (MMA), an inverse marker for 
vitamin B12 status (49, 50), were determined by a modified gas 
chromatography–mass spectrometry method based on ethylchloroformate 
derivatization (51) and plasma concentrations of holoTC II were analyzed by 
microbiological assays (52). These indicators of vitamin B12 status were only 
measured in the samples collected in 1997-1999. 
Serum creatinine levels were analyzed in the samples from 1997-1999 by a 
modification of a liquid chromatography-mass spectrometry (LC-MS/MS) 
procedure (53). Apolipoprotein-E (ApoE) genotypes (0, 1 or 2 APOE-ε4 
alleles) were determined using a one-stage polymerase chain reaction 
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method (54) and methylenetetrahydrofolate reductase (MTHFR) genotyping 
(677C→T) was performed by a real-time polymerase chain reaction (55). 
 
Statistical analyses 
Plasma concentrations of folate and vitamin B12 measured in 1992-1993 
and 1997-1999 were compared with a paired sample t-test. Relations 
between the different markers of vitamin B12 status measured in 1997-1999 
were evaluated with Spearman correlation tests. 
Principal component analysis (PCA) was used to create a summary score for 
cognitive performance that accounted for the correlations between the 
different cognitive performance tests and, thereby, maximized the explained 
variance. The number of components to be retained was determined 
according to 2 criteria: eigenvalues > 1 and by Cattles’s Scree plot (plot of 
the total variance related to each component). For comparison of cognitive 
performance on the individual tests across quartiles of the cognitive 
performance components created with PCA, univariate analysis of variance 
was used.  
In order to investigate single associations and interactions of folate and 
markers for vitamin B12 status in relation to cognitive performance, 
multivariate quantile regression and ordinary least squares (OLS) regression 
was used including the cognitive performance components extracted with 
PCA as the dependent variable. Single associations were assessed with 
regression models including a single marker for B-vitamin status as 
independent variable, whereas interactions were assessed with models 
including the combination of folate, a marker for vitamin B12 status and 
their interaction as independent variables. The quantile regression technique 
was used to provide distribution-free tests of whether the associations of 
folate, vitamin B12 markers and their interaction vary along the cognitive 
performance distribution. Plasma concentrations of folate and markers of 
vitamin B12 status were expressed as standardized z-scores to provide 
comparable associations per 1-SD increase. 
All analyses were adjusted for the covariates gender, education level, history 
of CVD/hypertension ApoE genotype, and creatinine. These covariates were 
strong predictors for cognitive performance or associated with both B-
vitamin levels and cognitive performance as demonstrated with analysis of 
variance or Pearson correlation coefficients. Body Mass Index (weight (kg)/ 
height (m2)), smoking status, consumption of coffee, alcohol use, MTHFR 
genotype, diabetes and depression score were associated with either plasma 
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markers for folate or vitamin B12 or with cognitive performance, but 
adjusting for these biological and lifestyle factors did not markedly change 
the results of the analysis.  
Descriptive analyses and PCA were performed using SAS 9.2 and regression 
analyses were performed with packages quantreg and mice of R version 
2.13.1. P-values <0.05 were considered statistically significant. 
 
RESULTS 
Characteristics of the study population  
Characteristics of the study population in 1997-1999 are presented in Table 
1. The mean age of the participants was 72.5 years and 44.9% were men. 
Fifty-one percent had a history of cardiovascular disease such as myocardial 
infarction, angina pectoris, stroke, thrombosis, phlebitis or a history of 
hypertension. Furthermore, 17 % of the participants suffered from 
depression (HADS-D score ≥8), and 14 % were current smokers. Plasma 
folate concentrations (median (5th -95th percentile) measured in 1992-1993 
were 12.5 (8.7-20.9) nmol/l after correction for folate degradation during 
storage, and lower than concentrations measured in 1997-1999, which were 
15.8 (12.0-34.0) nmol/l (P for difference <0.0001). Plasma vitamin B12 
concentrations in 1992-1993 were 338 (196-595) pmol/l and comparable 
with concentrations measured in 1997-1999 being 339 (192-651) pmol/l (P 
for difference =0.1246). In 1997-1999, 38.5% of the participants had low 
vitamin B12 status defined as plasma vitamin B12 concentrations <150 
pmol/l or MMA> 210 nmol/l (56) and 0.5% had folate concentrations >59 
nmol/l. Spearman correlations between plasma concentrations in ‘92-‘93 and 
‘97-‘99 were 0.41 (P<0.0001) for folate and 0.63 (P<0.0001) for vitamin 
B12. Plasma vitamin B12 correlated significantly with holoTC II (Spearman 
r= 0.66, P<0.0001) and  with MMA (Spearman r=-0.20, P<0.0001) and 
holoTC II also correlated significantly with MMA (Spearman r= -0.24, 
P<0.0001). 
 
Chapter 6: Folate-vitamin B12 interactions and cognitive performance 
148 
 
Table 1 Characteristics of the study population in ’97-’99 
Table 1 Characteristics of the study population in ’97-’99 
Characteristic na Number of subjects (%), mean (range) 
or mean/median (p5, p95) 
Age, y  2203 72.5 (71.4-74.3) 
Male sex 2203 990 (44.9) 
Education  
      No primary school 
      Primary school (≤9 y) 
      vocational secondary school (10-12 y) 
      theoretical secondary school (10-12 y) 
      college or university <4 y 
      college or university ≥4 y 
2024  
149 (7.4) 
648 (32.0) 
607 (30.0) 
238 (11.8) 
215 (10.6) 
167 (8.3) 
History of CVD or hypertensionb 2073 1050 (50.7) 
Diabetesc 2170 145 (6.7) 
APoE-genotype 
       0 APoE-ε4 alleles 
       1 APoE-ε4 alleled 
       2 APoE-ε4 alleles 
2187  
1485 (67.8) 
633 (28.9)  
69 (3.2)  
MTHFR C677T status 
       CC 
       CT 
       TT 
Depression 
       HADS-D score normal (<8) 
       HADS-D score depressed (≥8) 
2202 
 
 
 
1999 
 
 
1104 (50.1) 
915 (41.6) 
183 (8.3) 
 
1536 (76.8) 
463 (16.7) 
Smoking status 
       Smokers 
       ex-smokers 
       never smokers 
2203  
310 (14.1)  
943 (42.8) 
950 (43.1)  
Daily coffee consumption  
0-1 cup 
       1-4 cup(s) 
       ≥5 cups 
2146  
156 (7.3)  
1656 (77.2)  
334 (15.6)  
Alcohol consumption, glasses per week 1848 2 (0-37) 
Plasma vitamin B12, pmol/l 2194 392/339 (192-651) 
Plasma folate, nmol/le 2186 18.0/15.8 (12.0-34.0) 
Plasma MMA, µmol/ 2192 0.22/0.19 (0.12-0.36) 
Plasma holoTC II, pmol/l 2041 101/90 (43-192) 
Creatinine, mmol/l 2202 93/91 (72-120) 
m-MMSE 2181 11.5/12 (10-12)  
m-DST 2188 10.2/9 (5-18)  
m-BD 2186 15.0/16 (10-16)  
KOLT 2197 35.2/35 (23-48)  
COWAT  2193 15.1/15 (7-25)  
TMT-a 2193 57.7/44 (28-124)  
CVD: Cardiovascular diseases, HADS-D: Hospital Anxiety and Depression Scale—depression subscale, ApoE: apolipoprotein E, 
MTHFR: Methylenetetrahydrofolate reductase, m-MMSE: modified version of the Mini-Mental State Examination, m-DST: 
modified version of the Digit Symbol test, m-BD: short form of the Block Design, KOLT: Kendrick Object Learning Test, COWAT: 
abridged version of the Controlled Oral Word Association test, TMT-a: Trail Making Test part A 
a The sample numbers may vary across the different variables due to different numbers of missing data 
b based on self-reported CVD (myocardial infarction, angina pectoris, stroke, thrombosis and phlebitis) or hypertension at 
baseline or follow-up  
c-based on self-reported diabetes 
d E2E4 and E3E4 genotypes 
e Folate concentrations are corrected for degradation 
 
CVD:Cardiovascular diseases, HADS-D: Hospital Anxiety and Depression Scale—depression subscale, ApoE: 
apolipoprotein E, MTHFR: Methylenetetrahydrofolate reductase, m-MMSE: modified version of the Mini-Mental 
State Examination, m-DST: modified version of the Digit Symbol test, m-BD: short form of the Block Design, 
KOLT: Kendrick Object Learning Test, COWAT: abridged version of the Controlled Oral Word Association test, 
TMT-a: Trail Making Test part A 
a Th  sample numbers may vary across the different variables due to different numbers of missing data 
b based on self-reported CVD (myocardial infarction, angina pectoris, stroke, thrombosis and phlebitis) or 
hypertension at baseline or follow-up  
c-based on self-reported diabetes 
d E2E4 and E3E4 genotypes 
e Folate concentrations are corrected for degradation 
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Cognitive performance factors 
Median (5th-95th percentile) scores for the 6 cognitive performance tests 
are presented in Table 1. Based on m-MMSE scores ≤ 10 (36), 36% of the 
study population suffered from cognitive impairment. Eigenvalues and 
Cattel’s scree plot revealed that one component derived by PCA should be 
retained, explaining 40.5% of the total variance, whereas factors 2-4 
explained less than 14.6% each. The factor loading matrix is presented in 
Table 2. The first component strongly correlated with m-MMSE (r= 0.61), m-
BD (r=0.55), m-DST (r=0.72), KOLT (r=0.59), COWAT (r=0.63), TMT-a (r=-
0.70) and is further referred to as “overall cognitive performance”. Overall 
cognitive performance scores ranged from -4.80 to 2.49 with mean of 0 and 
SD of 1. Across increasing quartiles of overall cognitive performance, 
subjects performed better on each individual cognitive tests (For all tests P 
for difference <0.0001, data not shown). 
 
Table 2 Factor loading matrix from principal components analysis  
 Factor 1 Factor 2 Factor 3 Factor 4 
m-MMSE 0.61 0.01 0.66 0.30 
m-BD 0.55 -0.68 0.16 -0.19 
m-DST 0.72 -0.01 -0.38 0.12 
KOLT 0.59 0.46 0.15 -0.65 
COWAT 0.63 0.41 -0.10 0.39 
TMT-A -0.70 0.22 0.35 0.05 
Eigenvalue 2.43 0.88 0.77 0.72 
% Variance explained 40.5 14.6 12.8 12.0 
m-MMSE: modified version of the Mini-Mental State Examination, m-DST: modified version of 
the Digit Symbol test, m-BD: short form of the Block Design, KOLT: Kendrick Object Learning 
Test, COWAT: abridged version of the Controlled Oral Word Association test, TMT-a: Trail 
Making Test part A 
missing, n=47 
 
Cross-sectional associations of plasma concentrations of folate and 
vitamin B12 markers with overall cognitive performance assessed 
in 1997-1999 
Figure 1 shows no overall association of plasma vitamin B12, a significant 
positive association of folate, and a significant negative interaction term 
between folate and plasma vitamin B12 on the overall cognitive performance 
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distribution. The associations of gender, education, history of 
CVD/hypertension and ApoE4 status with overall cognitive performance were 
as expected. Notably, the associations between folate, education, history of 
CVD/hypertension, and ApoE4 and overall cognitive performance were 
asymmetric with strongest effects in the lowest ranges of the overall 
cognitive performance scores. When including holoTC II or MMA instead of 
plasma vitamin B12 in the model, the quantile regression plots showed non-
significant associations of holoTC II and MMA, a non-significant interaction 
between folate and the vitamin B12 markers, but similar associations of the 
other covariates (data not shown). 
Quantile regression estimates for the associations of both B-vitamins and 
most covariates were included in the 95 percent confidence intervals of the 
OLS regression estimates along the distribution of overall cognitive 
performance, suggesting that the OLS estimates are appropriate to 
represent the associations with overall cognitive performance. Table 3 
presents the multivariate adjusted OLS regression estimates for the single 
associations of plasma folate and markers of vitamin B12 on the overall 
cognitive performance score, as well as the interaction between plasma 
folate and markers of vitamin B12 in relation to the overall cognitive 
performance score. In agreement with Figure 1, folate was positively 
associated, plasma vitamin B12 was not associated, and their interaction 
term was negatively associated with the overall cognitive performance score. 
The markers MMA and HoloTC did not show significant associations with the 
overall cognitive performance factor, nor were any of the interactions with 
folate significant (Table 3) 
 
Prospective associations of plasma concentrations of folate and 
plasma vitamin B12 in 1992-1993 with cognitive performance 
assessed in 1997-1999 
We observed no significant associations (β (se), p-value) of folate (0.019 
(0.031), p=0.540) or plasma vitamin B12 (0.020 (0.033) p=0.541) 
measured in 1992-1993 along the distribution of overall cognitive 
performance. In addition, the interaction of folate and plasma vitamin B12 
measured 4-y years prior to measurement of overall cognitive performance 
was not significant (0.024 (0.028), p=0.394) (data not shown). 
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Figure 1 Changes in cognitive score according to plasma vitamin B12, folate 
and other determinants by quantile regression.  
The black points represent quantile regression fits, dark shaded gray zones represent the 95% 
pointwise confidence intervals for the estimates, the black horizontal lines indicates no (zero) 
changes in cognition. An upward or downward slope indicates the highest or lowest response at 
the upper or lower tail, respectively, of the distribution of the cognitive scores, whereas a 
horizontal graph below or above zero indicates similar effects through the whole distribution. 
The horizontal red solid lines represent the ordinary least-squares estimates of the conditional 
mean effects, and the red dotted lines represent the conventional 95% confidence intervals for 
the least-squares estimates. Plasma vitamin B12 and folate were given as z-scores, gender 
categorized as (1) men and (2) women, education as (0) no primary school, (1) primary school 
(≤9 y), (2) vocational secondary school (10-12 y), (3) theoretical secondary school (10-12 y), 
(4) college or university <4 y, and (5) college or university ≥4 y, history of CVD/hypertension 
as (1) yes, (0) no, ApoE4 genotype as (0) 0, (1) 1, or (2) 2 ApoE-ε4 alleles and creatinine was 
given as µmol/L. CVD=cardiovascular diseases. 
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DISCUSSION 
Main findings 
This population based study investigated the hypothesis that high folate 
concentrations in combination with low plasma vitamin B12 concentrations 
increased risk for cognitive impairment, and was conducted in a population 
which was not exposed to mandatory fortification of food items with folic 
acid. The study, which included 2203 elderly people aged 72-74 y, revealed 
a significant negative interaction between folate and plasma vitamin B12 
 concentrations in relation to cognitive performance. However, interactions 
between folate and other markers of vitamin B12 status, holoTC II or MMA, 
in relation to overall cognitive performance were not significant. 
 
The significant negative interaction between folate and plasma vitamin B12 
indicates that the linear association between folate and overall cognitive 
performance changes for different concentration of plasma vitamin B12 and 
vice versa. The observed association for the interaction-term suggests that, 
among elderly with plasma vitamin B12 concentrations 2 standard deviations 
above the mean, the significant positive association between folate and 
overall cognitive performance changes from β=0.097 to β=0.097+2*(-
0.058)=-0.019, and becomes negative. In contrast, among elderly with 
plasma vitamin B12 concentrations 2 standard deviations below the mean, 
the association between folate and overall cognitive performance changes 
from β=0.097 to β=0.097-2*(-0.058)=0.213, so becomes even stronger. 
Our findings are not in line with the results from the NHANES study 
(n=1459, mean age=70 y), which showed that low vitamin B12 status in 
combination with elevated folate concentrations (n=278) was associated 
with cognitive impairment. One explanation for the discrepant findings 
between the NHANES and the current study is that the NHANES study has 
been conducted in an area of mandatory folic acid fortification leading to 
frequent exposure of unmetabolized folic acid. As a consequence, high folate 
concentrations (>59 nmol/L) were present in 20.7% of the NHANES study 
population (n=1459), compared to less than 1% (‘92-‘93 and ‘97-‘99) in the 
present study. The prevalence of low plasma vitamin B12 concentrations 
(<148 pmol/l or MMA>210 nmol/l) was 25% in NHANES, and approximately 
38.5% in our study population.  
However, the NHANES study also showed that normal vitamin B12 status in 
combination with elevated folate concentrations was associated with 
protection against cognitive impairment as compared to normal 
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concentrations of both B-vitamins (OR (95% CI): 0.4 (0.2, 0.9)) (21). This is 
in line with our finding that folate concentrations were positively associated 
with overall cognitive performance and these results are also supported by 
previous observations that low folate concentrations were associated with a 
higher risk of cognitive impairment (6, 11, 15, 17).  
 
Metabolic and clinical effects of a combination of high folate and 
low vitamin B12 status 
Some (21, 22, 32, 57), but not all (33) studies have shown that elderly 
individuals with high folate and low vitamin B12 status have a higher 
prevalence of anemia, and higher concentrations of total homocysteine and 
MMA. As such, it has been proposed that high folate concentrations may 
exacerbate negative consequences of vitamin B12 deficiency. However, it is 
possible that subjects with a combination of low vitamin B12 and high folate 
in the studies decribed above suffered from severe vitamin B12 deficiency 
due to disorders that affected vitamin B12 absorption, such as pernicious 
anemia (58, 59). A recent study in healthy young adults without any medical 
conditions that could induce anemia or affect folate or vitamin B12 
absorption did not observe any adverse effects of high folate concentrations 
on biochemical abnormalities related to vitamin B12 deficiency (60). In 
agreement with these findings, the current study did not show that the 
positive associations between folate concentrations and cognitive 
performance was negatively affected by decreasing vitamin B12 status, as 
was also true for two cross-sectional studies in populations exposed to folic 
acid fortification (32, 33). In these latter two studies, high folate 
concentrations occurred in 39% (cut-off >45.3 nmol/l) (32) and 5% (Cut-off 
>60 nmol/l) (33). 
 
Both observational population based studies – whether or not exposed to 
folic acid fortification, and intervention studies show inconclusive results for 
the effects of B-vitamins on cognition. A recent meta-analysis (61) 
summarised the results from trials on the effects of folic acid 
supplementation on cognitive performance, and did not show an effect of 
folic acid on the prevention of age-related cognitive decline within 3 years of 
the start of treatment (61). Evidence from trials on the effects of vitamin 
B12 on the cognitive function was previously judged insufficient (62). In one 
trial including 233 elderly with mild cognitive impairment, 2 years of 
treatment with a combination of B-vitamins (0.8 mg folic acid, 0.5 mg 
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vitamin B12 and 20 mg vitamin B6 per day) showed beneficial effects on 
global cognitive performance, episodic memory and semantic memory 
among participants with elevated homocysteine concentrations (63). Other 
trials including 128 to 2009 participants did not show any effects of 
combined B-vitamin treatment on cognitive performance (64-69). However, 
one study suggested that supplementation reduced the risk of cognitive 
decline in participants with low dietary B vitamin intake at baseline (66). 
Taken findings from observational and intervention studies together, the 
efficacy of B-vitamins on cognition may depend on B-vitamin status and 
cognitive performance at baseline, the dosage of B-vitamins, and the 
duration of exposure to supplements. 
 
Strengths and limitations  
Data on cognitive performance and markers for vitamin B12 status (MMA 
and holoTC II) were only available for 1997-1999. As such, we were not 
able to investigate whether combined effects of folate and these sensitive 
vitamin B12 markers would affect future cognitive performance. 
Furthermore, folate degradation is likely to occur when stored for long 
periods (48). Even though we corrected plasma folate concentrations 
measured in 1992-1993 and in 1997-1999 for folate degradation by 
measuring PABA-Glu (70), concentrations measured in 1992-1993 were still 
lower than concentrations measured in 1997-1999. This may indicate either 
improved folate status over time or incomplete correction for folate 
degradation. 
A major strength of our study is the use of an extensive cognitive test 
battery covering global cognition, perceptual speed, visuo-spatial skills, 
episodic memory, access to semantic memory and executive function, 
whereas the majority of previous studies assessed cognition by global 
cognition or only one cognitive domain. The cognitive performance 
component as derived by PCA provides a robust measure for cognitive 
performance. As previously shown, the use of composite scores reduce the 
risk of measurement errors, reduce the total amount of data and thereby 
reduce chance findings (71, 72). 
In addition, we had the opportunity to include makers for vitamin B12 status 
that are considered more sensitive markers compared to plasma vitamin B12 
concentrations, namely MMA and holoTC II, although none of these markers 
are considered as a gold standard (73, 74). For diagnostic tools in 
epidemiologic settings, vitamin B12 in combination with holoTC II or MMA is 
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recommended (75). The utility of these markers of vitamin B12 status in 
relation to cognitive performance has been evaluated in a limited number of 
observational studies. So far, elevated concentrations of MMA were 
significantly associated with a decreased cognitive performance (3, 5, 9, 16, 
67), and for holoTC II both significant (2, 9) and non-significant positive 
associations with cognitive performance have been observed (5). In the 
current study, these associations could not be confirmed. Finally, we were 
able to adjust our analyses for a large panel of known risk factors, yielding 
reliable results. 
 
In conclusion, this large study population not exposed to mandatory food 
fortification with folic acid did not confirm the previous finding that a 
combination of high folate and low plasma vitamin B12 was associated with 
decreased cognitive performance. 
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The aim of this PhD-thesis is to contribute to standardization of the process to 
derive evidence-based, transparent and harmonized micronutrient 
recommendations across Europe. First the need for harmonization is substantiated 
by a descriptive study on the variation in published micronutrient 
recommendations across Europe. In addition methodological factors were 
identified that should be considered for alignment of recommended intakes across 
Europe. Secondly, the evidence-base for establishing recommended vitamin B12 
intakes was summarized in two systematic reviews. One review focused on 
requirements for the compensation of daily obligatory losses (factorial approach) 
and the other review evaluated the relation of vitamin B12 intake and status with 
cognitive performance (dose-response approach). Whether interactions between 
folate and vitamin B12 on cognitive performance should be considered for 
establishing recommended vitamin B12 intakes was evaluated in a large cohort 
study. In this final chapter, our main findings are summarized and complemented 
with information on dose-response data for concentration markers and other 
health endpoints that originated from the EURRECA NoE or from the literature. 
Pros and cons of different approaches that may be used for estimating vitamin 
B12 requirements will be discussed and gaps in current knowledge will be 
highlighted.  
 
MAIN FINDINGS 
In Europe, variation in recommended intakes for adults and elderly on 
vitamin B12 and other selected micronutrients mainly resulted from 
differences in the following issues (Chapter 2 and 3):  
a)- the selection of health indicators and criteria for adequacy,  
b)- assumptions regarding inter-individual variation in requirements,  
c)- assumed bioavailability factors, and  
d)- the selection and interpretation of evidence on requirements. 
To harmonize the process of setting micronutrient recommendations, 
standardized methods are needed to address each of these issues.  
 
In general there are two approaches for setting recommended intakes: the 
factorial approach and the dose-response approach. With the factorial 
approach, requirements are estimated as the mean intake needed to 
compensate daily losses assuming a specified level of bioavailability from the 
usual diet. A systematic review on daily losses of vitamin B12 in adults and 
elderly showed that the rate of loss was 0.13% of total body stores per day 
(95% confidence interval =0.10; 0.15) as estimated with a pooled analysis 
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of five studies including 52 subjects. Applying estimates of body stores 
among apparently healthy individuals (2-3 mg), absolute amounts of vitamin 
B12 lost per day will most likely range between 2.6 and 3.9 µg per day 
(Chapter 4). 
Absorption of vitamin B12 is dependent on the ingested dose and food 
source and varies substantially between individuals. However, the overall 
relation between intake of vitamin B12 and the absorbed amount could be 
described by a linear regression equation including the natural logarithm of 
both intake and the amount absorbed. Based on the regression equation 
and assuming that mean dietary intakes of vitamin B12 in European 
countries (3.5-9.3 µg per day) are equally divided over three meals, 
absorption ranged between 29-37% . These absorption estimates are lower 
than the 50% that is commonly assumed for estimating vitamin B12 
requirements (Chapter 4). Evidence on daily vitamin B12 losses and 
bioavailability can only be derived from relatively old studies published 
between 1958 and 1991 and can hardly be updated because this requires 
invasive methods or the use of isotopes that do not comply with current 
ethical standards. In view of the above, establishing recommended vitamin 
B12 intakes with the factorial approach can be based on evidence on the 
rate of loss (a relatively accurate and precise estimate) and bioavailability 
(large variability and uncertainty), together with an estimate of the required 
total body stores (crude estimate). However the available evidence is rather 
scarce and resulting estimates having considerable uncertainty . The 
commonly used coefficient of variation of 10-20% seems too low to cover 
uncertainty in all these underlying assumptions and may be at least 24% 
(Chapter 4).  
 
The dose-response approach for setting recommended intakes is based on 
associations between intake and physiological or clinical health outcomes. 
For vitamin B12, traditionally maintenance of an adequate hematological 
status, as measured by stable hemoglobin levels, normal mean cell volume 
and normal reticulocyte response, was used as a health indicator for setting 
recommendations in some countries. These hematological indices may 
change in case of vitamin B12 depletion. However, rather than merely 
focusing on the prevention of symptoms of severe deficiency, the prevention 
of chronic diseases or longterm outcomes such as cognitive performance 
might also be considered as health outcomes for setting recommended 
intakes. A systematic review indicated that limited dose-response evidence 
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from 2 randomized controlled trials and 21 prospective cohort studies does 
not show assocations of vitamin B12 intake and status with dementia, global 
cognitive function or domain-specific cognitive function (Chapter 5).  
Furthermore, in a population of 2203 Norwegian elderly people, cross-
sectional and prospective analyses revealed no associations between vitamin 
B12 and cognitive performance and we did not find evidence for  interaction 
of vitamin B12 and folate on cognitive performance (Chapter 6). Taking the 
review and the latter analysis together, the available evidence on the 
relation between vitamin B12 and cognitive performance is yet not 
convincing and thereby limits its use as an outcome for estimating vitamin 
B12 requirements. 
 
The methods used in this PhD-thesis to collate, select and interpret the 
evidence on vitamin B12 requirements of adults and elderly were systematic, 
objective and transparent and can be applied to other micronutrients as 
well. Thereby, the approach outlined in this thesis contributes to the 
harmonization of the process for setting micronutrient recommendations. 
 
VARIATION IN MICRONUTRIENT RECOMMENDATIONS 
As shown in chapter 2 and 3 of this thesis, published micronutrient 
recommendations for adults and elderly vary widely between European 
countries, for some nutrients even up to two-fold (folate). Although there 
may be small physiological differences between people across Europe, these 
do not justify the observed variation in recommendations. Factors that have 
been shown to contribute to the variation include the use of different 
concepts, definition of population groups, different approaches, selection of 
health outcomes, differences in the evidence-base, different assumptions 
and expert judgment (1-3). The relevance of addressing this variation is 
linked to the two main applications of micronutrient recommendations, 
assessing the adequacy and planning of micronutrient intakes. Both 
applications stress the need for transparency regarding the concept of the 
recommendation (ANR+2SD or AI) as they are applied in a different 
manner. Moreover the selection of different health outcomes for estimating 
requirements may result in different values for the ANR, SD or AI and may 
thereby influence the probability of inadequate intake for an individual or the 
prevalence of inadequate intakes in a population. Roman Vinas et al. (2011) 
evaluated intakes of the micronutrients studied in chapter 3 across Europe 
using the ANRs provided by the Nordic countries. Among men and women 
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aged 19 years and older, the prevalence of inadequate intakes below the 
ANR were 0-40% for vitamin B12 (ANR=1.4 µg), 10-91% for folate 
(ANR=200 µg), 0-21% for iron (ANR=6 mg for men and 7 mg for women) 
and 1-31% for zinc (ANR=6.4 mg for men and 5.7 mg for women) (4). In 
general, applying higher or lower ANRs as provided by other European 
countries will substantially affect these prevalence estimates, although 
probably not that markedly for vitamin B12 and iron as mean intakes for 
both these micronutrient were well above the recommended intakes.  
 
DEFINITION OF VITAMIN B12 REQUIREMENTS 
Figure 1 shows the different approaches and health outcomes that have 
been used up to now for estimating vitamin B12 requirements of adults and 
elderly people (maintenance of body stores and haematological status), the 
health outcomes that were evaluated in this thesis (cognitive performance), 
and in addition the health outcomes that were evaluated in the context of 
the EURRECA project (bone health). The relation between vitamin B12 
intake and status was also quantified as vitamin B12 status is considered as 
an intermediate in the relation between intake and health outcomes.  
Maintenance of 
body stores + 
additional needs *
Micronutrient 
status
Micronutrient 
intake
Daily losses
Bioavailability
* Additional needs may include needs for growth, pregnancy or lactation 
Factorial approach
Dose-response approach
Micronutrient 
intake
ANR =
Mean daily losses
Bioavailability factor
ANR =
AI =
Intake sufficient to 
fulfill health criteria in 
50% of the population 
Hematological status
Cognitive 
performance
Bone health
Mean intake of a 
population with a low 
prevalence of inadequacy
 
Figure 1. Schematic overview of approaches that may be used for 
estimating vitamin B12 requirements of adults and elderly 
 
Factorial approach  
The factorial approach is used to establish an ANR of vitamin B12 in the 
Netherlands. For defining an ANR based on the maintenance of body stores 
it would be necessary (by definition) to establish what body stores suffice to 
prevent deficiency or defined suboptimal function in 50% of the population. 
Such data cannot be obtained from healthy individuals for ethical reasons, 
therefore the ANR was based on stores from patients suffering from 
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malabsorption with normal hematological status and low serum vitamin B12, 
i.e. 525 µg (5). Strictly speaking this number is not reflecting an ANR, but 
rather defines minimum requirements for intake. It is not clear what stores 
will be sufficient for the general population to maintain health. Most 
estimates of body stores in apparently healthy people ranged between 2 and 
3 mg, but whether it is beneficial to maintain stores larger than 0.5 mg is 
not clear. Based on estimates of body stores in apparently healthy people 
(2-3 mg), a rate of loss of 0.13% of stores per day and assuming a 
bioavailability of 29-37% (ignoring the uncertainty in the bioavailability and 
between subject variability), requirements of apparently healthy individuals 
would range between 7.0 and 13.4 µg/day. These numbers indicate the 
daily intake necessary to maintain body stores in apparently healthy 
populations and therefore reflect a range of adequate intakes rather than an 
ANR. To be able to define appropriate body stores for estimating vitamin 
B12 requirements, more data are needed on the predictive value of body 
stores for health, e.g. normal hematological status.  
 
Dose-response approach: Maintenance of hematological status 
The ANR based on the maintenance of hematological status, as proposed by 
IOM (6), was based on one single study including 7 subjects that were not 
able to absorb vitamin B12 from foods due to pernicious anemia (PA) (7). 
The daily parenteral dose of vitamin B12 needed to maintain stable 
haemoglobin, normal mean cell volume and normal reticulocyte response in 
half of the subjects was used as the basis for estimating requirements taking 
into account the additional loss that only occurs in PA patients. In line with 
this study, more recent non-placebo-controlled trials showed (large) 
increases in hemoglobin concentrations or hematocrit after intramuscular or 
oral vitamin B12 administration in patients with PA or age-related food-
vitamin B12 malabsorption (8-11). However, the selection of hematological 
status as criterion for adequacy may be debatable for several reasons. 
Although the biological role of vitamin B12 in blood cell formation is well-
defined (12-14) it has been estimated that 19–28% of patients with PA do 
not have anemia, and 17–33% have a normal mean cell volume (15, 16). 
Secondly, potentially irreversible neurologic disorders due to vitamin B12 
deficiency may occur in the absence of anemia or an elevated mean cell 
volume (17-19). It is even suggested that the occurrence of neurological 
complications is inversely correlated with the degree of anemia; patients 
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who are less anemic show more prominent neurological complications and 
vice versa (20, 21). 
 
Dose-response approach: Vitamin B12 and cognitive function 
Based on the results of our systematic review we concluded that current 
evidence on the relation between vitamin B12 intake or status and cognitive 
function does not suffice for being considered in deriving vitamin B12 
recommendations. However, based on our results and following the 
conclusions from previous consensus meetings, some issues need to be 
considered in future studies to assess associations between vitamin B12 and 
cognitive performance including the selection of study populations and 
cognitive outcomes (22-27).  
For the selection of study populations for intervention studies, it needs to be 
considered that when selecting study subjects with cognitive impairment, 
the duration of cognitive symptoms may affect the response to treatment as 
brain damage may have already occurred. Therefore, trials may better be 
aimed at prevention of cognitive decline than at treatment, and selecting 
study participants at middle age instead of old age may be most appropriate 
for long-term interventions aiming at the prevention of cognitive impairment 
(23).  
Normal cognitive aging, so not including dementia or mild cognitive 
impairment, shows a large inter-individual variation and nutrition is one of 
the factors that may contribute to this variation. Furthermore, cognitive test 
performance is subject to temporal fluctuations due to various factors such 
as tiredness, attention, glucose levels, and depression or to demographic 
factors such as age, education, and sex. Power to detect significant effects 
of treatment will therefore require large study populations. For cohort 
studies it is very important to evaluate a broad range of population 
characteristics for their potential of being a confounding factor. 
Because the impact of vitamin B12 on the brain and on cognitive 
performance is still not fully understood, it is important to use a 
comprehensive range of cognitive performance tests that adequately 
differentiate between different cognitive domains to evaluate how vitamin 
B12 intake or status differentially affects different cognitive domains. 
Standardization of methods to assess cognitive function and diagnostic 
criteria for cognitive disorders could increase comparability across studies. 
In addition, brain imaging techniques may be used to assess whether the 
structure and function of the brain is affected by vitamin B12 intake or 
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status. Previous studies showed that brain atrophy and damage to the white 
matter was associated with serum/plasma vitamin B12, holoTC II and MMA 
over the normal range (28, 29). Furthermore, evidence from a single trial 
showed that 2 year supplementation with a combination of vitamin B6, 
vitamin B12 and folate, reduced the rate of brain loss in 271 elderly people 
with mild cognitive impairment (30). Whether the observed effects were due 
to the combination of B-vitamins, or that one B-vitamin was more important 
should be further identified.  
  
Dose-response approach: Vitamin B12 and bone health 
The relation of vitamin B12 intake and status with bone health was not 
studied in this thesis, but a systematic review was performed in 
collaboration with EURRECA colleagues using the same methodology as 
described for cognitive performance (31). Vitamin B12 may influence bone 
health through its potential role in bone metabolism and therefore may be a 
risk factor for osteoporosis (15, 32, 33). The latter review addressed three 
outcomes of bone health: fractures, bone mineral density (BMD) and bone 
turnover markers and included studies published through February 2009. 
Dose response evidence from 2 randomized controlled trials (RCTs) and 17 
observational studies on the relation of vitamin B12 intake and status with 
indicators of bone health is summarized in Table 1. Evidence on associations 
between intake and fractures (n=1), BMD (n=4) and bone turnover markers 
(n=2) was limited and yielded no or inconclusive results. A meta-analysis of 
4 cohort studies including 7532 elderly subjects with 3 to 12.6 years of 
follow-up showed a modest decrease in risk of fractures of 4% per 50 pmol/l 
increase in serum/plasma vitamin B12 concentrations, which was borderline 
significant (RR=0.96, 95% CI = 0.92-1.00, I2=0.0%). Out of nine cross- 
sectional and cohort studies on serum/plasma vitamin B12 concentrations in 
relation to BMD, 4 studies including 3031 adults and elderly observed that 
higher serum/plasma vitamin B12 concentrations were associated with 
improved BMD, whereas 5 other studies including 7428 subjects did not 
observe any associations. 
Due to a large variability in the presentation of data no meta-analysis on this 
association could be performed. 
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Evidence on the association between serum/plasma vitamin B12 and bone 
turnover markers was limited to one study, which observed significantly 
higher concentrations of bone turnover markers in women (n=289) with 
normal as compared to low serum/plasma vitamin B12 concentrations 
(p<0.05), but not in men (n=268) (35). Overall, the evidence-base is 
suggestive of an association between plasma/serum vitamin B12 
concentrations and bone health, although data on BMD are not 
unambiguous and data on bone turnover marker is limited. Evidence from 
prospective cohort studies and RCTs is needed to confirm the suggested 
association. Moreover, data on the functional markers of vitamin B12 status, 
MMA and holoTC II was very limited, and no conclusion about their 
associations with bone health could be drawn. 
 
Dose-response approach: Vitamin B12 intake and markers for 
vitamin B12 status 
The relation between vitamin B12 intake via diet, enriched foods or 
supplements, and different markers of vitamin B12 status (serum/plasma 
concentrations of vitamin B12, MMA and holoTC II) in adults and elderly was 
also systematically reviewed by EURRECA colleagues (35). Main results of 
studies published through January 2009 are summarized in Table 2. For 37 
RCTs (n=3398) and 19 observational studies (n=12570), regression 
coefficients between intake and serum/plasma vitamin B12 were estimated 
for each individual study, based on the assumption of a linear relation on the 
double log-scale (natural logarithm of intake versus natural logarithm of 
status). These regression coefficients were combined in a meta-analysis to 
estimate the dose-response relation between vitamin B12 intake and 
serum/plasma vitamin B12 concentrations as loge(y) = 0.16*loge(x)+5.31. 
This relation indicates that a doubling of vitamin B12 intake increases 
serum/plasma vitamin B12 concentrations by 20.16=12%. When only 
including studies including elderly or RCTs, the percentage increase in 
serum/plasma vitamin B12 was slightly more. In total 9 RCTs were identified 
that addressed vitamin B12 intake in relation to methylmalonic acid (MMA) 
concentrations. A pooled analysis revealed that a doubling in vitamin B12 
intake resulted in a 7% decrease in MMA concentrations. Three RCTs 
provided data on the relation between vitamin B12 intake and 
holotranscobalamin II (holoTC II). Each study showed that vitamin B12 
supplementation either through capsules or enriched food products  
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significantly increased the concentrations of holoTC II in serum or plasma, 
but the number of RCTs was too small and the heterogeneity in study 
characteristics was too large to justify a meta-analysis.   
The meta-analyses on dose-response relations between vitamin B12 intake 
and markers for vitamin B12 status showed a large between-study 
heterogeneity varying from 76-98%. Several factors that might explain the 
observed heterogeneity were considered by stratified analyses, including 
mean age of the study population, study design, percentage women in the 
study, duration of the trials and dose and form of vitamin B12 provided. 
However, these factors did not significantly explain the between-study 
heterogeneity.  
Based on the dose-response relationship between vitamin B12 intake and 
serum/plasma vitamin B12 concentrations as described above, an average 
intake of 0.2 µg, 0.9 µg, 5.6 µg or 11.7 µg would be sufficient to achieve 
plasma concentrations of 150 pmol/l, 200 pmol/l, 258 pmol/l or 300 pmol/l 
respectively. These plasma concentrations of vitamin B12 are generally 
accepted as cut-off for clinical practice (150 pmol/l and 200 pmol/l), or 
suggested as cut-off for subnormal vitamin B12 status (258 pmol/l and 300 
pmol/l) (36-38). Estimates of the average intake amounts needed to achieve 
these plasma concentrations can be denoted as plasma/serum based ANRs. 
 
Integration of data collated with the dose-response approach 
Within the scope of the EURRECA network, a bivariate normal model was 
used to describe the relation between vitamin B12 intake and status by 
incorporating the variability between individuals for both intake and status 
measures. The stochastic model was based on the RCTs and observational 
studies identified for serum/plasma vitamin B12 concentrations as described 
above. The other markers of vitamin B12 status were not considered as data 
were limited. 
First, the variation in requirements is derived under the assumptions that all 
measurements of intake (x) and plasma/serum vitamin B12 (y) are error-
free, and that a cut-off value of status defines exactly if individual 
requirements are met. Furthermore the joint distribution of loge intake and 
loge plasma/serum vitamin B12 concentrations is assumed to be bivariate 
normal with means (µX, µY), standard deviations (σX, σY) and correlation ρ, 
implying a linear dose-response relation on these scales. As the ANR is the 
intake sufficient for 50% of the population, an individual with an intake 
equal to the ANR has a probability of 50% that the intake is sufficient to 
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reach the cut-off for plasma/serum vitamin B12. Using this probability, the 
ANR may be derived based on the conditional distribution of plasma/serum 
vitamin B12 given an intake equal to the ANR. Subsequently the 
recommended intake may be derived under the assumption of parallel 
individual lines as the intake at which the probability of reaching 
plasma/serum vitamin B12 equal to or less than the cut-off is 2.5%.  
The ANR and recommended intake derived with the methods described here 
is shown in Table 3. 
The practicability of this stochastic method for deriving the ANR and 
recommended intake of vitamin B12 depends, as any other model, on the 
assumptions made. Some of these assumptions, e.g. the absence of 
measurement error, are unlikely to be met. Therefore, the model should be 
further developed to deal with these limitations. However, a major 
advantage of the stochastic method is that it allows the integration of 
different forms of data (e.g. mean or median, SD or confidence interval, 
regression-coefficients or correlations, log scale or normal scale) on the 
relation between intake and status of vitamin B12 that is widely available 
from different types of studies (RCTs and observational). Furthermore, the 
model can be extended to a trivariate model, also including health outcomes 
in addition to intake and status. However, so far this does not make sense 
for vitamin B12, as the evidence for a dose-response relation with cognitive, 
bone and other health outcomes is still inconclusive. 
 
Methodological considerations systematic review and meta-
analyses 
The systematic review methodology as used in this thesis for summarizing 
evidence on vitamin B12 requirements has several strengths and limitations. 
The main strength of the methodology is its rigorous and transparent nature 
that minimizes bias, which is important when used as a basis for decision 
making processes by authorities in charge of developing evidence-based 
recommendations and policies. Prior to conducting the systematic review, 
research questions to be addressed by the review and a description of each 
step of the review procedure including search strategies, in- and exclusion 
criteria, data extraction and data synthesis methods were specified in a 
protocol. As new data become available this information can facilitate the 
updating process. 
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In addition, to ensure complete retrieval of all potentially relevant papers, a 
multi-database search was conducted in MEDLINE, EMBASE and COCHRANE. 
Although the largest proportion of papers finally included in the reviews was 
identified with MEDLINE, a small number of studies originated from the 
other databases. To ensure objectivity and standardization of the process, at 
the beginning of each step of the review process, a quality control took 
place by duplication of 10% of the work by two independent reviewers. Each 
review presented the available body of literature on the specific topic of the 
review and concurrently illustrated the knowledge gaps and associated 
research needs.  
Where possible, data from different studies were aggregated by means of 
meta-analyses as this can increase statistical power and provide answers 
that no single study can give. Several limitations were encountered here. At 
first, studies included in our review did not always address our research 
question, and as a consequence the data needed could not be extracted. 
Therefore we contacted the study authors to obtain additional information or 
transformations of the original reported data were performed using validated 
methodology (101). Unfortunately not all authors responded to our request 
which limited the number of studies that could be included in the meta-
analyses.  
Secondly, meta-analyses are limited by the quality and availability of data. 
We addressed the quality of the different studies included in our review 
according to proposed methodology by the Cochrane collaboration. 
Nevertheless, we noticed that information needed to judge upon the quality 
of a study is often not reported clearly in the papers, for example, the 
methods used for sequence generation or allocation concealment in RCTs or 
variables tested for potential confounding (observational studies). This 
identifies the need for improvement in quality and nature of reporting, by 
following the CONSORT guidelines when reporting RCTs (102,103) or 
STROBE guidelines when reporting observational studies (104).  
Third, a common concern in meta-analyses is statistical heterogeneity 
between studies. In the meta-analyses performed for bone health and 
cognitive performance the heterogeneity between studies was low or 
moderate as the number of included studies was small and most studies 
showed results in a similar direction. However, for the intake-status meta-
analyses large heterogeneity was observed which could not be explained by 
study characteristics and is therefore likely to be related to a lack of 
standardization of methods for measuring intake and status and to a true 
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heterogeneity between study populations. This heterogeneity could be 
addressed by an individual participants data meta-analysis, however this is a 
major undertaking in terms of time, costs, and collaboration, and an inability 
to include individual participant data from all relevant studies may introduce 
selection bias.  
 
FROM REQUIREMENTS TO RECOMMENDATIONS 
When the available data on vitamin B12 requirements allow the estimation 
of ANR, we need an estimate of SD in order to derive recommended intakes. 
This SD should cover the inter-individual variation and uncertainties in the 
assumptions underlying the ANR, such as body stores and bioavailability. So 
far, no CV could be estimated for vitamin B12 requirements and therefore 
the usual CV of 10-20% is used for deriving recommended vitamin B12 
intakes. This usual CV is based on estimates of inter-individual variation in 
protein requirements, i.e. 12.5%, and energy requirements, i.e. 10% or 
20% depending on the methods used (105-107).  
Two factors that may influence inter-individual variation in requirements 
between individuals are polymorphisms, and interactions between nutrients. 
If these factors are considered for estimating a CV, this actually implies that 
the recommendations should be made specific according to these factors. 
This is only useful when polymorphisms or nutrient-nutrient interactions 
substantially affect micronutrient requirements and knowledge on 
polymorphism is available for the target population to which the NIVs are 
applied (108). For vitamin B12 several polymorphisms (GIF, CUBN, AMN, 
TCII, TCIIR) were identified in genes encoding proteins involved in vitamin 
B12 metabolism, that may evoke vitamin B12 deficiency (109). However 
such deficiency may not be cured by increasing intake and is therefore not 
relevant here. Furthermore no micronutrients or food components have 
been identified so far that influence the requirement for vitamin B12 (105). 
 
RECOMMENDATIONS FOR NUTRIENT RECOMMENDATION 
SETTING BODIES  
An objective of this thesis was to illustrate standardized, transparent and 
objective review methods that can be used to summarize and evaluate the 
evidence-base for setting recommendations, using vitamin B12 as a case 
micronutrient. Table 3 summarizes the implications for recommendations on 
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vitamin B12 intake based on all the evidence on vitamin B12 requirements 
gathered within the context of this thesis.  
As shown in Table 3, recommended intakes of vitamin B12 for maintenance 
of normal body stores are similar to recommendations for the prevention of 
subclinical deficiencies based on the estimated dose-response relation 
between intake and serum/plasma vitamin B12 (cut-off:258 pmol/l or 300 
pmol/l), namely 6.7-14 µg per day. These results are also supported by 
observations from five studies that showed that markers for vitamin B12 
status (plasma vitamin B12, MMA and holoTC II) leveled off at daily intakes 
between 4 and 10 µg per day (93, 96, 110-112). 
Recommendations based on the prevention of deficiencies (maintenance of 
minimal stores or hematologic status, serum/plasma vitamin B12 ≤150 or 
200 pmol/l) resulted in much lower values. However, it must be noted that 
the estimated dose-response relation was based on apparently healthy study 
populations with normal to high vitamin B12 intakes. Data on associations 
between intake and serum/plasma vitamin B12 concentrations from 
populations with marginal vitamin B12 intakes was not available. Therefore 
the estimated dose-response relation may be less appropriate to describe 
the relation between vitamin B12 intake and status in vitamin B12 
deficiency.  
 
This thesis illustrated that, at this point in time, evidence is not consistent 
that vitamin B12 intakes or status may be associated with long term health 
outcomes including cognitive function and bone health. 
If it had been possible to estimate a dose-response relation between vitamin 
B12 status and cognitive function and bone health, it may have been 
possible to derive an optimal range of plasma concentrations for markers of 
vitamin B12 status specifically for each separate health outcome.  
In that case, the most appropriate health outcome for estimating the ANR 
could be selected based on the highest intake required or the robustness of 
the dose-response relation. Another possibility would be to weigh the health 
outcomes in terms of disease burden (DALYs) and/or costs for society. 
However, selecting and weighing the health outcomes and choosing 
between policy alternatives is the responsibility of policy makers that 
requires expert deliberations in addition to scientific evidence, especially 
when uncertainties exist.  
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CONCLUDING REMARKS 
This thesis illustrated that evidence underlying current ANRs of vitamin B12 
(maintenance of minimal stores or hematological status) is old and has large 
uncertainties, whereas evidence on long term health outcomes in relation to 
vitamin B12 intake or status is yet very limited and not suitable for setting 
recommendations. The relation between vitamin B12 intake and markers of 
vitamin B12 status seem the best alternative and stochastic methods may 
provide a good opportunity to integrate dose-response data from different 
study types. However ways to define recommendations based on these 
dose-response data should be further developed.  
Intakes needed to maintain normal body stores or prevent subclinical 
deficiency may be up to 5 times higher than current recommendations, but a 
missing piece of information is the amount of vitamin B12 intake associated 
with observable health benefits beyond the prevention of signs and 
symptoms of deficiency. 
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SUMMARY IN DUTCH (SAMENVATTING) 
In de meeste Europese landen worden aanbevelingen opgesteld voor de 
hoeveelheden micronutriënten (voedingsstoffen) die iemand via de 
dagelijkse voeding zou moeten innemen. Deze aanbevolen hoeveelheden 
geven het niveau van inname aan dat toereikend is om te voorzien in de 
behoefte van bijna alle individuen in de algemene gezonde populatie. Ze 
dienen als basis voor voedingsbeleid op (inter)nationaal en regionaal niveau, 
voedingsvoorlichting en voedingsrichtlijnen. Er bestaat geen fysiologische 
reden waarom verschillende Europese landen verschillende hoeveelheden 
zouden moeten aanbevelen. Desondanks bestaat er toch een grote variatie 
in de aanbevolen hoeveelheden tussen Europese landen doordat 
verschillende landen op verschillende wijze aanbevolen hoeveelheden 
afleiden. Begin 2007 is het EURRECA (EURopean RECommendations 
Aligned) Netwerk opgericht met als doel de methoden voor het afleiden van 
aanbevolen hoeveelheden voor micronutriënten binnen Europa te 
harmoniseren. Hierbij wordt speciale aandacht gegeven aan aanbevelingen 
voor kwetsbare populatiegroepen zoals oudere mensen. 
Het doel van dit proefschrift, geschreven in de context van EURRECA, is 
tweeledig: 
1. Het bestuderen van de variatie in de huidige aanbevelingen binnen 
Europa en helder krijgen welke verschillen in methodologische aspecten 
het meest van belang zijn voor het harmoniseren van aanbevolen 
hoeveelheden in Europa. 
2. Het demonstreren van transparante gestandaardiseerde review 
methoden die gebruikt kunnen worden om het wetenschappelijke 
bewijs dat relevant is voor het afleiden van aanbevelingen samen te 
vatten en te evalueren. Hierbij wordt het micronutriënt vitamine B12 als 
voorbeeld gehanteerd. 
 
Hoofdstuk 2 geeft een overzicht van de huidige aanbevelingen voor 
micronutriënten in Europa. Daarnaast wordt per land informatie gegeven 
over de aanbevolen hoeveelheden en de daarvoor gehanteerde concepten 
en definities. Verder laat dit hoofdstuk de variatie in Europese aanbevelingen 
zien voor vitamine A en vitamine D en worden mogelijke verklaringen voor 
deze variatie besproken door de verschillende methodes te vergelijken, die 
gebruikt zijn om deze aanbevelingen af te leiden. De informatie over de 
gebruikte methodes is verzameld op basis van de achtergrondinformatie uit 
de aanbevelingsrapporten en met een vragenlijst die is ingevuld door 
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vooraanstaande informanten werkzaam op het gebied van aanbevelingen. 
Uit deze studie blijkt dat de gehanteerde concepten en definities voor het 
uitdrukken van aanbevelingen in principe gelijk waren tussen de 
verschillende Europese landen, maar dat de terminologie tussen landen zeer 
verschillend was (bijvoorbeeld “aanbevolen nutrient inname” versus 
“referentie inname van de populatie”). 
De variatie in aanbevolen hoeveelheden voor vitamine A en vitamine D blijkt 
samen te hangen met de volgende factoren: verschillen in aannames,  
verschillen in geselecteerde gezondheidsuitkomsten en verschillen in 
typeswetenschappelijk bewijs dat gebruikt is om de behoefte te schatten.  
De beschikbare achtergrondinformatie in de rapporten was te beperkt om de 
kwantitatieve bijdrage van deze verklarende factoren te kunnen bepalen. 
Verschillen in concepten en verschillen in definities van bevolkingsgroepen 
(kinderen, adolescenten, volwassenen en ouderen) zijn minder van belang. 
Deze bevindingen geven aan dat er richtlijnen nodig zijn om binnen Europa 
‘evidence-based’ aanbevelingen af te leiden. 
 
Belangrijke aandachtspunten voor de harmonisatie van methodes voor het 
afleiden van aanbevelingen voor de inname van micronutriënten zijn 
geïdentificeerd in Hoofdstuk 3 door gedetailleerde informatie te zoeken 
waarmee de variatie in de huidige aanbevelingen kan worden verklaard. 
Eerst zijn de verschillen in aanbevolen hoeveelheden voor foliumzuur, 
vitamine B12, ijzer en zink voor volwassenen geïnventariseerd door 
aanbevelingen uit negen Europese en niet-Europese landen te vergelijken. 
Vervolgens zijn de aannames en methoden vergeleken die gebruikt zijn om 
tot de aanbevelingen te komen, alsook de gezondheidsuitkomsten die 
gebruikt zijn om de behoefte te schatten en de wetenschappelijke studies 
die hiervoor geraadpleegd zijn. Resultaten van deze vergelijkingen laten zien 
dat de variatie in aanbevelingen vooral gerelateerd is aan verschillen in de 
geraadpleegde wetenschappelijke studies (foliumzuur en zink), de 
geselecteerde gezondheidsuitkomsten (vitamine B12) en aannames ten 
aanzien van variatie in de behoefte tussen personen (vitamine B12), 
referentie gewichten van de populatie (ijzer) en biobeschikbaarheid (ijzer en 
zink). Deze resultaten laten zien dat voor het harmoniseren van methodes 
om aanbevolen hoeveelheden voor foliumzuur, vitamine B12, ijzer en zink af 
te leiden binnen Europa, gestandaardiseerde methoden nodig zijn voor a)-de 
selectie van gezondheidsuitkomstmaten op basis waarvan de behoefte 
geschat wordt, b)-de definitie van biomarker concentraties die 
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corresponderen met een adequate gezondheid, c)-het maken van 
veronderstellingen over de tussen-persoons variatie in behoefte, d)-het 
vaststellen van de biobeschikbaarheidsfactor, en e)-het selecteren en 
interpreteren van wetenschappelijk bewijs over behoefte. 
 
Eén van de methodes om de behoefte voor een micronutriënt te schatten is 
de factoriële methode. Met deze methode worden alle dagelijkse obligate 
verliezen waarvoor gecompenseerd moet worden via de voedselinname bij 
elkaar opgeteld en gecorrigeerd voor de biobeschikbaarheid vanuit de 
voeding. Vitamine B12 aanbevelingen voor volwassenen en ouderen die zijn 
opgesteld met behulp van de factoriële methode zijn gebaseerd op een 
beperkt aantal studies die voornamelijk zijn gepubliceerd in de jaren 60 van 
de vorige eeuw. Hoofdstuk 4 beschrijft een systematische literatuur review 
over dagelijkse vitamine B12 verliezen en biobeschikbaarheid van vitamine 
B12 uit verschillende soorten voedingsmiddelen met schattingen van de 
variatie tussen personen. Deze review laat zien dat dagelijkse vitamine B12 
verliezen in gezonde volwassenen en ouderen waarschijnlijk tussen de 2.6 
en 3.9 µg per dag ligt, waarbij wordt verondersteld dat de totale 
lichaamsvoorraad van vitamine B12 tussen de 2 en 3 mg bedraagt.  
Gebaseerd op gebruikelijke inname data en de relatie tussen vitamine B12 
inname en de hoeveelheid vitamine B12 die geabsorbeerd wordt, kan een 
biobeschikbaarheid van vitamine B12 worden afgeleid tussen de 29 and 
37% in plaats van 50% zoals meestal verondersteld wordt. Deze resultaten 
suggereren dat een vitamine B12 inname tussen 7.0 and 13.4 µg nodig is 
om te compenseren voor dagelijkse vitamine B12 verliezen in gezonde 
volwassenen en ouderen. Deze inname is 2.5 tot 5 maal hoger dan de 
inname die nodig is om verschijnselen van vitamine B12 tekort te 
voorkomen. De huidige vitamine B12 aanbeveling van 1.4-3.0 µg is mogelijk 
niet voldoende om een lichaamsvoorraad van 2-3 mg en optimale plasma 
concentraties van biomarkers voor vitamine B12 status te handhaven. Om 
goed te kunnen evalueren welke vitamine B12 status en lichaamsvoorraad in 
verband staan met waarneembare gezondheidsvoordelen zijn er meer 
gegevens nodig over de relatie tussen plasma concentraties van biomarkers 
van vitamine B12 status, de lichaamsvoorraad van vitamine B12 en 
gezondheidsuitkomsten op lange termijn. 
 
Om te bepalen of in de toekomst de relatie tussen vitamine B12 en cognitief 
functioneren moeten worden meegenomen bij het afleiden van vitamine B12 
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aanbevelingen voor volwassenen en ouderen, is in Hoofdstuk 5 een 
systematische literatuur review beschreven van gerandomiseerde 
voedingsproeven (RCTs) en prospectieve cohortstudies die de relatie tussen 
vitamine B12 en cognitief functioneren bestuderen. De twee 
geïndentificeerde RCTs en 19 cohort studies lieten geen of een inconsistent 
verband zien tussen enerzijds vitamine B12 inname of status en anderzijds 
dementie, ziekte van Alzheimer, algemeen cognitief functioneren of domein-
specifiek cognitief functioneren. Dit betekent dat het huidige 
wetenschappelijke bewijs voor de relatie tussen vitamine B12 en cognitief 
functioneren te gering is om mee te nemen bij het afleiden van aanbevolen 
hoeveelheden vitamine B12. Om deze relatie beter te onderzoeken zal 
toekomstig onderzoek zich moeten richten op meer gevoelige biomarkers 
voor vitamine B12 status en cognitieve functie. Dit zijn bijvoorbeeld 
methylmalonzuur (MMA) en holotranscobalamine II (holoTC II) voor vitamin 
B12 status, en de mate van vermindering van hersenweefsel (hersen atrofie) 
bij voorkeur in combinatie met domein-specifieke testen als cognitieve 
uitkomstmaat. 
 
In 2007 toonde een studie in de Verenigde Staten dat een lage vitamine B12 
status in combinatie met een hoge foliumzuur inname door consumptie van 
foliumzuur-verrijkte meelproducten mogelijk een cognitieve achteruitgang in 
een ouderen-populatie veroorzaakt. In Hoofdstuk 6 is onderzocht of zulke 
interacties ook aanwezig zijn in een populatie die niet is blootgesteld aan 
voedingsmiddelen verrijkt met foliumzuur. Hierbij is gebruik gemaakt van 
gegevens van 2203 Noorse ouderen verzameld binnen de Hordaland 
homocysteïne studie in de regio Bergen. Cross-sectionele analyses lieten een 
significante negatieve interactie zien tussen plasma concentraties van 
foliumzuur en vitamine B12 in relatie tot cognitieve prestatie. Dit resultaat 
suggereert dat onder ouderen met een lage vitamine B12 status, de 
positieve associatie tussen foliumzuur en cognitieve prestatie juist sterker 
wordt. Echter, wanneer holoTC II of MMA in plaats van plasma concentraties 
van vitamine B12 in het model worden opgenomen, is de interactie tussen 
foliumzuur en de marker van vitamine B12 status in relatie tot cognitieve 
prestaties niet significant. De resultaten van deze studie geven in lijn met 
Hoofdstuk 5 aan dat de relatie tussen vitamine B12 en cognitief functioneren 
momenteel onzeker is en daardoor niet geschikt als 
gezondheidsuitkomstmaat om de vitamine B12 behoefte te schatten.  
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In het laatste hoofdstuk van dit proefschrift (Hoofdstuk 7), worden de 
belangrijkste bevindingen samengevat en aangevuld met bewijs over dosis-
respons gegevens voor de relatie tussen vitamine B12 inname of status en 
gezondheidsuitkomsten die zijn bestudeerd binnen het EURRECA Netwerk 
(hematologische kenmerken en botgezondheid). Daarnaast is de relatie 
beschreven tussen inname van vitamine B12 en biomarkers van vitamine 
B12 status. Voor- en nadelen van de verschillende methoden die gebruikt 
kunnen worden om vitamine B12 behoeftes te schatten worden 
bediscussieerd en hiaten in de huidige kennis worden benadrukt.  
De belangrijkste conclusie van dit proefschrift is dat het bewijs op grond 
waarvan de huidige aanbevolen hoeveelheden voor vitamine B12 zijn 
afgeleid (handhaven van minimale lichaamsvoorraden of hematologische 
kenmerken) oud is en wordt omgeven door grote onzekerheden, terwijl 
bewijs over gezondheidsuitkomsten in relatie tot vitamine B12 inname of 
status (cognitief functioneren, bot gezondheid) tot nu toe zeer beperkt is en 
niet geschikt als basis voor het opstellen van vitamine B12 aanbevelingen. 
Het beste alternatief is om op basis van de relatie tussen vitamine B12 
inname en status de inname af te leiden die correspondeert met een 
vitamine B12 status die in het algemeen als gezond kan worden beschouwd. 
De statistische methode hiervoor dient echter nog verder te worden 
ontwikkeld. 
Tot slot laten de berekeningen in dit proefschrift  zien dat innames die nodig 
zijn om normale lichaamsvoorraden van vitamine B12 te handhaven mogelijk 
tot 5 maal hoger kunnen liggen dan de huidige vitamine B12 aanbevelingen 
die gericht zijn op het voorkomen van signalen en symptomen van 
subklinisch deficiëntie/tekort. Doordat gegevens over het verband tussen de 
lichaamsvoorraad van vitamine B12 en waarneembare effecten op de 
gezondheid ontbreken, blijft het helaas onzeker of deze hogere vitamine B12 
aanbeveling daadwerkelijk gezondheidsvoordeel oplevert.  
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